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Abbreviations 
Aβ                  amyloid beta  
AD                 Alzheimer Disease  
ADP               adenosine diphosphate  
APP                amyloid beta precursor protein  
APC/C            anaphase Promoting Complex/Cyclosome 
BSA                bovin serum albumin  
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2+
               calcium  
cdk                  cyclin dependent kinase  
CNS                central nervous system  
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PS 1/2              persenilins 1/2  
ROS                 reactive oxygen species  
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1. SUMMARY  
Alzheimer’s disease (AD) is the most common cause of dementia among elderly 
individuals above 65 years. Estimations suggest that there are currently about 47.5 
million people worldwide suffering from dementia, of which 60-70% are AD cases 
(World Health Organization, 2015). It is an irreversible disease of progressive 
nature, which leads to deterioration in cognitive functions beyond what is normal 
in a healthy aging process. Among the affected cognitive functions are memory, 
thinking skills and orientation.   
AD is one of the major causes of disability among older people and has a big 
impact on socio-economical capacities. There is currently no treatment to cure AD 
and it is a very active field in biomedical research. Numerous new treatments are 
being tested in various stages of the disease to alter its progressive course. 
The pathological hallmarks of AD are deposition of plaques of amyloid peptides 
and the formation of neurofibrillary tangles (NFTs), which are mainly constituted 
by hyperphosphorylated aggregates of the microtubule-associated protein tau. 
These accumulations cause damage to cells and trigger progressive, diffuse and 
massive neuronal loss. The most affected areas are the neocortex, hippocampus, 
amygdala, and their associated cortices. Moreover, various molecules and 
signalling pathways are altered in AD, which might contribute substantially to the 
onset and/or progress of the disease. In this work we analyzed the implication of 
the E3 ubiquitin ligase, the anaphase promoting complex/cyclosome (APC/C) in 
AD. 
APC/C is a large protein complex, forming an E3 RING finger ubiquitin ligase that 
is one of the main regulators of the cell cycle in proliferating cells. APC/C 
recognizes proteins by specific amino acid motifs, like KEN-BOX or D-BOX 
9 
 
sequences and targets them for degradation. Within the last decade, important 
neurobiological functions of APC/C and its activator subunits cdh1 and cdc20 have 
been discovered. It was shown that APC/C is involved in the control of neuronal 
G0 maintenance, axonal growth, coordinates neurogenesis and synaptic 
development. Up to date, 15 substrates have been identified, which are directly 
involved in processes in the nervous system. Accumulation of some of these 
proteins has been associated with neurodegeneration. In this work we tested the 
hypothesis that APC/C could have a relevant pathophysiological role in AD.  
We showed in neurons in primary culture that amyloid beta (Aβ), a peptide related 
to AD, causes the degradation of cdh1 in a proteasome-dependent manner. This 
leads to a subsequent increase of the APC/C substrate glutaminase, which causes 
an elevation of glutamate levels. Increased glutamate levels cause intraneuronal 
Ca
2+
 dysregulation, resulting in excitotoxicity and neuronal apoptosis. Glutaminase 
inhibition prevents these Aβ-induced alterations. Ca2+ dysregulation induced by 
glutamate causes a similar effect on cdh1 and glutaminase as Aβ. We confirmed 
these findings in vivo using microinjection of either Aβ or glutamate in the CA1 
region of the rat hippocampus. We showed here for the first time in vivo that both, 
Aβ and glutamate, cause nuclear exclusion of cdh1 and a subsequent increase of 
glutaminase. These results indicate that maintaining normal APC/C-Cdh1 activity 
may be a useful target in AD treatment.  
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2. INTRODUCTION 
2.1. APC/C Ubiquitin Ligase: An Introduction 
Ubiquitination is a post-translational modification in which ubiquitin, a small 
regulatory protein (8,5 kDa), is attached to a substrate protein. The ubiquitination 
system consists of three classes of enzymes termed, E1 ubiquitin-activating 
enzymes, E2 ubiquitin-conjugating enzymes and E3 ubiquitin ligases. The E3 
ligases impart the specificity to the substrates (Ciechanover et al., 1978, 
Ciechanover et al.,1980, Hershko et al., 1982; Pickart et al., 2004). A sequential 
cascade of these enzymes results in the addition of ubiquitin to an amino group of 
the target protein. An isopeptide bond is formed between terminal glycine of 
ubiquitin and, in most cases, a lysine residue in the amino group (Bloom et al., 
2003). Ubiquitination can affect the substrate activity, the cellular localization or 
promote their degradation (Pickart et al., 2004). In general, ubiquitin-dependent 
proteolysis is a major regulatory mechanism for the reorganization of the proteome.  
APC/C was first discovered by King et al. (1995) when they observed that cyclin B 
was degraded at the onset of the anaphase by an ubiquitin-dependent proteolytic 
system. It is a multimeric protein complex that belongs to the cullin–RING 
ubiquitin ligases, which represent the largest known class of E3 ubiquitin ligases. 
Cullins are proteins that are part of ubiquitin ligases and they combine with RING 
proteins (Bosu and Kipreos, 2008). Nine cullins are encoded in the human genome 
(Cul1, 2, 3, 4A, 4B, 5, and 7, PARC, and APC2), and each uses a different set of 
adaptors and substrate specificity factors. They are collectively termed as the 
cullin-RING ligases (Emanuele et al., 2011). In the APC/C complex the catalytic 
module is formed by the APC2 (cullin) and APC11 (RING) proteins.  
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The activity of APC/C strictly depends on regulatory coactivator subunits, which 
promote the interactions and stimulate the catalytic reaction of APC/C and the 
substrate. They are termed cell-division cycle protein 20 (cdc20) and cdc20 
homologue-1 (cdh1) (Visintin et al., 1997; Chang et al., 2014). The coactivators 
recognize conserved destruction motifs, the D box (RxxLxxxxN/D/E), KEN box 
(KENxxxN), A box and Cry box (CRYxPS) (Glotzer et al., 1991; Pfleger and 
Kirschner, 2000; Reis et al., 2006; Littlepage and Ruderman, 2002) and recruit the 
substrates to the APC/C. However, these consensus sequences can also be found in 
proteins that are not substrates of APC/C. Therefore, more information about 
recognition and ubiquitination mechanisms is necessary to identify putative APC/C 
substrates only by their sequence (Li and Zhang, 2009).  
The timed activation of APC/C-Cdc20 and APC/C-Cdh1 has a critical role for cell 
cycle regulation. APC/C is also implicated in other essential processes including 
genomic integrity and metabolism, and has major functions in development and in 
the nervous system (Qiao et al., 2010; Almeida et al., 2010; Almeida 2012; 
Delgado-Esteban et al., 2013). The structure and functions of APC/C will be 
discussed in more detail in the following sections.  
 
2.1.1. Components and structure of APC/C 
Chang et al. (2014) identified the definite molecular structure of all subunits of the 
APC/C complex. Moreover, Chang et al. (2015) described the atomic structure of 
APC/C and its mechanism of protein ubiquitination. They determined the structural 
architecture by reconstruction of cryo-electron microscopy of a human APC/C-
coactivator-substrate complex. APC/C is a large multimeric protein complex of 1,2 
mDa that consist of 15 different proteins assembled to 20 subunits (see Table 2.1).  
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Table 2.1 | APC/C subunits: their functions, location and structural domains. MCC: mitotic 
checkpoint complex, PC: Proteasome/cyclosome, TPR: Tetratricopeptide repeat, N: stoichiometry, 
total mass includes subunit stoichiometry (Table from: Chang et al., 2014).  
 
APC/C forms a triangular shape. Seven subunits function as scaffolds for the 
coordination of the juxtaposition of the catalytic and recognition modules. All of 
them contain multiple repeat motifs. However, the authors do not exclude that 
some of the scaffold subunits might also have a direct role in interactions with 
substrates or with E2 ubiquitin conjugating enzymes (e.g. UbcH10). The 
tetratricopeptide repeat (TPR) proteins and their accessory subunits form at the 
back and the top of the complex a bowl shaped lobe, consisting of V-shaped 
homodimers. The platform subunits, APC4 and APC5 combine with two domains 
of APC1, which contacts the TPR lobe. For substrate recognition two subunits, 
APC10 and coactivator cdc20 or cdh1, are responsible. The recognition module is 
located at the top of the cavity where APC10 interacts with the APC1 
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Proteasome/cyclosome (PC) domain. The catalytic subunits APC2 and APC11 are 
positioned at the front of the cavity below APC10 and coactivator (see Figure 2.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 | APC/C-Cdh1 ternary structure. EM reconstruction of APC/C-Cdh1 of H. sapiens at 7.4 
Å resolution. The EM map is coloured according to subunit assignments (Figure from: Chang et al., 
2014). 
 
The coactivator proteins cdc20 and cdh1 are WD40 proteins. WD-repeat proteins 
are made up of highly conserved units forming structural repeated motifs. They 
usually contain a tryptophan-aspartic acid dipeptide end. The C-terminal end of 
cdh1 and APC10 share structurally related Ile-Arg motifs that interact with the 
TPR motif (with the C-terminal end of APC3 homo-dimer). Substrates bind 
between the WD40 β-propeller domain of cdh1. Independent of substrate 
recognition, the N-terminus of the coactivator induces conformational changes of 
the APC/C complex that stimulate the activity of the APC/C ubiquitin ligase 
(Chang et al., 2014).  
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2.1.2. APC/C-Cdh1 coactivator substrate recognition  
The recognition site of the KEN box is centred on the upper surface of Cdh1 
WD40. The D-box recognition site was observed as a channel on the edge of Cdh1 
WD40 domain, where the residues P1-P7 RxxLxx(V/I/L) are engaged. The 
residues P8 to P10 interact with a surface of APC10. Mutation of P8-P10 attenuates 
APC/C-Cdh1 ubiquitination activity. The authors confirm that the D-box motif is a 
bipartite degron, which had been previously suggested (Fonseca et al., 2010), with 
a N-terminal RxxLxx(V/I/L/M) site and a hydrophilic C-terminal APC10 binding 
site (P8-P10) (Chang et al., 2014). Furthermore it was shown that the catalytic site 
of UbcH10 has a distance of about 40 A° from the D box or KEN box binding site 
to the coactivator cdh1. Therefore an extended linker of ten amino acid residues in 
C-terminal direction of the D-box places the lysine (ubiquitin binding site) at the 
UbcH10-ubiqutin catalytic site. Consistent with this finding, peptides with lysines 
at positions K1, K4 or K7 relative to the D box were not ubiquitinated, while 
lysines at positions K10, K13 and K18 were ubiquitinated (Chang et al., 2015). 
This additional information for D-box and KEN box recognition and ubiquitination 
sites could be helpful for the identification of putative APC/C substrates. 
 
The following recognition motifs are common among APC/C substrates (including 
the recently found features by Chang et al., 2014; Chang et al 2015):  
Destruction box consensus: RxxLxx[LIVM]. Example: Securin  
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Figure 2.2 | The D-box degron of X1 Securin. The bipartite degron of the D-box consist of residues 
P1-P7 with the sequence motif RxxLxx[LIVM], which is recognized by cdh1, and a hydrophilic C-
terminal end (P8-P10), which is recognized by APC10. The lysine residues are indicated. According 
to Chang et al. (2015) lysine residues with a distance of K > 10 amino acids can be ubiquitinated by 
UbcH10. Here, possible ubiquitination sites are K11, K15 and K17 (Figure adapted from: Chang et 
al., 2015).      
 
KEN box consensus: KENxx(P). Example: Cdc20 
 
 
 
 
Figure 2.3 | The KEN-box degron of Hs Cdc20. The degron of the KEN-box has the sequence motif 
KENxx(P) which is recognized by cdh1. The lysine residues are marked, starting in the position after 
the “N”. According to Chang et al. (2015) lysine residues with a distance of K > 10 amino acids can 
be ubiquitinated by UbcH10. In this example possible ubiquitination sites are K10, K11. (Figure 
adapted from: Chang et al., 2015)      
 
These two, the D-box and KEN-box motifs, are the most commonly recognized 
APC/C sequence degrons. Other sequence motifs that have been related to APC/C 
are: ORC destruction box (O-box) LxxxN, GxEN box and LxExxxN. Furthermore, 
“pseudo-substrates” of APC/C have been identified. These are proteins that contain 
the recognition sequence D-box or KEN-box, but are not targeted for degradation 
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by APC/C. This can have an inhibitory effect on APC/C activity. For example 
Emi1, Mad3 and Acm1 have been identified as pseudo-substrates (Pines, 2011). 
 
2.1.3. Functions of APC/C: The cell cycle 
A key mechanism in the cell cycle is the rapid destruction of specific cell cycle 
proteins to provide a directional switch to ensure that mitosis follows DNA 
replication and that each cell receives an identical set of chromosomes. These 
timed transitions are regulated mainly by two ubiquitin ligases: APC/C and 
Skp1/CUL1/F-box protein (SCF) (Li et al., 2009; Sajman et al., 2015).  
The cell cycle can be divided in four major phases: G1, a gap phase, in which cells 
are prepared to enter the S-phase, when the DNA replication takes place; this is 
followed by G2, the second gap phase, for the preparation to the following M-
phase in which the cell division occurs.  
Within the regulation of the APC/C activity in these phases, the temporal 
coordination of the two coactivators Cdc20 and Cdh1 promotes cell cycle 
progression. They mediate proteolysis of regulatory proteins that control 
maintenance of G1, the initiation of DNA replication, chromosome segregation, 
events of cytokinesis, and mitotic exit (Pines, 2011). Specifically, APC/C-Cdc20 is 
primarily active in early mitosis in the metaphase to anaphase transition and in 
mitotic exit, while APC/C-Cdh1 becomes active at the end of the mitotic exit and 
in the early G1 phase (Figure 2.4). There, it also regulates DNA damage response 
and repair, acting as an important checkpoint regulator. Dysregulation of Cdh1 
causes impaired cytokinesis, DNA re-replication and aberrant centrosome 
formation. Therefore a crucial role for Cdh1 in maintaining genomic integrity has 
been appointed (Wasch et al., 2010).  
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Figure 2.4 | Activation of Cdc20 and Cdh1 during mitosis and G1 progression. The initiation of 
DNA replication, the onset of the anaphase, cytokinesis and mitotic exit are coordinated by Cdc20 
and Cdh1 through the sequential destruction of cell cycle proteins (Figure from: Qiao et al., 2010). 
 
Another emerging role for APC/C-Cdh1 has been described. It regulates the 
decision to divide or to differentiate through degradation of inhibitors of cyclin-
dependent kinases and transcription factors, which are involved in cell cycle 
withdrawal and onset of differentiation. The stabilization of p21 and p27 via the 
downregulation of Skp2 is a key event in cell cycle withdrawal. To induce terminal 
differentiation, the destruction of the transcriptional inhibitors Id1, 2 and 4 is 
crucial. This occurs typically in in the G1 phase where the transition into G0 phase 
is made when they commit to differentiate. Examples include lens differentiation, 
the generation of cardiomyocytes, bud formation and neuronal morphogenesis, 
which will be discussed in detail in the following sections (Qiao et al., 2010). 
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2.2. Functions of APC/C and Its Targets in the Nervous System 
First indications of an implication of APC/C in the central nervous system were 
shown by mRNA expression data in neurons of the APC/C subunits APC1 and 
APC8 (Starborg et al., 1994; Zhao et al., 1998).  
Gieffers et al. (1999) reported for the first time presence of APC/C subunits and 
cdh1 in several human tissues which contain differentiated cells, including the 
adult brain. They observed that APC/C and cdh1 were ubiquitously expressed in 
fully differentiated cultured rat hippocampal neurons. In brain sections of mouse 
and human samples they detected APC/C subunits including cdh1, but not cdc20, 
in neurons of the cortex, hippocampus and cerebellum. They proposed that APC/C-
Cdh1 functions were not restricted to cell cycle regulation in proliferating cells but 
may regulate unidentified substrates for ubiquitination in differentiated cells 
(Gieffers et al., 1999). These findings initiated the search for functions of APC/C-
Cdh1 in neurons. Since then, several fundamental processes in the central nervous 
system have been described to be regulated by APC/C-Cdh1: Axonal growth and 
patterning (Konishi et al., 2004; Stegmüller et al., 2006), neuronal cell cycle exit 
(Lasorella et al., 2006), neuronal differentiation (Harmey et al., 2009) and 
neurogenesis (Delgado-Esteban et al., 2013), degradation of AMPA regulating 
homeostatic plasticity (Fu et al., 2011),  long term potentiation (Li et al., 2008) and 
long-term depression (Huang et al., 2015). Furthermore, Kim et al. (2009) 
discovered that also APC/C-Cdc20 is involved in the central nervous system as it 
controls dendrite morphogenesis in postmitotic neurons (Kim et al., 2009). 
Here a summary of experimentally identified APC/C substrates is presented, which 
are directly related to the processes in the nervous system (Table 2.2).  
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Table 2.2 | This APC/C substrates are directly involved in the regulation of various processes in 
the central nervous system. APC/C-Cdh1 and APC/C-Cdc20 regulate neurogenesis, axonal and 
dendrite growth, synaptic differentiation, synaptic regulation, cell cycle exit, neuronal survival and 
metabolic processes in neurons.  
 
 
 
 
UniProt Substrates Function Motif Coactivator Reference
Q15784
Neurogenic 
differentiation factor 2 
(Neuro D2)
Regulates presynaptic 
differentiation
D-box cdc20 Yang et al., 2009
Q9VM93 Liprin-alpha
Regulation of synaptic size and 
activity
D-box cdh1
van Roessel et al., 
2004
P42261
Glutamate receptor 1 
(GluR1)
Regulation of AMPA receptors in 
homeostatic plasticity
D-box cdh1 Fu et al., 2011
P41134
DNA-binding protein 
inhibitor (Id1)
Invovled in dendrite morphogenesis 
in neurons
D-box cdh1, cdc20 
Kim et al., 2011; 
Wang et al., 2008
P12757 SnoN
Cell-intrinsic regulation of axonal 
morphogenesis 
D-box cdh1
Stroschein et al., 
2001; Stegmüller 
et al., 2006 
Q9HCE7 Smurf1 
E3 Ubiquitin ligase that targets 
RhoA, regulates axon growth 
D-box cdh1 Kannan et al., 2012
Q02363
DNA-binding protein 
inhibitor (Id2)
Axonal growth and cell cycle exit D-box cdh1
Lasorella et al., 
2006
P48730 Casein Kinase 1 δ
Regulation of cerebellar granule cell 
neurogenesis
D-box cdh1 Penas et al., 2015 
O00716 Transcription factor E2F3
Cell cycle exit and neuronal 
differentiation
D-box cdh1 Ping et al., 2012
P07818 Cyclin B1
Maintains cell cycle exit and 
promotes neuronal survival
D-box cdh1
King et al., 1996; 
Maestre et al., 
2008
Q16875
6-phosphofructo-2-
kinase/fructose-2,6-
bisphosphatase 3 (Pfkfb3)
Downregulates glycolytic pathway in 
in neurons, prevents 
neurodegeneration  
KEN box cdh1
Rodriguez-
Rodriguez et al., 
2012
O94925
Glutaminase kidney 
isoform, mitochondrial
Regulates the levels of the 
neurotransmitter glutamate in 
neurons
KEN box cdh1
Colombo et al., 
2010 
Q06787  FMRP
Drives mGluR-dependent synaptic 
plasticity
D-box cdh1 Huang et al., 2015
Q8IWQ3
Brain-specific kinase 2 
(BRSK2)
Serine/threonine kinase, regulates 
polarization of neurons and 
axonogenesis, cell cycle progress 
and insulin secretion
KEN box, D-box cdh1 Li et al., 2012 
Q7JUM5
Drosophila MCPH1 
(isoform B)
Cell cycle; Homolog of a causative 
gene for autosomal recessive 
primary microcephaly in human
D-box cdh1
Hainline et al., 
2014
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2.2.1. APC/C-Cdh1 and axonal growth in the cerebellar cortex 
Axon growth is essential in the developing brain but it is very limited in the adult 
brain due to intrinsic and extrinsic inhibition. The activity of APC/C-Cdh1 is 
required for the inhibition of axon growth in mammalian neurons (Konishi et al., 
2004). This was shown by using RNA interference to acutely knockdown cdh1 in 
primary cerebellar granule neurons, which had no effect on the survival of the 
neurons, but induced a change in the morphology of neuronal processes. They 
measured growth of dendrites and axons (marked by the somato-dendritic marker 
MAP2 and the axonal marker Tau) and observed that the cdh1 knockdown caused 
a substantial increase in growth rate and significant elongation of the axonal length, 
but not of dendrites. Moreover, they generated a dominant interfering form of the 
subunit APC11 in granule neurons which caused an induction of axonal growth. 
The inhibition of APC/C by Emi1 had the same effect. This was also tested in vivo 
by using shcdh1 plasmid in the cerebellar cortex of P6 rat pups. The shcdh1 and an 
expression plasmid encoding GFP were injected and then the animals were 
subjected to electroporation. Five days later they isolated the cerebellum and it was 
analysed using immunohistochemistry. The injection of a control plasmid was used 
to confirm cdh1 specificity. Shcdh1expressing granule neurons were drastically 
altered and several axons grew abnormally off a regular track in parallel fibres. 
Furthermore, cdh1 knockdown was shown to override the effect of adult rat myelin 
on axonal growth inhibition. The authors suggested that APC/C-Cdh1 has a cell-
autonomous function in axonal growth and patterning of granule neurons in the 
developing cerebellum in vivo and that it may also contribute to the inhibition of 
axon growth in injured neurons in the adult brain (Konishi et al., 2004).     
Stegmüller et al. (2006) reported a mechanism by which the ubiquitin ligase 
APC/C-Cdh1 controls axonal morphogenesis. They showed that APC/C-Cdh1 
operates in the nucleus for inhibition of axonal growth by targeting the 
transcriptional corepressor SnoN for ubiquitin-dependent proteasomal degradation. 
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The knockdown of SnoN in primary cerebellar granule neurons reduced the growth 
of axons and inhibited the previously observed growth of axons when 
simultaneously using cdh1 RNA interference. High protein levels of SnoN 
stimulated the growth of axons. This was also confirmed in vivo by knockdown of 
SnoN in the developing rat cerebellum, which caused inhibition of elongation of 
granule neuron parallel fibres. Thereby, the authors described a mechanism of 
axonal growth regulation through APC/C-Cdh1 and the SnoN substrate. 
Additionally, it was shown that the APC/C-Cdh1/SnoN pathway is co-regulated by 
TGFβ/Smad2. Smad2 signalling influences axonal growth, as it associates with 
SnoN in neurons and recruits APC/C-Cdh1 to its substrate. Inhibition of TGFβ 
inactivates Smad2 signalling, which caused an increase in SnoN and thereby 
axonal growth was stimulated (Stegmüller et al., 2008).  
Furthermore, the inhibitor of DNA binding 2 (Id2) protein is involved in axon 
growth regulation as APC/C-Cdh1 substrate. In the developing nervous system Id2 
is an inhibitor of neurogenic basic helix-loop-helix transcription factors, enhances 
cell proliferation and promotes tumor progression. It is a very unstable protein, 
which is degraded by APC/C-Cdh1 as the cells enter a quiescent state. Depletion of 
cdh1 causes the stabilisation of Id2. High levels of Id2 enhance axonal growth in 
cerebellar granule neurons. Activation of helix-loop-helix transcription factors 
induces the expression of genes with inhibitory effect on axonal growth, e.g. the 
Nogo receptor. Therefore, degradation of Id2 by APC/C-Cdh1 allows the 
accumulation of axon growth inhibitors (Lasorella et al., 2006).  
Another novel APC/C-Cdh1 target is Smurf1, an E3 ubiquitin ligase, which is also 
involved for axon growth regulation. Smurf1 had previously been related to axon 
initiation and growth of neurons (Cheng et al., 2011; Sato and Heuckeroth, 2008). 
Knockdown of Smurf1 in cerebellar granule neurons causes a decrease in axonal 
length. In vivo knockdown of Smurf1 causes a disruption of neuronal migration in 
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the developing cerebellar cortex. When Smurf1 is stabilized it overcomes myelin-
induced inhibition of axon growth. Furthermore, it was shown that a protein 
targeted by Smurf1, the small GTPase RhoA, has a crucial role in axon growth 
inhibition. APC/C-Cdh1 acts upstream of the Smurf1/RhoA pathway in the control 
of axon growth, and it was shown that this pathway acts in parallel to the 
previously identified substrates SnoN and Id2 (Kannan et al., 2012).   
 
2.2.2. APC/C-Cdh1 and neurogenesis 
APC/C-Cdh1 coordinates the cell cycle exit and initiates the differentiation of 
neural progenitors.  
In Sox2-Cre cdh1-conditional knockout mice (embryo-restricted cdh1 knock-out), 
the cell cycle exit is delayed in neural progenitor cells and that causes replicative 
stress and p53-mediated apoptotic death. This results in increased length of the 
ventricular and the subventricular zone, while cortical neurons are decreased in 
number and a reduction of cortical size occurs. It was shown that these aberrations 
occur due to a dysregulation of Skp2, a F-box protein that had previously been 
described as a substrate of APC/C-Cdh1 (Bashir et al., 2004). The degradation of 
Skp2 promotes the stabilization of p27, which is an inhibitor of Cdk’s, and that 
results in cell cycle exit. In this cdh1 knock-out model, Skp2 accumulates and that 
results in delayed cell-cycle exit (Delgado-Esteban et al., 2013). It was also shown 
that E2F3A, an APC/C-Cdh1 substrate, decreases steadily in differentiating 
neuroblastoma cells in an APC/C-Cdh1 dependent manner. This was accompanied 
by an increase in p27 and a decrease in cyclin A (Ping et al., 2012).  
The phenotype of cdh1 knockout mice resembles the one of microcephaly. 
Interestingly, the Drosophila homolog of MCPH1 B, a protein encoded by a 
causative gene of autosomal recessive primary microcephaly, was identified as a 
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substrate of APC/C-Cdh1 (Hainline et al., 2014). Further research would be needed 
to deepen the understanding of the involvement of APC/C-Cdh1 in microcephaly.   
Eguren et al., (2013) analysed mice in which cdh1 was eliminated in the 
developing nervous system by a Cre recombinase which was expressed under a 
nestin regulatory sequence. They suffered defects in neural progenitor cells, 
accumulation of cerebrospinal fluid in the brain cavities, and death. Cdh1 is 
required during neurogenesis as it prevents replicative stress. In cdh1-depleted 
neuronal progenitors, replicative stress induces p53-dependent apoptosis. The 
ablation of p53 prevents apoptosis, but not replicative stress, which results in the 
presence of damaged neurons in the adult brain (Eguren et al., 2013).  
Penas et al. (2015) showed that casein kinase 1 (ck 1) δ is an APC/C-Cdh1 
substrate, which regulates neurogenesis in cerebellar granule cells.  The ck 1 family 
is highly conserved in eukaryotes and controls a broad spectrum of biological 
processes, e.g. circadian rhythms, signal transduction, apoptosis, neurite outgrowth. 
It was shown that ck 1 δ is an APC/C-Cdh1 substrate in a D-box dependent 
manner.  Knockout of cdh1 in cerebellar granule cell progenitors (GCP’s) stabilizes 
ck 1 δ. APC/C-Cdh1 normally downregulates the kinase during cell cycle exit and 
thereby controls the balance of proliferation and cell cycle stop in the developing 
brain. Overexpression of the kinase results in increased proliferation, while loss of 
ck 1 δ inhibits the expansion of GCP’s (Penas et al., 2015).  
 
2.2.3. APC/C-Cdh1 in the regulation of synaptic plasticity  
The adaptive response of the nervous system to experience is thought to be 
represented by synaptic plasticity. The physiological correlation of learning and 
memory has been characterized by two forms of synaptic plasticity: Long-term 
potentiation (LTP) and long-term depression (LTD). Synaptic plasticity is often 
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affected in neurological diseases. Several studies showed that ubiquitin-dependent 
regulations are involved in synaptic plasticity. In the recent years the role of 
APC/C-Cdh1 has been studied in this context. In the following section the main 
findings of the involvement of APC/C-Cdh1 in synaptic plasticity will be 
summarized. 
In the nematode C. elegans APC/C regulates the abundance of GLR1, a non-
NMDA glutamate receptor (GluR). Mutations in APC/C subunits increased GLR1 
in the ventral nerve cord, while the overexpression of ubiquitin decreased GLR1 in 
synapses. APC/C mutants have increased synaptic strength and that caused defects 
in locomotion. However, based on amino-acid sequence analysis GLR1 seems to 
be unlikely a direct target of degradation of APC/C and the authors hypothesized 
that it is possible that GLR1 might be associated to a scaffolding protein that is 
targeted for ubiquitination (Juo and Kaplan, 2004).  
Moreover, in the mammalian brain in rodents, a role of APC/C-Cdh1 in synaptic 
plasticity was shown. It is involved in the regulation of homeostatic plasticity, 
which is the counteraction on synaptic strength to unrestrained changes and thereby 
the neuronal output is maintained. This occurs when chronic elevation of synaptic 
activity reduces the amplitude of miniature excitatory postsynaptic currents 
(mEPSC). EphA4 belong to the Eph receptor family that bind ephrins, and that are 
involved in synaptic plasticity and memory by regulating excitatory 
neurotransmission and play a role in cytoskeleton remodelling. They are activated 
by elevated synaptic activity. This leads to phosphorylation of EphA4, which 
causes its association to APC/C-Cdh1 and thereby targets GluR1 for degradation, 
resulting in an attenuation of the mEPSC amplitude. In neurons in vitro the 
depletion of cdh1 prevented the EphA4-dependent degradation of GluR1 (Fu et al., 
2011).  
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In Drosophila, APC/C subunits and cdh1 are located at neuromuscular synapses. 
Loss of function of APC/C subunits leads to overgrowth of synaptic boutons. That 
was accompanied by altered synaptic transmission and lead to an increase in the 
amount of postsynaptic glutamate receptors. This was correlated to an increase in 
Liprin-alpha, a possible substrate of APC/C (van Roessel et al., 2004).  
 
APC/C-Cdh1 and LTP  
Li et al. (2008) showed that APC/C-Cdh1 has a role in learning and memory. In 
this study cdh1 deficient mice were analysed. The lack of cdh1 (a gene-trap 
construct was inserted in intron 5 of cdh1) causes early lethality in homozygous 
mice. In heterozygous mice, where a reduction of cdh1 of 50% had occurred, late-
phase long-term potentiation (LTP) in the hippocampus was impaired. 
Furthermore, they showed defects in contextual fear-conditioning (Li et al., 2008).  
In a conditional knockout model, in which cdh1 was specifically eliminated in 
neurons from the onset of differentiation by using a neuron-specific enolase 
promotor, a role for cdh1 in long-term potentiation was confirmed. Hippocampal 
slices from cdh1 knock-out mice displayed reduced late-phase LTP. These animals 
exhibited impaired flexibility in behavioural tasks and reduced extinction of 
associative fear memory. However, in this model, spatial memory tasks were not 
affected (Pick et al., 2013).  
In an alternative conditional knockout model for cdh1, based on a cre-lox system, 
cdh1 was eliminated in adult mice from excitatory neurons in the forebrain, to test 
the effects of post-developmental removal of cdh1. In coronal slices from the 
amygdala from these cdh1 knock-out mice, late-phase LTP was impaired compared 
to wildtypes when thalamic afferents were stimulated and recorded in the 
amygdala. After the LTP-inducing stimulation the proteins Shank1, a scaffolding 
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protein and the NMDAR subunit, NR2A, accumulated in the amygdala in the cdh1 
knockout. Coherently, contextual and cued fear memory was impaired. However, 
in this cdh1 mouse model, no change in hippocampal LTP was detected (Pick et 
al., 2013). 
  
APC/C-Cdh1 and LTD 
Huang et al. (2015) reported for the first time a role of APC/C-Cdh1 in the 
regulation of LTD. They created a forebrain-specific conditional knockout of cdh1 
(mice carrying Cre recombinase, which is expressed in neocortical and 
hippocampal excitatory neurons, under the control of the forebrain-specific driver 
Emx) and showed that metabotropic glutamate receptor (mGluR)-dependent LTD 
is impaired in the hippocampus in this mouse model. It was shown in the CA1 
layer in the hippocampus that the induction of mGluR-dependent LTD is 
dysregulated, but not NMDAR-dependent LTD.  
In this study it was also reported that the fragile X syndrome protein (FMRP) is a 
substrate of APC/C-Cdh1. FRMP governs the mGluR-dependent LTD. A major 
feature of the fragile X syndrome is exaggerated mGluR-dependent LTD. 
Surprisingly, mGluR-LTD is regulated by cdh1 in the cytoplasm rather than in the 
nucleus (Huang et al., 2015).   
 
In the following Table 2.3, cdh1 knock-out models, which were discussed in the 
previous sections, are summarized. Most of them show phenotype defects related 
to the nervous system.  
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Table 2.3 | Summary of cdh1 knock-out mouse models and their phenotype defects in the 
nervous system.   
 
2.2.4. Functions of APC/C-Cdc20 in the nervous system  
The regulation of synapse development depends on ubiquitin-proteasome 
pathways, however it was not clear which E3 ubiquitin ligases are involved in the 
regulation of presynaptic differentiation (DiAntonio and Hicke, 2004).  
It was shown in the rat cerebellar cortex and in primary post-mitotic neurons that 
APC/C-Cdc20 controls presynaptic differentiation by targeting the transcription 
Cdh1 knock-out (Fzr1  gene) Description Phenotype defetcs Reference
homozygous mice Cdh1gt/gt 
(intercrossed heterozygous mice Cdh1gt) 
early embryonic lethality (died 
at   ̴ E9.5),  replicative 
senescence
prematurely of fibroblasts
Li et al., 2008
heterozygous Cdh1gt (50% cdh1 
reduction)
defects in hippocampal late 
phase LTP,  deficient in 
contextual fear-conditioning
Li et al., 2008
loss of genomic stability, 
increased susceptibility to 
spontaneous tumours
García-Higuera et al., 
2008
replicative stress, p53-
mediated apoptotic death, 
alterations in neurogenesis 
resembling  microcephaly
Delgado Esteban et 
al.,  2013
Two loxP sites eliminate exons 
2 and 3 from the Frz1  gene, cre 
recombinase expressed 
under nestin regulatory 
sequences
conditional cdh1 knockout mice, knock 
out restricted to the developing 
nervous system
hypoplastic brain and 
hydrocephalus
Eguren et al., 2013
Two loxP sites eliminate exons 
2 and 3 from the Frz1  gene, cre 
recombinase expressed under a 
CaMKII promoter
conditional cdh1 knockout mice, 
deletion of cdh1 in excitatory neurons 
in the adult hippocampus and forebrain 
late in brain development
impaired memory,  impaired 
long-term potentiation in 
amygdala slices
Pick et al., 2013
Two loxP sites eliminate exons 
2 and 3 from the Frz1 gene,  cre 
recombinase exressed under a 
neuron-specific enolase 
promoter 
conditional cdh1 knockout mice, 
restricting neuronal cdh1 expression 
from the beginning of development in 
neurons
impaired behavioral flexibility 
and extinction of previously 
consolidated memories, 
impaired long-term 
potentiation in hippocampal 
slices
Pick et al., 2013
Two loxP sites eliminate exons 
2 and 3 from the Frz1 gene, Cre 
recombinase expressed under 
the control of the forebrain-
specific driver Emx
conditional cdh1 knockout mice, 
deletion in 
neocortical and hippocampal excitatory 
neurons but 
not GABAergic interneurons 
profoundly impaired induction 
of mGluR-dependent long-term 
depression in the hippocampus 
Huang et al., 2015
Two loxP sites eliminate exons 
2 and 3 from the Frz1  gene, cre 
recombinase expressed under 
the Sox2 promoter 
conditional cdh1 knockout mice, embry-
restricted Cdh1 knock-out
Gene-trap (gt) construct, 
inserted into intron 5 of Fzr1 , 
generating a dysfunctional 
allele of Fzr1
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factor NeuroD2 for degradation. The target gene of NeuroD2, Complexin II, acts at 
presynaptic sites to suppress presynaptic differentiation. This finding identifies the 
ubiquitin signalling pathway APC/C-Cdc20 as a major regulator of neuronal 
plasticity and connectivity in the brain (Yang et al., 2009).  
Kim et al. (2009) discovered that APC/C-Cdc20 is required for dendrite 
morphogenesis in post-mitotic neurons in the mammalian brain. It was shown that 
Cdc20 promotes growth and maintenance of dendritic arbores. It is enriched at the 
centrosome in neurons, where it is regulated by the class II b histone deacetylase 
HDAC6. In this study they also identified Id1 as a target of APC/C-Cdc20, which 
inhibits dendrite growth and is localized at the centromere (Kim et al., 2009; Puram 
et al., 2010).   
 
2.3. Alzheimer’s Disease: A Short Introduction 
The majority of AD cases arise sporadically. Only in 1-5% of all cases is the 
disease inherited in an autosomal dominant pattern. Specific gene defects, like 
those of amyloid beta precursor protein (APP) or presenilins 1 and 2 (PS1 and 
PS2), were identified. Mutations in any of these genes are sufficient to cause a 
heritable form of AD. The majority of mutations in these genes influence β-site 
APP-cleaving enzyme (BACE1) and γ-secretase cleavages, which produce the 
neurotoxic peptide amyloid beta1-42 (Aβ) (Price et al., 1998; Purves et al., 2004; 
Golde et al., 2011). In sporadic AD cases, mutations in certain alleles of the Apo E 
gene are known to increase the risk for AD (Bertram et al., 2008; Perrin et al., 
2009).  
However, there is a common pathogenic cascade of anomalies in AD, which results 
from both inherent and sporadic forms of AD. The pathological hallmarks of AD 
are the deposition of plaques of amyloid peptides and the formation of 
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neurofibrillary tangles (NFTs). The first of the two main hypothesis about AD 
describes the “amyloid cascade” as a common denominator of AD. It proposes that 
the accumulation of the toxic peptide Aβ is critical to the onset of the pathogenesis 
of AD. In neurons, APP is cleaved by β- and γ-secretases in endocytic 
compartments and in the plasma membrane, producing Aβ. These peptides are 
liberated to the extracellular space and where they form a major component of 
amyloid plaques (Buxbaum et al., 1998). Although these observations suggest that 
the accumulation of Aβ is the major initiator of the disease, the density of NFTs 
correlates more with the severity of the dementia. NTFs are intracytoplasmic 
inclusions in cell bodies, proximal dendrites and axons of affected neurons. They 
are mainly constituted by hyper-phosphorylated aggregates of the microtubule-
associated protein tau. In normal conditions tau stabilizes tubulin and is therefore 
critical for microtubule assembly and stability. It was suggested that there might be 
a various molecular signalling connection between Aβ and tau pathology, whereby 
Aβ might initiate or enhance the phosphorylation of tau (Lloret et al., 2015).  
Additional to these pathological hallmarks of AD, several other alterations have 
been described in the disorder, such as oxidative stress, ectopic cell cycle re-entry, 
impaired LTP, excitotoxicity and dysregulations of various signalling pathways. 
Some of these events can be related to altered APC/C activity, and we suggest that 
this might play a crucial role in the onset and in the pathophysiology of the disease.  
 
2.3.1. The ectopic cell cycle in AD and its relation to APC/C-Cdh1 
Once cells are committed to differentiate, they enter in the G0 phase in the cell 
cycle in a quiescent state. Neurons in adult brain are terminally differentiated cells 
are generally incapable of re-entering the cell cycle. This quiescent state underlies 
an active degradation of cell cycle related proteins. The re-entrance in an erroneous 
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departure of G0 into the G1 phase and S phase was related to neurodegeneration 
(Almeida et al., 2005).  
It has been reported that the reactivation of an ectopic cell cycle in neurons occurs 
in AD. These neurons exhibit elevated levels of cell cycle markers compared to age 
matched controls (Smith et al., 1995; McShea et al., 1997; Nagy et al., 1997; 
Vicent et al., 1997). Moreover, progression through the S-phase of these neurons 
has been demonstrated, as they have elevated markers of DNA replication (Bonda 
et al., 2009).  
In neuron cell culture, Aβ induces cell cycle re-activation resulting from increased 
levels of cdk’s and cyclins. Neurons progress through the S-phase and replicate 
their DNA, but enter into apoptosis before mitosis (Copani et al., 2007). APC/C-
Cdh1 targets the degradation of cyclin B1, a cell cycle protein that accumulates in 
neurons in AD brains (Vicent et al., 1997).  
 
 
 
 
 
 
 
 
Figure 2.5 | Schematic representation of the ectopic cell cycle re-entry in post-mitotic neurons. 
Under normal conditions terminally differentiated neurons exit the cell cycle and remain in G0. Toxic 
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stimuli like Aβ, can induce cell cycle re-entry. In G2, cyclin B1 accumulates, before neurons undergo 
mitosis they enter into apoptosis. 
 
A protein that has an important role in keeping up a post-mitotic status of neurons 
is cdk5, a non-traditional cdk. It is highly expressed in differentiated neurons and it 
is involved in the regulation of cell differentiation and migration, synapse 
formation and synaptic plasticity (Lopes et al., 2011). It was shown that neurons re-
enter the cell cycle after Aβ treatment, and that this was accompanied by a 
translocation of cdk5 from the nucleus to the cytoplasm. When the nuclear export 
of cdk5 is blocked pharmacologically, neurons do not re-enter the cell cycle after 
the treatment. In cdk5
-/-
 mutant brains of mice, cell cycle re-entry occurred in post-
mitotic neurons, giving further evidence that cdk5 acts as a cell cycle suppressor 
(Zhang et al., 2008). Furthermore, cdk5 was shown to be activated in neurons in 
culture by an excitotoxic stimulus. Maestre et al. (2008) showed that cdk5 
phosphorylates cdh1 which stabilizes cyclin B1 and induces neuronal apoptosis. 
 
2.3.2. Impaired neurogenesis in AD and its relation to APC/C-Cdh1  
A growing body of evidence suggests that neurogenesis is impaired in AD. 
Enhanced neurogenesis in the adult hippocampus represents an early critical event 
in the course of AD (Mu and Gage, 2011). An increased number in proliferating 
progenitors was detected in APP/PS1 using bromodeoxyuidine (BrdU) staining 
(Yu et al., 2009). However, although proliferation of neuronal progenitors is 
increased, it was shown that the newly generated neurons do not become mature 
neurons in the dentate gyrus of AD brains (Li et al., 2008). 
Furthermore, Crews et al. (2011) showed that aberrant cdk5 signalling is involved 
in defects in neurogenesis in AD. In an in vitro model of neuronal progenitor cells, 
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which were exposed to Aβ and infected with a viral vector expressing p35, they 
observed neurite outgrowth and impaired maturation. This was reversed by 
inhibition of cdk5. Moreover, in a transgenic mouse model of AD in vivo, the 
inhibition of cdk5 rescued impaired neurogenesis (Crews et al., 2011). 
It has been reported that cdk5 phosphorylates cdh1 (Maestre et al., 2008), 
suggesting that the ubiquitin ligase which has a major role as a regulator of 
neuronal progenitors, might be involved in impaired neurogenesis in AD. 
Furthermore, enhanced proliferation of neuronal progenitors together with decrease 
in mature neurons, which has been observed in AD, is in line with the phenotype of 
cdh1 knock-out models.  
 
2.3.3. Oxidative stress in AD and its relation to APC/C-Cdh1 
AD has long been related to the occurrence of oxidative stress. Aβ has been shown 
to cause oxidative stress through the interference with normal electron flow caused 
by the interaction of Aβ with heme groups in the mitochondrial membrane. This 
results in the production of reactive oxygen species and causes damage (Lloret et 
al., 2008; Viña et al., 2011). Besides the direct cause of ROS by Aβ, the toxic 
peptide induces alterations in various signalling ways in neurons, which were 
related to oxidative stress and neurodegeneration. Among these, it was shown that 
the downregulation of APC/C-Cdh1 induces impaired regulation of the oxidant and 
antioxidant homeostasis in neurons.  
Neurons are the cells in the brain which have the highest energy consume with a 
comparatively low rate of glycolysis. They metabolize glucose through the 
pentose-phosphate pathway (PPP), which helps them to maintain their antioxidant 
status by regenerating reduced glutathione. They are unable to upregulate 
glycolysis due to low levels of 6-phosphofructo-2-kinase/fructose-2, 6-
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bisphosphatase-3 (pfkfb3), the enzyme that generates fructose-2, 6-bisphosphate. 
This is the most potent activator of of the 6-phosphofructo-1-kinase (pfk1), one of 
the main regulators of glycolysis. Pfkfb3 levels are downregulated by APC/C-
Cdh1. The inhibition of cdh1 in neuron culture leads to increased levels of pfkfb3 
resulting in activation of glycolysis. Less glucose is used for the PPP, which results 
in oxidative stress and apoptosis (Herrero-Mendez et al., 2009). Furthermore, it 
was shown that an excitotoxic stimulus inhibits APC/C-Cdh1 activity, leading to an 
accumulation of pfkfb3, causing neurodegeneration (Rodriguez-Rodriguez et al., 
2012).   
 
 
 
 
 
 
 
2.3.4. Excitotoxicity in AD and its relation to APC/C-Cdh1 
The amino acid L-glutamate is the major excitatory neurotransmitter in the brain 
and spinal cord. It is mostly synthesized in neurons through the following ways: 
 The most prevalent precursor of glutamate in synaptic terminals is 
glutamine. The conversion from glutamine to glutamate is driven by the 
phosphate activated glutaminase in mitochondria. Glutamate directed to act 
as neurotransmitter is compartmentalized in synaptic vesicles. Glutamate is 
Figure 2.6 | Schematic representation of 
pfkfb3-induced neurodegeneration. High 
levels of pfkfb3 stimulate glycolysis, which 
reduces glucose metabolism through the 
pentose-phosphate pathway (PPP). Reduced 
glutathione (GSH) is a potent antioxidant 
enzyme. This causes oxidative stress and 
neurodegeneration in neurons.   
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released at neuronal terminals and the majority of glutamate is taken up by 
surrounding glia cells (transport by e.g. GLT). There, glutamate is 
converted to glutamine through glutamine synthetase, a cytosolic enzyme 
of astrocytes and oligodendrocytes which is not expressed in neurons. 
Glutamine, which does not have a neurotransmitter function, is then 
transported (SN1/SN2 transporters) to neurons where it is again converted 
to glutamate. This cycle is called the ‘glutamate-glutamine cycle’.  
 Reuptake of neurons at glutamatergic nerve terminals has been shown for a 
GLT isoform.  
 Glutamate can also be synthesized by transamination. Glucose is converted 
to α-ketoglutarate in the tricarboxylic (TCA) cycle, which can be converted 
to glutamate.  
 
 
 
 
 
 
 
 
 
Figure 2.7 | Glutamate-Glutamine metabolism in neurons and astrocytes. Figure from: Synaptic 
Plasticity: Gliotransmission and the tripartite synapse (Santello et al., 2012).  
35 
 
Glutamate binds to receptors that can be divided into two broad categories: 
ionotropic (iGluR) and metabotropic (mGluR) receptors. iGluR are ligand gated 
channels, where the channel opens directly by ligand binding, while mGluR are G-
protein coupled receptors that gate channels indirectly through second messengers. 
There are three major subtypes of iGluRs: N-methyl-D-aspartate (NMDA), α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate 
receptors.  
The NMDA receptor is widespread throughout the CNS. It mediates post-synaptic 
Ca
2+
 as well as Na
+
 and K
+
 influx when activated by glutamate and glycine. The 
intracellular rise of Ca
2+ 
activates various calcium-dependent signalling cascades. 
These biochemical signals can lead to long lasting changes in synaptic strength. 
Long term synaptic plasticity is important during development and also for the 
regulation of neuronal circuits in the adult brain involved in memory storage. In 
particular, long term potentiation (LTP), mediated by e.g. the calcium-calmodulin-
dependent protein kinase II (CaMKII) depends on glutamate receptor activation 
(Kandel et al., 2013; Brady et al., 2011).  
Excitotoxicity, refers to the injuries caused by excessively high concentration or 
prolonged exposure of glutamate. It is a pathological phenomenon in various 
diseases, such as stroke, Huntington’s disease and AD. Increased glutamate causes 
an overload of Ca
2+
 in neurons which is neurotoxic, leading to degradation of 
proteins, membranes and nucleic acids, induces oxidative stress, altered synaptic 
plasticity, apoptosis and necrosis (LaFerla el al., 2002; Dong et al., 2009) (see 
Figure 2.8).  
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Figure 2.8 | Schematic summary of excitotoxicity in neurons. Excessive glutamate levels lead to 
prolonged opening of glutamate receptors (e.g. NMDA receptors) and increased entrance of Ca2+ 
ions. This induces various processes leading to neurotoxicity.   
 
Furthermore, some signalling cascades have been described, which are altered by 
excitotoxicity. Among these, one can be linked to APC/C-Cdh1. High levels of 
intracellular Ca
2+ 
activate calcium dependent proteases and phospholipases, which 
alter the cyclin dependent kinase 5 (cdk5) signalling. The Ca
2+
-dependent protease 
calpain stimulates the cleavage of p35 to the more stable p25, an activator of cdk5. 
Excessive cdk5-p25 activation can, among other toxic effects, lead to hyper-
phosphorylation of cytoskeletal proteins, like tau. It was also reported that a 
dysregulation of Ca
2+
 homeostasis enhances the production of Aβ (Bordji et al., 
2011).  
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Therefore, cdk5 has been proposed to be an attractive candidate to link Aβ toxicity 
and tau phosphorylation (Lopes and Agostinho, 2011; Lloret et al., 2015). 
Additionally, increased cdk5 levels lead to an activation of further catabolic 
enzymes, which degrade neuronal structural proteins that can lead to a cytoskeletal 
breakdown (Hynd et al., 2004).  
Experimental evidence has shown that Cdk5-p25 phosphorylates cdh1 in 
excitotoxicity, which demonstrates a direct link between the AD-related kinase 
cdk5 and the ubiquitin ligase APC/C-Cdh1 (Maestre et al., 2008).   
 
2.3.5. LTP impairment in AD and its relation to APC/C-Cdh1  
Defects in synaptic plasticity often appear in neurobiological disease, such as in 
AD (Chen et al., 2002; Koch et al., 2012). It was shown in APP/PS1 mice that they 
have defects in LTP (Gengler et al., 2010). Alterations of APC/C-Cdh1 have been 
widely related to impaired synaptic plasticity, LTP and LTD (see section 2.2.3). 
EphA4 receptors, which are involved in excitatory neurotransmission, interact with 
APC/C-Cdh1 to stimulate the degradation of GluR1. Simón et al. (2009) reported 
in mouse models of AD changes in hippocampal Eph receptors appear before the 
onset of memory decline. They found reduced EphA4 and EphB2 levels in the 
hippocampus (Simón et al., 2009). These data suggest that the interaction of 
EphA4 and APC/C-Cdh1 signalling might be involved in LTP deficiency in AD 
models. However, more research will be needed to clearly demonstrate their role in 
LTP impairment in AD.   
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2.4. Summary of APC/C Substrates in the Nervous System  
In the previous sections major functions of APC/C and their substrates in the 
nervous system were discussed, and how some of them are related to AD. Based on 
these data we built up a hypothesis that paved the way for the investigation of 
APC/C in AD in this project. At the end of this introductory chapter, a graphical 
summary of APC/C and its substrates in the nervous system is presented (Figure 
2.9). 
 
 
 
 
 
 
 
 
 
 
Figure 2.9 | Summary of APC/C-Cdh1 and APC/C-Cdc20 substrates in the nervous system. They 
are implicated in regulation of axon growth, dendrite morphogenesis, glutamate metabolism and 
glycolysis, neurogenesis, maintenance of cell cycle exit, presynaptic differentiation and synaptic 
plasticity.  
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3. HYPOTHESIS & OBJECTIVES  
Many experimental evidences have shown a major role of APC/C in the nervous 
system, underlying a complex regulation. We spotted a link between the ubiquitin 
ligase and AD, when it was described that cdk5 phosphorylates cdh1 in 
excitotoxicity, a kinase which has been shown to be dysregulated in AD. 
Furthermore, accumulation of various targets of APC/C has been related to 
neurodegeneration. Based on these facts, we hypothesized that APC/C-Cdh1 might 
be involved in the pathophysiology of AD.  
First, we were interested in evaluating whether Aβ affects cdh1 protein steady state 
levels and the activity of the ubiquitin ligase in vitro. Then, it should be determined 
whether this is mediated by cdk5 and if other kinases or phosphatases regulate 
cdh1 in neurons.  
The second main goal was to describe if there was a relevant regulation of APC/C-
Cdh1 of glutaminase in neurons, which was previously described as a target of the 
ubiquitin ligase in lymphocytes (Colombo et al., 2010). The regulation of 
glutaminase by APC/C might be of potential great importance, as this would link 
APC/C activity with glutamate metabolism in neurons. Alterations in glutamate 
metabolism and excitotoxicity play a major role in AD. Then we addressed if the 
impaired APC/C signalling caused neurodegeneration.  
This can be carried out by in in vitro assays, but finally this should be tested in the 
mouse model APP/PS1, which is commonly used in AD research. Based on this 
hypothesis, we defined the objectives listed below.   
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1. Determination of the effect and mechanism of Aβ on the cdh1 steady state 
protein level in neurons in vitro. 
 
2. Analysis of upstream regulators of cdh1 in neurons in vitro. 
 
3. Measurement of protein levels of AD-related substrates of APC/C-Cdh1 in 
neurons in vitro upon Aβ treatment. 
 
4. Determine the regulation of the ubiquitin ligase of its substrate glutaminase 
in neurons and measure further downstream effects of this regulation on 
glutamate, ammonia and Ca
2+
 levels. 
 
5. Test whether APC/C-Cdh1 and glutaminase dysregulation is involved in 
neurodegeneration. 
 
6. Investigate the effect of Aβ and glutamate on APC/C-Cdh1 and its 
substrates in vivo.  
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4. MATERIAL & METHODS  
 
4.1. Material and Equipment 
4.1.1. Buffers, solutions and mediums 
 APS 10% [10% (w/v) ammonium peroxo disulphate p.a.] 
Dilute 1 g ammonium peroxo disulphate p.a. in 10 ml dH2O, stored 
in 1 ml aliquots at 4°C. 
 Blocking solution [5% (w/v) non-fat dry milk or BSA] 
Dilute 5 g non-fat dry milk or BSA in 100 ml 1x TBST. Prepared 
fresh, stored at 4°C. 
 Immunoblot transfer Buffer [25 mM Tris, 190 mM glycine, 20% (v/v) 
methanol p.a.] 
Add 3 g Tris, 14,4 g glycine and 200 ml methanol p.a. to 1000 ml 
dH2O, stored at RT. 
 Lysis Buffer [50 mM Tris, 2% (w/v) SDS, 10% (v/v) glycerol]  
Dilute 0,927 g Tris in 100 ml ddH2O and bring it to pH 6.8. Take 
83 ml and add 2 g SDS and 10 ml glycerol.  
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 SDS 10% [10% (w/v) sodium dodecyl sulfate p.a.] 
Dilute 1 g sodium dodecyl sulfate p.a. in 10 ml dH2O, stored in 1 
ml aliquots at RT. 
 SDS gel-loading buffer 1x [60 mM Tris HCl pH 6.8, 3% (w/v) SDS, 10% 
(v/v) glycerol, 0,005% (w/v) bromophenol blue, 5% (v/v) 2-
mercaptoethanol] 
Add 0,6 ml 1 M Tris HCl pH 6.8, 1,5 ml 20% (w/v) SDS, 1 ml 
glycerol, 50 μl 1% (w/v) bromophenol blue and fill up to 9,5 ml 
dH2O, stored at RT. Prior to use 500 μl 2-mercaptoethanol is 
added. 
 Separating gel acrylamide mix 12,5% [1,5 M Tris pH 8.8, 40% (w/v) 
acrylamide/ bisacrylamide 29:1, SDS 10%, APS 10%, TEMED] 
Add 1686 µl dH2O, 1000 µl Tris 1,5 M, 1250 µl 
acrylamid/bisacrylamid, 40 µl SDS, 20 µl APS, 4 µl TEMED, 
stored at 4°C.  
 Stacking gel acrylamide mix 4% [0,5 M Tris pH 6.8, 40% (w/v) 
acrylamide/ bisacrylamide 29:1, SDS 10%, APS 10%, TEMED] 
Add 1880 µl dH2O, 750 µl Tris 0,5 M, 300 µl 
acrylamid/bisacrylamid, 30 µl SDS, 30 µl APS, 3,8 µl TEMED, 
stored at 4°C.  
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 Transfer Buffer [Tris 25 mM, 192 mM glycine, 20% (v/v) methanol] 
 
Add 6,06 g Tris, 28,8 g glycine, 400 ml methanol and fill up to 
2000 ml dH2O.  
 
 TBS [10 x TBS] pH 7.6 
            Add 24,2 Tris and 80 g NaCl, fill up to 1000 ml dH2O.  
 
 TBS-T 1x [0,1% TweenÒ]  
Dilute 100 ml 1x TBS in 900 ml dH2O, add 1 ml Tween, prepared 
fresh.  
 
 Tris-glycine electrophoresis buffer [25 mM Tris, 190 mM glycine, 0,1% 
(w/v) SDS] 
Add 15 g Tris, 71,88 g glycine, 5 g SDS and fill up to 5000 ml 
dH2O, stored at RT. 
 
 Tris HCl [1 M], pH 6.8 
Add 60,55 g Tris to 400 ml dH2O and adjust to pH 6.8 with HCl 
conc., fill up to 500 ml with dH2O, stored at RT. 
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 Tris HCl [1.5 M], pH 8.8  
Add 90,83 g Tris base to 400 ml dH2O and adjust to pH 8.8 with 
HCl conc., then fill up to 500 ml with dH2O, stored at RT.  
 
 Ponceau S staining Solution [0,2% (w/v) Ponceau S, 3% (w/v) TCA]  
Add 2 g Ponceau S (3-hydroxy- 4-(2-sulfo-4-[sulfophenylazo]-
phenylazo)-2,7-aphthalene disulphuric acid, 30 g trichloro acetic 
acid (TCA) and fill up to 1000 ml.  
 
 Phosphate-Buffered Saline (PBS), pH 7.4, 10010-056, Gibco. 
 Dulbecco's Modified Eagle Medium 1x (DMEM), 41965-062, Gibco. 
 Dulbecco's Modified Eagle Medium 1x (DMEM), 11960-044, Gibco.  
 Fetal Bovine Serum (FBS), Qualified E.U. Approved 10270-106, Gibco. 
 Penicillin-Streptomycin Antibiotics, 15140-122, Gibco. 
 
 
4.1.2. Reagents and kits 
 Fluorescence mounting medium, S3023, DAKO. 
 Folin & Ciocalteu’s phenol reagent, F9252-500ML (18 ml added to 80 ml 
ddH2O), Sigma. 
 High Capacity cDNA Reverse Transcription Kit, 4368814, Thermo Fisher. 
 High Pure PCR Template Preparation Kit, 11796828001, Roche.  
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 Luminata Classico Western HRP Substrate, WBLUC0500, Millipore.  
 Lowry Reagent, L3540-1VL (2 g added to 40 ml ddH2O), Sigma.  
 Maxima SYBR Green/ROX qPCR Master Mix (2X) K0223, Thermo 
Scientific. 
 Poly-l-lysine solution [0,01%], P4707, Sigma-Aldrich.  
 Restore Western Blot Stripping Buffer, 21059, Thermo Scientific. 
 TRIzol Reagent, 15596-026, Life technologies. 
 VECTASHIELD Mounting Medium with DAPI, H1200, Vector 
Laboratories.  
 Ammonia Assay Kit, AA0100, Sigma.  
 Apoptosis Detection Kit FITC, ANXVKF-100T, Immunostep. 
 NE-PER® Nuclear and Cytoplasmic Extraction Reagents, 78835, Thermo 
scientific. 
 
4.1.3. Fluorochromes 
 Annexin V: Alexa Fluor® 555 (555/565), A35108, Invitrogen Molecular 
Probes. 
 SYTOX® Green Nucleic Acid Stain, S7020, Invitrogen Molecular Probes.  
 Fluo-4, AM, cell permeant, F-14201, Life Technologies.  
 Hoechst, H3570, Invitrogen Molecular Probes. 
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4.1.4. Proteins 
Primary Antibodies 
CDC20, 4823, Werfen, molecular wt.: 51 kDa, source: rabbit. In this work this 
antibody was used for detection of cdh1 in immunoblots of samples of rat primary 
culture neurons (dilution: 1:1000). 
Cdh1, NBP1-54465, Novus Biologicals, molecular wt.: 55 kDa, source: mouse. In 
this work this antibody was used for detection of cdh1 in immunoblots of samples 
of rat primary culture neurons (dilution: 1:500). 
Cdh1, NBP2-15840, Novus Biologicals, molecular wt.: 55 kDa, source: rabbit. In 
this work this antibody was used for detection of cdh1 in immunohistochemical 
preparations (dilution 1:100) and for immunocytochemistry of rat primary neurons 
(1:100). 
Cdh1, ab3242, Abcam, molecular wt.: 55 kDa, source: mouse. In this work this 
antibody was used in to detect cdh1 in immunoblots (dilution 2 μg/ml) of samples 
of mouse brain homogenates. 
Cdh1, 34-2000, Invitrogen, molecular wt.: 55 kDa, source: rabbit. In this work this 
antibody was used for detection of cdh1 in immunohistochemical preparations 
(dilution: 1:100). 
Cyclin B1, 4138, Cell Signaling Technology, molecular wt.: 60 kDa, source: 
rabbit. In this work this antibody was used for detection of cyclin B1 in 
immunoblots (dilution: 1:1000) of samples of rat primary culture neurons. 
Cdk5, 2506, Cell Signaling Technology, molecular wt.: 30 kDa, source: rabbit. In 
this work this antibody was used for detection of cdk5 in immunoblots (dilution: 
1:1000) of samples of rat primary culture neurons. 
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p25/p35, 2680, Cell Signaling Technology, molecular wt.: 25, 35 kDa, source: 
rabbit. In this work this antibody was used for detection of p25/p35 in immunoblots 
(dilution: 1:1000) of samples of rat primary culture neurons. 
Glutaminase 1, 12855-1-AP, Proteintech, molecular wt.: 65 kDa, 58 kDa, source: 
rabbit. In this work this antibody was used for detection of glutaminase 1 in 
immunoblots (dilution: 1:1000) of samples of rat primary culture neurons and of 
mouse brain homogenates. 
Histon H3, ab1791, Abcam, dilution: 1:50000, molecular wt.: 17 kDa, source: 
rabbit. In this work this antibody was used for detection of histone H3 in 
immunoblots (dilution: 1:1000) of samples of the nuclear fractions of rat primary 
culture neurons.  
MAP2, M9942, Sigma, dilution: 280 kDa, 70 kDa, source: mouse. In this work this 
antibody was used for detection of Map2 in immunocytochemical preparations 
(dilution 1:100) of rat primary neurons. 
Pfkfb3, 13763-1-AP, Proteintech, molecular wt.: 75 kDa, source: rabbit. In this 
work this antibody was used for detection of pfkfb3 in immunoblots (dilution: 
1:300) of samples of rat primary culture neurons.  
α-Tubulin, sc-8035, Santa Cruz Biotechnology, molcular wt.: 55 kDa, source: 
mouse. In this work this antibody was used for detection of tubulin in immunoblots 
(dilution: 1:1000) of samples of rat primary culture neurons and samples mouse 
brain homogenates. 
β-actin, A1978, Sigma Aldrich, dilution: 1:1000, molecular wt.: 42 kDa, source: 
mouse. In this work this antibody was used for detection of actin in immunoblots 
(dilution: 1:1000) of samples of the nuclear and cytosolic of fractions of rat 
primary culture neurons. 
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Secondary Antibodies 
Anti-Mouse IgG, H&L Chain Specific Peroxidase Conjugate 401215, Calbiochem, 
dilution: 1:3000. 
Anti-Rabbit IgG, HRP-linked Antibody 7074, Cell Signaling, dilution: 1:3000. 
Anti-Rabbit IgG (H+L), F(ab’)2, Fragment (Alexa Fluor 488 Conjugate), 4412, 
dilution: 1:1000, Cell Signaling. 
Anti-Mouse IgG (H+L), F(ab’)2, Fragment (Alexa Fluor 647 Conjugate ), 4410, 
dilution: 1:1000, Cell Signaling. 
Anti-Rabbit IgG Alex Fluor 700, A21038, Molecular Probes, dilution: 2-5 
fluorophore molecules per IgG molecule. 
 
Peptides 
Amyloid-beta (1-42), Human RP10017-1, Gene Script. 
Amyloid-beta (1-42), 20276, AnaSpec. 
 
Enzymes  
L-Glutamic Dehydrogenase from bovine liver, G2626, Sigma Aldrich. 
 
4.1.5. Inhibitors 
Compound 968 (glutaminase inhibitor), 352010, Merk Millipore Calbiochem. 
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MG-132 (proteasome inhibitor), M7449, Sigma.  
proTAME (APC/C inhibitor), I-440, Boston Biochem. 
Roscovitin (cdk inhibitor), R7772, Sigma.  
 
4.1.6. Equipment 
 Analogue Block Heater, Stuart SBH130, Stuart. 
 Balance AHZ-600, Gram. 
 Biomolecular imager, ImageQuant™ LAS 4000, GE Healthcare Bio-
Sciences. 
 Confocal laser-scanning microscope, TCS SP2 scanning multiphoton and 
confocal unit with an inverted DM1RB microscope, Ar-He-Ne, LEICA 
Microsystems. 
 FACSVerse™ flow cytometer, BD Biosciences. 
 Homogenizer Rw20 DZM, Janke & Kunkel. 
 Fast Real-Time PCR System, 7900HT, Applied Biosystems. 
 Incubator Sanyo CO2, MCO-19AIC, Sanyo. 
 Lab-Tek II Chambered 1.5 German Coverglass System 155382, 155409, 
Lab-Tek. 
 Microcentrifuge, Sigma 1-14, 90616, Sigma. 
 Microscope cell culture, Eclipse Ts 100, Nikon.  
 Mid bench centrifuge, Hettich Rotina 35R, Labcare. 
 Nanodrop, 2000c, Thermo Scientific.  
 PH Meter, GLP 21, Crison. 
 Pipettes: Finnpipette F1 (0,2 µl – 2 µl), Finnpipette F1 (2 µl– 20 µl), 
Finnpipette F1 (20 µl – 200 µl), Finnpipette F1 (100 µl– 1000 µl), GH 
65970 (1 µl– 10 µl), GH 78060 (10 µl – 100 µl), Thermo scientific.   
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 Platform shaker Duomax, 1030, Heidolf. 
 Roller-mixer, 51788, Labolan. 
 Spectrophotometer, cecil 3021, Cecil. 
 TPP cell scraper, 99003, TPP. 
 TPP centrifuge tubes, 91015 (15 ml), 91050 (50 ml), TPP. 
 TPP seriological pipettes, 94005 (5 ml), 94010 (10 ml), 94024 (25 ml), 
TPP. 
 TPP tissue culture flask, 90026 (growth area 25 cm²), TPP. 
 
4.2. Primary Culture of Cortical Neurons 
Primary culture of cortical neurons was prepared from brains of Wistar rat fetus 
(14 days of gestation). Cortices were dissected mechanically, dispersed in 
Dulbecco's Modified Eagle Medium (DMEM) and filtered through a nylon net (90 
μm pores). Per brain we added 5 ml standard culture medium (DMEM 
supplemented with 10% (v/v) fetal bovine serum (FBS) and 1% antibiotics 
Penicillin and Streptomycin mix (P/S)). Three ml of the medium containing cells 
were carefully poured on poly-L-lysine-covered T-25 flask (25 cm
2
) and gently 
rocked, resulting in an average amount of cells of 1-2*10
4
 cells/cm
2
. The culture 
flasks were incubated at 37°C in a 5% CO2-containing atmosphere. Within 2 hours, 
the cells attached to the poly-L-lysine-covered culture flasks, and the supernatant 
was discarded, fresh standard culture medium was added and they were further 
incubated. Three days after plating the cells, cytosine-arabinosid (10 mM) was 
added to the culture medium, and one day later it was replaced by culture medium 
containing the half amount of cytosine-arabinosid, in order to inhibit proliferation 
of mitotic cells (e.g. glia cells, fibroblasts). The following day, the medium was 
removed and replaced by standard culture medium. After 6-7 days, we obtained a 
95% pure neuron culture, which was used for treatments (see Figure 4.1). For 
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fluorescent microscopy, neurons were seeded on poly-L-lysine covered chambered 
coverglass plates. Culture and treatment conditions were accomplished as 
described above. 
 
 
 
 
 
 
 
 
 
Figure 4.1 | Light microscope images show the development of neurons from the first day of 
isolation to differentiated neurons. On day 0 (photo was taken two hours after plating the cells) the 
cells were round and did not yet resemble neurons. After one day of culture, neurons started growing 
prolongations. After three days of culture we could observe further development of neuron cells and 
glia cells and cytosine-arabinosid was added to the culture medium. On the following day 4, the cells 
were incubated with medium containing the half concentration of cytosine. On day 5 the number of 
glia cells was clearly reduced and a further progression of growth of axonal and dendritic arbors of 
neurons was observed. On day 6 developed neurons were used for treatments.  
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4.2.1. Treatments of neurons in primary culture 
Previously, oligomeric Aβ was prepared: an alkaline solution, 100 µl of NH4 (1% 
in 1x PBS) or 20 µl DMSO, was added to 1 mg of Aβ(1-42), which dissolves 
immediately. Subsequently, 1x PBS was added to dilute the dissolved Aβ in total 
volume of 2216 µl and incubated the solution at 4°C for 24 h to allow the 
formation of oligomers. It was then used immediately or stored at -20°C and used 
within 2 months after preparation (Protocol for Aβ oligomer preparation was 
adapted from Teplow 2006, Dahlgren et al., 2002, Lambert et al., 1998).  
The culture medium was replaced by fresh culture medium by the time of the 
treatments. The components were previously mixed with the culture medium and 
after addition, the plates were gently rocked. The neurons were treated at the 
following concentrations if not indicated otherwise: Aβ (5 µM) (amyloid-beta 1-42, 
20276, AnaSpec, Fremont, USA), glutamate (500 µM) (G-1251, Sigma, St. Louis, 
USA), proTAME (12 µM) (I-440, BostonBiochem, Cambridge MA, USA), 
glutaminase inhibitor ‘compound 968’ (100 µM) (352010, Calbiochem, 
Nottingham, UK), cdk inhibitor ‘roscovitine’ (15 µM) (R 7772, Sigma, Missouri, 
USA); the incubation times are indicated in the figure legends.  
 
4.2.2. Cdh1 silencing by siRNA interference in neurons in primary culture 
For silencing of cdh1, ON-TARGETplus SMART pool silencing RNA (siRNA) 
was used with the target sequence 5’ - UGAGAAGUCUCCCAGUCAG - 3’ 
(Thermo Scientific, Rockford IL, USA). We used GenMuteTM siRNA 
Transfection Reagent, which is preoptimized for transfection of neurons in primary 
culture, (SL100568-PNN, SignaGen Laboratories, Ijamsville, USA) according to 
manufacturer’s instructions. For a T-25 flask a total volume of 3 ml (medium plus 
containing reagents) was used. Sixty minutes before the transfection, the culture 
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medium was removed and fresh culture medium was added. The siRNA (90 pmol) 
was incubated with 1x transfection buffer (300 μl) and transfection reagent (9 μl) 
for 15 min at RT to let the transfection complex form. Then the transfection mix 
was added to the cells and incubated. The transfection medium was replaced by 
growth medium 5-8 h afterwards. The neurons were collected for analysis 48 h 
after the transfection.  
Alternatively, we used Accell SMARTpool Fzr1 siRNA (E-100432-00-0050, 
Dharmacon), and Accell non-targeting siRNA as control (D-001910-01-20, 
Dharmacon): 1 µM siRNA per ml culture medium with reduced serum to 1% for 
96 h, then the cells were collected for analysis. 
 
4.2.3. Lysate preparation of neurons in primary culture 
Sixteen to 24 h after the initiation of the treatments (if not indicated otherwise) the 
supernatant was collected and used for further analysis and the neurons were 
washed two times with 2 ml of 1x PBS. When the samples were collected for 
western blot analysis 100 μl of 1x lysis buffer were added to the cells in each flask 
and put on ice for 2 min. They were scraped from the flask surface and collected in 
tubes. The cell extracts were heated to 95°C for 10 min and stored at this stage at -
80°C or directly used for protein determination. 
One hundred μl 1x PBS were added to samples which were used for 
nucleus/cytosol separation or for glutamate determination. The cells were carefully 
scraped down and transferred into reaction tubes. Cell extracts in 1x PBS were 
directly preceded to nucleus and cytosol separation or stored at this stage at -80°C 
till use.  
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4.2.4. Separation of nucleus and cytosol  
NE-PER Nuclear and cytoplasmic extraction reagents kit was used for separation 
of nucleus and cytosol according to manufacturer’s instructions (REF Thermo 
Scientific). Histon and actin specific antibodies were used to demonstrate a 
successful separation of proteins from nucleus and cytosol.  
 
4.3. Experimental Animals 
Double transgenic mice APPswe, PSEN1dE9-85Dbo/J (APP/PS1) were used as an 
animal model for AD. Animals were maintained in the animal facility in the 
Central Investigation Unit in the Faculty of Medicine, University of Valencia. Mice 
were maintained individually under a 12:12-h dark-light cycle at 23±1˚C and 60% 
relative humidity, and were provided with a standard chow diet (PANLAB S.L.) 
and water ad libitum.  
Transgenic mice and wild type mice from the same colony aged nine months were 
used in this study. DNA was extracted from tale samples using the High Pure PCR 
Template Preparation Kit (Roche) and the genotype determination was carried out 
by the “Unidad de genotipado y diagnostic genetico”, Facultat de Medicina, 
Valencia. In the image the amplified fragments of APP and PS are visible (Figure 
4.2).  
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Figure 4.2 | Genotype determination of wildtyp and heterozygous APP/PS1 mice. In this example 
samples in wells B01-B07 are wildtypes, while B08-B12 were determined as transgenic animals.  
 
4.3.1. Preparation of mouse brain homogenates   
The animals were anesthetized with inhalatory anesthesia (SEVOrane®) and then 
sacrificed. Hippocampi and cortices were isolated, freeze-clamped and stored at      
-80ºC. The tissues were weighted out and the according amount of 1x lysis buffer 
(Tris: 76,5 mM, pH: 6.8, SDS: 2%, Glycerol 10%; supplemented with sodium 
ortovanadate (2 mM) and protease inhibitor (Sigma-Aldrich)) was added (1 ml 1x 
lysis buffer/100 mg brain tissue) and the tissues were homogenized for Western 
blot determinations. For immunohistological analysis, animals were transcardially 
perfused as described below.  
 
4.3.2. Intrahippocampal infusion 
For microinjections in the hippocampus of Wistar rats, they were treated with 
atropine methyl nitrate (0,4 mg/kg, i.p.), anesthetized with a mixture of Ketamine 
(60 mg/kg i.p.) (Imalgen, 0.05 g/ml; Rhone Mérieux, Lyon, France) and Xylazine 
(10 mg/kg i.p.) (Xilagesic, 20 mg/ml; Lab. Calier, Barcelona, Spain), and mounted 
in a Kopf stereotaxic apparatus (Kopf Instruments, Tujunga, USA). In order to 
minimize animals’ suffering, subcutaneous lidocaine was injected in the surgery 
area. The scalp was incised and retracted, and the head position was adjusted to 
place bregma and lambda references in the same horizontal plane. Small trephine 
holes (1 mm in diameter) were drilled in the skull unilaterally.  
Intrahippocampal infusions were made using a stainless steel cannula system 
(Plastics One, Roanoke, VA) consisting of an outer guide tube (24 gauge) and an 
inner infusion tube (31 gauge). The cannulas were stereotaxically placed 4,36 mm 
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posterior to bregma, 1,4 mm lateral from the mid-sagittal line, and implanted 3,4 
mm below the outer surface of the skull into the left-side CA1 hippocampal region, 
according to the atlas of Paxinos and Watson (1998) (see Figure 4.3). The infusion 
cannula was connected to a 10 μl Hamilton microsyringe by a polyethylene tube. A 
total volume of 10 μl of infusion solutions (1 mM glutamate in 1 x PBS; 5 μM Aβ 
dissolved in 0,5% DMSO in 1x PBS) were injected into hippocampus at 0,5 μl/min 
controlled by a syringe pump. Control rats received vehicle solution (same volume 
and same rate). 
 
 
Figure 4.3 | Stereotaxic placement of injection site in rat hippocampus. The red dot indicates the 
approximate injection site. Atlas Source: Paxinos, George, and Charles Watson. The rat brain in 
stereotaxic coordinates: hard cover edition. Access Online via Elsevier, 2006. 
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4.3.3. Fixation and tissue preparation 
After 48 h of the treatments, animals were anaesthetised with a lethal dose of 
sodium pentobarbital (100 mg/kg, 20%) (Dolethal Vetoquinol Madrid, Spain) and 
transcardially perfused with heparinized saline (0,1%, pH 7) followed by 
paraformaldehyde (4%) in phosphate buffer (0,1 M, pH 7.4). Brains were post-
fixed for 24 h at 4ºC and maintained for 2 days in sucrose (30%) at 4ºC for 
cryoprotection. Coronal sections of 40 μm were obtained by freezing microtomy 
(Leica) and stored in phosphate buffer (0,1 M, pH 7.4) at 4ºC.   
 
 
4.3.4. Tissue preparation for immunoblotting 
Brain tissue (10 mg - 100 mg) was weighted out and the corresponding amount of 
1x lysis buffer was added (1 ml lysis buffer/100 mg brain tissue). The tissue was 
homogenized using a tissue homogenizer and the samples were stored at -80°C or 
directly used for protein determination. 
 
 
4.4. Analytical Methods 
4.4.1. Protein determination 
Protein concentrations in cell suspensions were determined using the Lowry 
protein assay. Bovine serum albumin was used in different concentrations as a 
standard (0,39; 0,78; 1,56; 3,125; 6,25; 12,5; 25; 50 mg/ml). Ten μl of sample (or 
standard solution) were added to 990 μl ddH2O; for the blanc 10 µl of ddH2O was 
used. One ml lowry reagent was added, shortly vortexed and kept for 20 min in the 
dark. Then, 500 μl of folin reagent were added and kept for 30 min in the dark. The 
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protein concentration in the samples was then measured by absorbance at 660 nm 
in disposable cuvettes in a standard photometer (Cecil 3021). 
 
4.4.2. SDS PAGE and immunoblotting 
After determination of the protein concentrations using Lowry protein assay, to the 
same amounts of total protein in the samples (20 μg - 30 μg), 8 μl of 1x loading 
buffer was added and the samples were heated to 95°C for 10 min. Afterwards they 
were subjected to sodium dodecyl sulphate (SDS) polyacrylamide gel 
electrophoresis (PAGE) to separate the proteins according to their molecular 
weight. They were blotted on a nitrocellulose membrane using a wet protein 
transfer system. The membranes were blocked in 5% (w/v) low-fat milk or 5% 
BSA in 1x TBST for 1 h at room temperature (RT). They were incubated with a 
specific primary antibody, at an appropriate concentration, for 1-2 h at RT or 
overnight at 4°C: cdh1 (DCS-266, 1:500, Novus Biologicals), glutaminase 1 
(12855-1-AP, Proteintech, 1:1000), cdk5 (2506, Cell Signaling Technology, 
1:1000), p35/25 (2680, 1:1000, Cell Singaling Technology), α-Tubulin (sc-8035, 
Santa Cruz Biotechnology, 1:8000), histone H3 (07-690, Merk Millipore, 1:25000), 
β-actin (A1978, Sigma, 1:1000). We used two distinct ladder proteins as indicators 
for molecular weight correspondence of specific proteins: The ‘PageRuler Plus 
Prestained Protein Ladder’ (26620, Thermo Scientific, Rockford, USA) and 
‘Precision Plus Protein Standards Dual Color’ (161-0374, BioRAD, CA, USA) 
(Figure 4.4). Membranes were incubated with corresponding secondary antibodies 
and signal detection was performed using “Luminata Classico Western HRP 
Substrate” (WBLUC0500, Millipore Corporation). Western blot images were 
developed with a biomolecular imager (ImageQuant™ LAS 4000, GE Healthcare 
Bio-Sciences). After identification of a specific band at the corresponding 
molecular weight, the bands were quantified by densitometry using 
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ImageGauge4.0. Loading control proteins (α-tubulin, histones or β-actin) were also 
quantified and the specific antibody band was normalized to the band of the 
loading control. 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 | Representative images for ladder proteins used for western blotting within this 
work. (a) PageRuler Plus Prestained Protein Ladder and (b) Precision Plus Protein Standards Dual 
Color.  
 
4.4.3. Immunohistochemistry using DAB staining  
Hippocampi were isolated and fixed in 4% formaldehyde in 1x PBS and embed in 
paraffin. Sections (5 µm) were analysed using glutaminase (12855-1-AP, 
Proteintech, 1:100) and cdh1 (NBP2-15840, Novus Biologicals, 1:500) antibodies. 
A 3,3′-Diaminobenzidine (DAB) Peroxidase Substrate Solution for staining. Nuclei 
were stained using haematoxylin.  
 
 
a b 
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4.4.4. Immunohistochemical labelling with fluorescent antibodies 
Free floating sections were washed 3 times in 0,1% TBST at RT. Sections were 
incubated for 3 h at RT in a blocking solution of 2% BSA in TBST. The tissue was 
incubated 2 days at 4ºC in 2% BSA in TBST with the primary antibodies: rabbit 
anti-Glutaminase (Proteintech, 1:200), mouse anti-Cdh1 (Abcam, 1:100) or rabbit 
anti-Cdh1 (Novusbio, 1:250). Afterwards, sections were rinsed 2 times in TBST 
and 2 times in HEPES (10 mM) in PBS and were then incubated for 3 h at RT in a 
solution of 2% BSA in HEPES (10 mM) with the secondary antibody: Alexa Fluor 
488 anti-rabbit (CellSignaling Tech, 1:1000) and Alexa Fluor 647 anti-mouse 
(CellSignaling Tech, 1:1000). Finally, sections were rinsed in HEPES (10 mM), 
mounted onto pig skin gelatin-coated slides (0,5%) and covered with a drop of 
VECTASHIELD Mounting Medium with DAPI (H1200, Vector) for nuclear 
staining and a drop of fluorescence mounting medium (S3023, DAKO).  
 
4.4.5. Immunocytochemical labelling  
Neuron cells were fixed in 4% formaldehyd in 1x PBS for 5 min at RT, to preserve 
the morphology of the cell. Afterwards the cells were incubated with methanol (-
20°C) for 1 min, for further fixation. Then, they were washed in 1x PBS and at this 
step they were eventually stored at 4°C for several days or weeks, or they were 
directly proceeded to be used for staining. To reduce unspecific bindings, the cells 
were incubated in blocking solution (5% BSA) for 1 h at RT. The neurons were 
incubated with a specific primary antibody at an appropriate concentration 
overnight at 4°C. The next day, the cells were washed with 1x PBS and incubated 
with a fluorescent secondary antibody for 1 h at RT. The cells were washed in 1x 
PBS and were ready for analysis. For nucleus staining sytox green was added 5 
min before analysis (S7020 SYTOX Green Nucleic Acid Stain, Molecular Probes).  
Sytox green stains nucleic acids that easily penetrates cells with compromised 
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plasma membranes. The emission maximum of the fluorochromes is at 523 nm. 
Sytox green (5 mM) was diluted 1:5000 in a phosphate free buffer, to reach a final 
concentration of 10 nM – 1 μM.  
 
For analysis in living cells the following fluorochromes were used:  
Annexin V – 555 is a marker of apoptotic cells and has an emission maximum at 
560 nm (green). It binds to phosphatidylserine (PS) which is translocated from the 
inner to the outer leaflet of the plasma membrane in apoptotic cells. Five μl of the 
fluorochrome were added to 100 μl medium and incubated for 15 min at room 
temperature. Then the cells were washed with 1x PBS and analysed. Nuclei were 
stained with Hoechst for 5 min (H3570, Invitrogen). 
Fluo-4 is a cell permeant Ca
2+
 indicator and has an emission maximum at 526 nm. 
Labeled calcium indicators are molecules that exhibit an increase in fluorescence 
upon binding of Ca
2+
. Fifty μg of Fluo-4 (F-14201, Invitrogen) were dissolved in 
50 μl filtered DMSO. Then 5 μl/ml medium were added directly to the culture 
medium and incubated for 45 min at 37°C. Then the medium was changed and the 
cells were further incubated for 30 min at 37°C and analysed. Nuclei were stained 
with Hoechst for 5 min (H3570, Invitrogen). 
 
4.4.6. Image acquisition and image analysis 
Immunocytochemical and immunohistochemical preparations were observed with 
a confocal laser-scanning microscope (Leica TCS SP2 scanning multiphoton and 
confocal unit with an inverted DM1RB microscope; Ar-He-Ne). Images containing 
hippocampal CA1 were analysed with ImageJ. To determine the nuclear and 
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cytoplasm localization of cdh1, the “intensity ratio nuclear cytoplasm” plugin for 
ImageJ with threshold setting “Huang” was used.  
To compare protein levels, we used area proportions of the specific antibody signal 
normalized to nuclear staining (dapi). Ca
2+
 measurement  in cells were analysed 
comparing changes in the intensity level of Fluo4 normalized to nuclear staining 
(hoechst); all images were taken with the same exposure settings.     
 
4.4.7. Flow Cytometry analysis of neurons  
For apoptosis assays, neurons were analysed with a BD FACSVerse™ flow 
cytometer using the annexin V-FITC Apoptosis Detection Kit (ANEXVKF-100T, 
Immunostep).  
Neurons cells were detached from culture plates with trypsin (2 min, 37°C) and 
centrifuged (400 g, 5 min). Supernatants were also centrifuged to collect floating 
cells. Medium containing serum (10%) was added to inactivate trypsin and 
centrifuged. Neurons were washed twice in 1x PBS and re-suspended in 100 µl 
Annexin Buffer. Five µl of both, Annexin and Propidium Iodide (PI) were added to 
the cells for 15 min at RT. Neurons were further diluted in Annexin Buffer and 
analysed by flow cytometry. The measurements were previously calibrated using 
neurons with either Annexin or PI staining alone and unstained cells. Flow 
cytometry results were analysed with BD FACSuite software. Results are shown as 
2D dot plots, with Annexin V-FITC on the x-axis and PI on the y-axis. The 
bivariate staining allows discrimination of the following groups (Figure 4.5): intact 
cells (Annexin negative, PI negative) in the square left/down-sided Q3, early 
apoptosis (Annexin positive PI, negative) in the square right/down-sided Q4, late 
apoptotic (Annexin positive, PI positive) in the square right/up-sided Q2, and 
necrotic cells (Annexin negative, PI positive) in the square left/up-sided Q1.  
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Figure 4.5 | 2D dot plot of apoptosis measurement in neurons by flow cytometry. Q3: live cells, 
Q4: apoptotic cells, Q2: late-apoptosic cells, Q1: dead cells.  
 
4.4.8. Glutamate measurement  
To measure L-glutamate we followed the protocol of Bernt E. and Bergmeyer H.U. 
(1994), a photometric assay, based on the enzymatic reaction of glutamate 
dehydrogenase (GlDH, G2626, Sigma, St. Louis, USA). 
 
  L-Glutamate  +  NAD+  +  H2O           2-Oxoglutarate  +  NADH  +  NH4
+
 
 
The amount of L-glutamate that is oxidized to 2-oxoglutarate is proportional to the 
increase of NADH, which is measured by the extinction change at 340 nm. ADP is 
added to activate and stabilize the reaction. 
Solutions and reagents used in the assay:  
Glycine-hydrazine buffer [0,5 M glycine; 0,4 M hydrazine; pH 9.0] 
GlDH 
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3,75 g glycine and 5,50 g of 24% hydrazine hydrate were dissolved in 
ddH2O and adjusted to pH 9.0 with 1 N H2SO4 and filled up to 100 ml with 
ddH2O.  
Adenosine-5’-diphosphate [33,5 mM ADP]  
45 mg ADP-Na2 were dissolved in 2,5 ml ddH2O. 
Nicotinamide-adenine dinucleotide [27 mM β-NAD]  
100 mg NAD were dissolved in 5 ml ddH2O.  
Glutamate dehydrogenase, GlDH [ca. 10 mg protein/ml]  
Perchloric acid [1 M]  
8,6 ml  perchloric acid (70%) were diluted to 100 ml with ddH2O. 
Phosphate solution [1,93 M K3PO4] 
51 g of K3PO4 were diluted in 100 ml ddH2O. 
Samples of cell-free supernatants of cultured neurons were deproteinized using 
perchloric acid (6%). The pH was adjusted using tripotassium phosphate solution. 
The mix was centrifuged for 10 min at 3000 g. One ml of the supernatant was 
adjusted to pH 9.0 by adding 200 µl phosphate solution and then the samples were 
put on ice for 10 min. The supernatant was used for the assay adding the following 
amounts: 
 750 µl glycine – hydrazine buffer  
 375 µl sample 
 37,5 µl ADP 
 75 µl NAD  
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Standard [mM] A [T=0] A [T=45] ΔA
5 0,292 2,16 1,868
2,5 0,301 1,532 1,231
1,25 0,3 1,084 0,784
0,625 0,296 0,779 0,483
0,315 0,301 0,55 0,249
0,156 0,309 0,429 0,12
0,078 0,287 0,365 0,078
0,031 0,29 0,332 0,042
0 0,295 0,296 0,001
After the components were mixed together the extinction was measured for the first 
time t = 0 (E1). Ten µl GlDH were added and absorption was measured after t = 45 
min (E2). That was when the values stabilized, the reaction was saturated. Then the 
absorption ΔA was calculated: ΔA= E2 – E1. Then we calculated the concentration 
of glutamate in the sample: 
 
Glutamate (mM)  =                                                      =      ΔA340 x 1,280 
 
ΔA340 = Final maximum absorbance at 340 nm 
2 = dilution with 6% PCA  
1,2 = dilution with phosphate salt  
1246,9 = total reaction volume (µL) 
375 = volume of sample in cuvette (µL) 
6,22 = mM/cm (extinction coefficient of NADH at 340 nm) 
1 = Lightpath (cm) 
As control, we used a glutamate standard solution with the following 
concentrations and verified that samples up to 2,5 mM glutamate show an accurate 
measurement:  
 
 
 
 
 
ΔA340 * 2 * 1,2 * 1246,9 
         6,220 * 1 * 375 
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Figure 4.6 | Glutamate standard measurement. Glutamate standard concentrations (0-5 mM) 
measured in samples before (T=0) and after (T=45) the addition of glutaminase dehydrogenase. ΔT 
shows the increase of absorption (A).   
After determination and calculation of the glutamate concentration in the sample, 
they were normalized to the protein concentration in the samples of neurons of the 
corresponding flask. 
4.4.9. Ammonia measurement 
For ammonia determination, cell-free supernatant samples were analyzed using the 
ammonia assay kit (Sigma-Aldrich, Saint Lois USA) according to manufacturer’s 
instructions. 20 µl of supernatant was mixed with 200 µl assay buffer and 2 µl 
GlDH solution in 96-well plate for 5 min, and absorbance was measured at 340 nm. 
The background concentration of ammonia in the culture medium was substracted 
and the results are expressed as the increase of ammonia/100 µg protein.  
 
4.4.10. Determination of mRNA expression by quantitative rtPCR  
Total RNA was isolated from tissues or cells using the TRIzol Reagent (Life 
technologies, 15596-026) according to manufacturer's instructions. RNA 
concentration was determined using a NanoDrop spectrophotometer. One µg of 
purified RNA was reverse transcribed using High-Capacity cDNA Reverse 
Transcription Kit (Thermo Fisher, 4368814) according to the manufacturer's 
instructions. The quantitative PCR was performed using the detection system 
7900HT Fast Real-Time PCR System (Applied Biosystems). Gene-specific primer 
pairs were designed using NCBI/Primer-BLAST:  
cdh1 (Mus musculus) FW: 5’-GGACCAGGACTATGAGCGAA-3’, 
cdh1 (Mus musculus) RV: 5’-GGGTTCTCCGCATCTCTGAA -3’;  
APC/C 2 (Mus musculus) FW: 5’-ACCGTATCTATGCCACCCTAC-3’,  
67 
 
APC/C 2 (Mus musculus) RV: 5’-GACACAAGAAGTTGCTGCCT-3’;  
gls (Mus musculus) FW: 5’GATGTGTTGGTCTCCTCCTCT-3’,  
gls (Mus musculus) RV: 5’-GGTTTATCACCGACTTCACCC-3’;  
GAPDH (Mus musculus) FW: 5’- TGCTGAGTATGTCGTGGAGT-3’,  
GAPDH (Mus musculus) RV: 5’-AGATGATGACCCGTTTGGCT-3’;   
cdh1 (Rattus norvegicus) FW: 5’- TCGTATCGTGTCCTCTACCTG-3’,  
cdh1 (Rattus norvegicus) RV: 5’- AACCGAAGGGTCTCATCTCC-3’;  
APC/C2 (Rattus norvegicus) FW: 5’- GAGAGAGTGGTTGGTTGGCT-3’, 
APC/C2 (Rattus norvegicus) RV: 5’-GGCTGGCATAGATTCGGTAGA-3’; 
 gls (Rattus norvegicus) FW: 5’  ATTACGACTCCAGAACAGCCC, 
gls (Rattus norvegicus) RV: 5’-GCTTCCAGCAAAAACTTCACAAC-3’;  
GAPDH (Rattus norvegicus) FW: 5’ TGATGGGTGTGAACCACGAG-3’, 
GAPDH (Rattus norvegicus) RV: 5’-TCATGAGCCCTTCCACGATG’-3.  
The primers were obtained from Life Technologies. For the reaction, Maxima 
SYBR Green/ROX qPCR Master Mix (2X) (Thermo Scientific, K0223) was used 
and each sample was analysed in triplicates.  
 
The relative standard curve method was used to evaluate the expression levels. 
Standard curves were prepared from dilutions of cDNA mix of the samples for 
each gene. The efficiency was estimated using a semi-log regression line plot of 
CT value vs. log of input nucleic acid (see example Figure 4.7). 
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Figure 4.7 | Relative standard curve method for qPCR quantification. The diagram shows a semi-
log regression line plot of CT value vs. log of input nucleic acid. The slope (here: -3,34) indicates the 
efficiency of the amplification of the gene.  
 
For all experimental samples, the relative target quantity was determined by 
interpolating the threshold cycle (Ct) values from the standard curve. GAPDH was 
used in all samples to normalize gene expression for sample-to-sample differences 
in RNA input and quality. The fold change of samples of the control group 
compared to treated groups was represented. 
 
 
4.5. Statistical analysis  
To calculate protein half-life we used the following method: It was assumed that 
protein degradation follows first-order decay kinetics. The measured protein 
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intensity data was initially log-transformed, then a linear least-squares fit was used 
to determine the decay rate constant k, yielding a coefficient of determination (r-
square). Moreover, we estimated the standard error of the slope. For assessing 
difference significance we used a Z-test. It is known that, under normality 
assumption of the fit errors, difference between slope estimates divided by the 
mean square root of their standard error follow a standard normal distribution. 
Finally, from the decay rate constant, the half-life was calculated (T(1/2) = ln(2)/k). 
The results are expressed as mean ± SD of data of at least three independent 
experiments. Statistical analyses were carried out, using a one-tail t-tests analysis 
or Mann Whitney U-test. P-values were graduated in the units of significance 
which were set as following: p < 0,05 significant (*), p < 0,01 very significant (**), 
p < 0,001 highly significant (***). 
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5. RESULTS 
5.1. Cdh1 in Aβ Treated Neurons 
5.1.1. Cdh1 protein level decreases upon Aβ treatment 
In order to study the implication of APC/C-Cdh1 in AD, we first tested the effect 
of Aβ on cdh1 in vitro in neurons in primary culture. After six days of culture, the 
neurons were fully differentiated. For the Aβ treatment, culture medium was 
changed for all neurons and either standard culture medium (for controls) or 
medium containing soluble oligomeric Aβ1-42 (5 µM) was added. The cells were 
collected after different time points between 0 and 24 h, and cdh1 protein levels 
were determined by western blotting. We detected cdh1 by a specific antibody at 
the corresponding molecular weight at 55 kDa (see Figure 5.1 a). Cdh1 protein 
levels were significantly decreased when treated with Aβ for 24 h compared to 
control conditions in three independent experiments (see Figure 5.1 a-c, 5.2). This 
result shows that Aβ affects cdh1 steady state levels directly or indirectly.  
Therefore we assumed that cdh1 and APC/C might have a potential role in AD. 
a 
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Figure 5.1 | Cdh1 decreases after Aβ treatment. (a-d) Neurons in primary culture were treated with 
Aβ and collected after different time points. Cdh1 and α-tubulin levels were determined in whole-cell 
lysates by immunoblotting using specific antibodies for cdh1 (dilution 1:1000) and α-tubulin (dilution 
1:1000). Western blot images show a decrease of cdh1 with incubation of Aβ after approximately 10 
h compared to control conditions. Blots were quantified by densitometry and normalized with α-
tubulin; values are indicated below the blots. 
 
 
 
 
 
 
 
b c 
d 
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Figure 5.2 | Quantification of cdh1 shows a significant decrease of cdh1 after Aβ treatment after 
20 h. Blots of three independent experiments were quantified. The mean values ± SD of cdh1 
normalized to the loading control protein are shown and are statistically significant (p < 0,05). 
  
5.1.2. Cdh1 protein level decreases in the nucleus upon Aβ treatment 
The intracellular localization of cdh1 is determined by its phosphorylation status. 
Non-phosphorylated cdh1 is localized in the nucleus where it activates APC/C.  
Upon phosphorylation cdh1 is translocated to the cytoplasm where it is targeted for 
degradation by the SCF-complex (Zhou et al., 2003; Almeida, 2012). Therefore, in 
the following experiment we analysed whether cdh1 decreases after Aβ treatment 
in the nucleus and/or in the cytoplasm of neurons.  
Cultured primary neurons in control conditions or treated with Aβ for 20 h were 
carefully collected in PBS and cytosol and nucleus were separated. A successful 
separation was demonstrated by quantification of cell compartment-specific 
proteins in the fraction of nucleus (Histone H3) and the cytosol (β-actin). These 
proteins were also used as a loading control in densitometry analysis of the blot.  
We showed that cdh1 decreased significantly in the nucleus in three independent 
experiments after the Aβ treatment (Figure 5.3 a-c, 5.4). This indicates that Aβ 
induces nuclear export of cdh1, probably caused by phosphorylation of cdh1. There 
is no commercially available antibody for phopho-cdh1, therefore we could not 
directly test phosphorylation of cdh1.  
 
While the decrease of nuclear cdh1 upon Aβ occurred in all repetitions, the cdh1 
level in the cytosol did not decrease equally in all repetitions. This difference might 
have occurred due to a differential regulation of the degradation of cdh1 by the 
SCF complex.  
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Figure 5.3 | Cdh1 decreases after Aβ treatment in the nucleus. (a-c) Neurons were treated with Aβ 
for 20 h. Cdh1 levels were determined by immunoblotting using specific antibodies for cdh1 (dilution 
1:1000), histone (dilution 1:30000) or β-actin (dilution 1:1000) as loading controls. Western blot 
images show a decrease of cdh1 after treatment with Aβ for 20 h in the nucleus compared to control 
conditions. Blots were quantified by densitometry and normalized with H3 (for nuclear extracts) or β-
actin (for cytosol extracts), values are indicated below the blots.  
 
 
 
 
 
Figure 5.4 | Quantification of cdh1 shows a significant decrease of cdh1 after Aβ treatment in the 
nucleus. Blots of three independent experiments were quantified. The mean values ± SD of cdh1, 
a b 
c
b 
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normalized to the loading control protein, are shown in the histogram. The result is statistically 
significant (p < 0,01). 
 
To further confirm this result we analysed the cellular localization of cdh1 by 
confocal microscopy. Neurons were grown on chamber slides, and treatments were 
accomplished as stated above. Immunocytochemical analysis of cdh1 showed that 
the nucleus/cytosol ratio of cdh1 decreases significantly upon Aβ treatment  
(Figure 5.5). 
 
 
 
 
 
 
 
Figure 5.5 | Cdh1 decreases after Aβ treatment in the nucleus. Confocal microscope analysis of 
neurons shows cdh1 (red) and nuclei (sytox green). Representative images of three independent 
experiments are shown. Scale bar = 21.4 µm. 
 
Additionally, we co-stained neurons with Map2, a neuronal marker, to confirm that 
nuclear-cytoplasm translocation of cdh1 upon Aβ treatment occurs specifically in 
neurons (Figure 5.6).  
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Figure 5.6 | Cdh1 decreases after Aβ treatment in the nucleus of neurons. (a) Confocal 
microscope analysis of neurons shows cdh1 (red) and nuclei stained by Hoechst (blue). Map2 staining 
(green) was used as a neuronal marker. Representative images of three independent experiments are 
shown. (b) Mean value ± SD of cdh1 in the nucleus is shown in the histogram. Scale bar = 47,62 µm. 
 
 
 
a 
b 
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5.1.3. Protein half-life of cdh1 is reduced upon Aβ treatment 
We tested if the protein half-life of cdh1 changed with Aβ treatment. Therefore we 
measured cdh1 protein level when protein synthesis was inhibited using 
cycloheximide (CH) alone or in the presence of Aβ. We observed that the protein 
half-life of cdh1 was reduced from 5,9 h to 4,8 h when treated with Aβ, than in its 
absence (Figure 5.7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 
b 
c 
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Figure 5.7 | Cdh1 half-life decreases with Aβ. (a-c) Western blot images of cdh1 at different time 
points after treatment with cycloheximide (CH) or CH + Aβ. (d) Blots of three independent 
experiments were quantified by densitometry and normalized against α-tubulin; the mean values ± SD 
are indicated. 
 
5.1.4. Cdh1 is degraded by the proteasome when treated with Aβ 
In the previous experiments, we observed a decrease of cdh1 when treated with Aβ. 
This decrease could have occurred due to transcriptional, translational or post-
translational changes. Here we tested whether the inhibition of the proteasome 
using the specific inhibitor MG132 rescues cdh1 protein levels when treated with 
Aβ. We tested different concentrations and observed that the proteasome inhibition 
at a concentration of 10 µM MG132 was most effective to revert the effect of Aβ 
on cdh1 (Figure 5.8 a). We observed a statistical significant difference in cdh1 
levels in three independent experiments (Figure 5.8 b-d, 5.9 e).  
 
 
 
d 
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Figure 5.8 | Cdh1 after Aβ treatment is degraded by the proteasome. (a-d) Neurons in primary 
culture were treated with Aβ for 24 h and/or MG132. Cdh1 levels were determined by 
immunoblotting using specific antibodies for cdh1 (dilution 1:1000) and α-tubulin (1:1000) as 
loading controls. Western blot images show a decrease of cdh1 with incubation of Aβ after 24 h, but 
not when treated with MG132. Blot were quantified by densitometry and normalized to α-tubulin, 
values are indicated below the blots. 
 
 
 
 
 
Figure 5.9 | Quantification of cdh1 shows a significant decrease after Aβ treatment which does 
not occur when the proteasome is inhibited. Blots of three independent experiments were 
a b 
c 
d 
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quantified. The mean values ± SD of cdh1, normalized to the loading control protein, are shown in the 
histogram. The results are statistically significant (p < 0,05; p < 0,05).  
 
5.1.5. mRNA levels of cdh1 and APC/C2 when treated with Aβ  
In the previous experiments we had observed a proteasome-dependent decrease in 
cdh1 when treated with Aβ. Next, we tested whether there was a change in mRNA 
expression of cdh1 and in the catalytic subunit APC/C2 of the protein complex. We 
measured the mRNA levels of cdh1 and of APC/C2 using qPCR in control 
conditions and upon Aβ treatment. We observed no statistically significant 
differences in the expression levels in the two conditions and concluded therefore 
that changes in cdh1 protein levels when treated with Aβ occurred  exclusively 
post-translational (Figure 5.10).  
 
 
 
 
 
 
Figure 5.10 | mRNA levels of APC/C2 and cdh1 in neurons. Neurons in primary culture were 
treated with Aβ. After 24 h, the cells were collected and mRNA was isolated and retro-transcribed to 
cDNA. Relative expression levels were determined by real time qPCR using specific primers. Mean 
values ± SD of cdh1 and APC/C2 are shown in the histograms. There is no statistically significant 
difference (n=3).  
 
a b 
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5.2. Cdc20 protein level upon Aβ treatment in neurons 
We also tested the protein level of cdc20, another co-activator subunit of APC/C, 
in control conditions and upon Aβ treatment. We identified a band of cdc20 at the 
corresponding molecular weight of 51 kDa (Figure 5.11 a). In three independent 
experiments we showed that there was a tendency of cdc20 decrease upon Aβ 
treatment, which was however not statistically significant (Figure 5.11 b-e). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 
b c 
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Figure 5.11 | Cdc20 levels in neurons after Aβ treatment. (a) Neurons in primary culture were 
treated with Aβ and collected after different time points (b-c) or after 24 hours. Cdc20 and α-tubulin 
levels were determined in whole-cell lysates by immunoblotting using specific antibodies for cdc20 
(dilution 1:1000) and α-tubulin (dilution 1:1000). (e) Blots were quantified by densitometry and 
normalized with α-tubulin. Mean values ±SD are shown in the histogram. There was no statistically 
significant difference.  
 
5.3. Analysis of APC/C-Cdh1 Substrates Cyclin B1 and Pfkfb3 
To test the regulation of APC/C of its substrates in neurons, we either directly 
inhibited APC/C using the specific inhibitor proTAME and measured the protein 
levels of AD-related APC/C substrates or tested if those proteins accumulated after 
Aβ treatment, as we had observed that this treatment reduces cdh1. The APC/C-
Cdh1 substrates (King et al., 1995, Maestre et al., 2008, Colombo et al., 2010) that 
we measured here were: Cyclin B1, Pfkfb3 and glutaminase 1.  
 
5.3.1. Cyclin B1 accumulation upon APC/C inhibition by proTAME or Aβ 
Cyclin B1 has been identified as a target of APC/C and was shown to be involved 
in neuronal survival (King et., 1995; Maestre et al., 2008). 
d e 
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For APC/C inhibition, the culture medium was changed for all neurons and either 
standard culture medium (for controls) or standard culture medium containing 
proTAME (12 µM) was added. Then the cells were collected at different time 
points between 3 and 30 h after the inhibition. The samples were subjected to 
western blotting and we detected cyclin B1 at the corresponding molecular weight 
of 60 kDa by a specific antibody (Figure 5.12 a). Results of three independent 
experiments showed a significant increase of cyclin B1 with proTAME treatment 
in a time-dependent manner (Figure 5.12 a-b, 5.13).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 
b 
c 
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Figure 5.12 | Cyclin B1 increases when APC/C is inhibited in neurons by proTAME. (a-b) 
Neurons in primary culture were treated with proTAME. Cdh1 and α-tubulin levels were determined 
in whole-cell lysates by immunoblotting using specific antibodies for cyclin B1 (dilution 1:1000) and 
α-tubulin (dilution 1:1000). Western blot images show a time-dependent increase in cyclin B1 
compared to control conditions. Blots were quantified by densitometry and normalized with α-
tubulin; values are indicated below the blots. 
 
 
 
 
 
 
Figure 5.13 | Quantification of cyclin B1 shows a significant increase after 22 h and 30 h of 
proTAME treatment. Blots of three independent experiments were quantified. The mean values ± 
SD of cyclin B1, normalized to the loading control protein, are shown in the histogram. The result is 
statistically significant (p < 0,05).  
 
After we observed an accumulation of cyclin B1 in neurons by direct APC/C 
inhibition, we tested if the treatment with Aβ, which had previously induced a 
decrease of cdh1, also led to an accumulation of cyclin B1. The Aβ treatments were 
accomplished as described above. Neurons were collected 20 h after the treatment 
and cyclin B1 protein levels were determined. It was shown in three independent 
experiments that cyclin B1 accumulates significantly in Aβ-treated cells (Figure 
5.14 a-d). 
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Figure 5.14 | Cyclin B1 increases upon Aβ treatment. (a-c) Neurons in primary culture were treated 
with Aβ for 20 h. Cyclin B1 and α-tubulin levels were determined in whole-cell lysates by 
immunoblotting using specific antibodies for cyclin B1 (dilution 1:1000) and α-tubulin (dilution 
1:1000). Blots were quantified by densitometry and normalized with α-tubulin; values are indicated 
below the blots. (d) The mean values ± SD of cyclin B1 normalized to α-tubulin increased 
significantly upon treatment (p < 0,01). 
 
5.3.2. No increase in pfkfb3 protein level upon Aβ treatment 
Pfkfb3 has been described as a target of APC/C and unregulated accumulation of 
pfkfb3 in neurons has been shown to be involved in oxidative stress in AD 
(Rodriguez et al., 2012). 
Here, we measured protein levels of pfkfb3 after treatment with Aβ in neuron 
primary culture. The Aβ treatment was accomplished as described above and 
pfkfb3 protein level was determined by western blotting. We detected pfkfb3 at the 
corresponding molecular weight of 60 kDa by a specific antibody (Figure 5.15 a). 
a b 
c
c 
d
c 
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We could not observe differences in the protein level of pfkfb3 in neurons under 
control conditions and after the treatment (Figure 5.15, a-c). A possible reason for 
this result might be that the basal expression of pfkfb3 is not sufficient to observe 
an accumulation after 20 h of treatment. It might also be possible that pfkfb3 is 
regulated by additional mechanisms independent from APC/C-Cdh1.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.15 | Protein level of pfkfb3 did not change after Aβ treatment. (a-c) Neurons in primary 
culture were treated with Aβ for 20 h. Pfkfb3 and α-tubulin levels were determined in whole-cell 
lysates by immunoblotting using specific antibodies for Pfkfb3 (dilution 1:1000) and α-tubulin 
(dilution 1:1000). Blots were quantified by densitometry and normalized with α-tubulin; values are 
indicated below the blots. There was no detectable difference in protein levels between the controls 
and after the treatment. 
a b 
c 
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5.4. Analysis of APC/C-Cdh1 Substrate Glutaminase  
Glutaminase was identified as a substrate of APC/C-Cdh1 in lymphocytes 
(Colombo et al., 2010). To the best of our knowledge no studies had investigated 
its regulation by the ubiquitin ligase in neurons before. In the following sections 
the results of glutaminase as a target of APC/C-Cdh1 in neurons are summarized.  
 
5.4.1. Glutaminase accumulation upon inhibition of APC/C  
Here, we measured glutaminase protein levels in neurons in primary culture after 
the inhibition of APC/C by proTAME. The treatment was accomplished as 
described above.   
The cells were collected at different time points between 0 and 24 h after the 
inhibition of APC/C or in control conditions. The samples were subjected to 
western blotting and we detected glutaminase at the corresponding molecular 
weight of 65 kDa by a specific antibody (Figure 5.16 a). We observed that 
glutaminase accumulates significantly when APC/C is inhibited (Figure 5.17 a-d, 
5.18). We concluded that APC/C is involved in the regulation of glutaminase in 
neurons.   
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Figure 5.16 | Glutaminase level in neurons in primary culture in control conditions. The glutaminase 
band was detected at 65 kDa.  
 
 
 
 
 
 
 
 
 
 
Figure 5.17 | Glutaminase increases upon APC/C inhibition. (a-e) Neurons in primary culture were 
treated with proTAME and collected at different time points between 0 and 24 h. Glutaminase and α-
tubulin levels were determined in whole-cell lysates by immunoblotting using specific antibodies for 
glutaminase (dilution 1:1000) and α-tubulin (dilution 1:1000).  
 
 
 
 
 
a b 
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Figure 5.18 | Quantification of glutaminase protein shows a significant increase after 10, 16 and 
24 h of proTAME treatment. Blots of three independent experiments were quantified. The mean 
values ± SD of cyclin B1, normalized to the loading control protein, are shown in the histogram. The 
result is statistically significant (p < 0,01; p < 0,05; p < 0,05).  
 
5.4.2. Glutamate increases when APC/C is inhibited  
We observed a significant increase of glutaminase in neurons when APC/C is 
inhibited and therefore next tested whether the levels of glutamate in the 
supernatants change after the treatment with proTAME. Before the treatments, cell 
culture medium was changed in all plates of controls and in proTAME treated 
cells. Supernatants were collected at different time points between 3 and 24 hours 
after the change. The samples were prepared as described in the method section 
and glutamate was measured. There was a significant increase in glutamate upon 
inhibition of APC/C in the supernatant of neurons (Figure 5.19).  
 
 
 
 
   
 
 
Figure 5.19 | Extracellular glutamate increases when APC/C is inhibited by proTAME in 
neurons. Glutamate levels in the extracellular culture medium of neurons after 3, 10, 16 and 24 h 
under control conditions or with proTAME (12 µM). Glutamate concentrations were normalized to 
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protein levels measured in neuron lysates from the corresponding cell culture plates. Mean values ± 
SD of three independent experiments are shown and are statistically significant (p < 0,001).  
 
5.4.3. Glutaminase accumulates when treated with Aβ  
We have previously observed a decrease in cdh1 levels upon Aβ treatment and then 
measured here glutaminase levels after the same treatment. The Aβ treatment was 
accomplished as described above and glutaminase protein levels were determined 
by western blotting. There was a significant increase in glutaminase after the 
treatment with Aβ in neurons (Figure 5.20 a-d).  
 
 
 
 
 
 
  
 
 
 
Figure 5.20 | Glutaminase increases upon Aβ treatment. (a-c) Neurons in primary culture were 
treated with Aβ for 24 h. Glutaminase and α-tubulin levels were determined in whole-cell lysates by 
immunoblotting using specific antibodies for glutaminase (dilution 1:1000) and α-tubulin (dilution 
1:1000). Blots were quantified by densitometry and normalized with α-tubulin; values are indicated 
a b 
c d 
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below the blots. (d) The mean values ± SD of glutaminase, normalized to α-tubulin are shown in the 
histogram, and are statistically significant (p < 0,01). 
 
5.4.4. mRNA expression levels of glutaminase upon Aβ treatment 
In the previous experiment we have observed that glutaminase increases in neurons 
when treated with Aβ. Here we tested whether mRNA expression of glutaminase 
increases in this treatment conditions. We measured glutaminase mRNA level by 
qPCR and observed no statistically significant difference in controls or with Aβ 
(Figure 5.21). This result indicates that glutaminase accumulates with Aβ due to 
post-translational modifications (decreased degradation of glutaminase by APC/C-
Cdh1) and not because of changes in mRNA expression.  
  
 
 
 
 
 
Figure 5.21 | mRNA levels of glutaminase in neurons. Neurons in primary culture were treated with 
Aβ. After 24 h the cells were collected and mRNA was isolated and retro-transcribed to cDNA. 
Relative expression levels were determined by real time qPCR using specific primers. Mean values ± 
SD of glutaminase normalized to GAPDH are shown in the histogram. There is no statistically 
significant difference (n=3).  
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5.4.5. Intracellular glutamate levels upon Aβ treatment 
Primary neurons were treated with oligomeric Aβ (5 µM) for 16 or 20 h. The 
neurons were washed 3 times with 2 ml 1x PBS, collected in 1x PBS containing 
protease inhibitor and ortovanadate and stored at -80°C till use. The protein 
concentration was determined and glutamate was measured in whole cell lysates in 
duplicates. We could not detect a significant difference of glutamate in the cell 
lysates (Figure 5.22). 
 
 
 
 
 
 
 
 
 
Figure 5.22 | Glutamate concentration (µM) in neurons. C1, C2 are duplicates of controls; Aβ1, 
Aβ2 are duplicates of neurons treated with Aβ. Samples from 3 animals (R1, R2, R3) with indicated 
times of Aβ incubation or in control conditions. 
 
5.4.6. Extracellular glutamate levels upon Aβ treatment 
We then measured extracellular glutamate levels in Aβ-treated samples. The Aβ 
treatment was accomplished as described above and supernatants were collected at 
different time points after the treatment. Glutamate levels were significantly 
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increased in samples treated with Aβ after 20 h in three independent experiments 
(Figure 5.23).  
 
  
 
 
 
 
 
 
 
Figure 5.23 | Extracellular glutamate increases upon Aβ treatment. Glutamate levels in 
extracellular culture medium of neurons after 10, 16 and 20 h under control conditions or with Aβ. 
Glutamate concentrations were normalized to protein levels measured in neuron cell lysates from the 
same culture flasks. Mean values ± SD of three independent experiments are shown. There is a 
statistically significant increase when treated with Aβ.  
 
5.4.7. Glutaminase accumulates in cdh1-silenced neurons 
We have observed that glutaminase accumulates in neurons when APC/C is 
inhibited or when treated with Aβ. To determine whether the change in the 
glutaminase level occurs specifically due to a decrease of cdh1, we silenced cdh1 
using smart pool on target siRNA. We observed a slight but significant increase in 
glutaminase in cdh1 silenced neurons (Figure 5.24).  
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Figure 5.24 | Glutaminase (gls) increases in cdh1-silencend neurons. (a-b) Western blot image of 
cdh1 and gls in cdh1-silenced neurons. Cdh1, glutaminase and α-tubulin levels were determined in 
whole-cell lysates by immunoblotting using specific antibodies for cdh1 (1:1000), glutaminase 
(dilution 1:1000) and α-tubulin (dilution 1:1000). (c) Western blots were quantified by densitometry 
and normalized with α-tubulin, mean ± SD of three independent experiments are indicated. 
 
We measured glutamate in the supernatants of cdh1-silenced neurons. We observed 
a tendency of glutamate increase, which was however not significant. Since there 
was only a small increase in glutaminase in cdh1-silencend neurons, we speculated 
that this increase was not sufficient to significantly increase extracellular glutamate 
levels (Figure 5.25).  
a b 
c 
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Figure 5.25 | Extracellular glutamate levels in cdh1-silenced neurons. Glutamate levels in the 
extracellular culture medium of neurons in control conditions or upon treatment with smart pool on 
target siRNA. Mean values ± SD of three independent experiments are shown. There is no 
statistically significant difference between the two groups.  
 
In order to improve cdh1 silencing efficiency, we repeated cdh1 silencing using 
‘Accell siRNA’, which is specialized siRNA for ‘difficult-to-transfect’ cells, like 
primary neurons. This siRNA does not require any transfection reagent but has to 
be used at higher concentrations (1 µM). Neurons were incubated in standard 
culture medium with reduced serum concentration (1%) for 96 hours with either 
control siRNA or cdh1 siRNA. The silencing of cdh1 was highly efficient and 
glutaminase significantly increased in cdh1-silenced neurons. When the cells were 
additionally treated with Aβ, it was added in the last 24 hours to the neurons upon 
silencing treatment. This caused a further increase in glutaminase in the samples 
(Figure 5.26 a-d).    
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Figure 5.26 | Glutaminase (gls) increases in cdh1-silencend (accell siRNA) neurons compared to 
control siRNA. (a-c) Western blot image of cdh1 and gls in cdh1-silenced neurons with or without 
Aβ. Cdh1, glutaminase and α-tubulin levels were determined in whole-cell lysates by immunoblotting 
using specific antibodies for cdh1 (1:1000), glutaminase (dilution 1:1000) and α-tubulin (dilution 
1:1000). (d) Glutaminase levels were quantified by densitometry and normalized with α-tubulin, 
mean ± SD of three independent experiments are indicated and are statistically significant (p < 0,05). 
 
We measured glutamate in the supernatants in these cdh1-silenced neurons and 
observed an increase, which was however not significant due to high standard 
deviations.  
The glutamate increase by APC/C inhibition using proTAME is higher than the 
glutamate increase caused by cdh1 depletion. The fact that inhibition of the whole 
ubiquitin ligase complex causes a more potent increase in glutamate than cdh1 
depletion alone indicates that other coactivators (e.g. cdc20) might be involved in 
targeting glutaminase. It is also possible that the treatment conditions (96 h in low 
serum medium) leads to lower basal glutaminase expression levels. This would 
d 
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cause that glutaminase and glutamate needed more time to accumulate upon a lack 
of degradation.  
 
 
 
 
 
 
Figure 5.27 | Extracellular glutamate levels in cdh1-silenced neurons. Glutamate levels in 
extracellular culture medium of neurons with accell control siRNA or upon treatment with accel cdh1 
siRNA. Mean values ± SD of three independent experiments are shown. There is a no statistically 
significant difference between the two groups.  
 
5.4.8. Glutamate increase is caused by glutaminase accumulation 
We observed a correlation between increasing glutaminase and glutamate levels 
when neurons were treated with proTAME or Aβ. To test if the glutamate increase 
induced by proTAME or Aβ is mediated by glutaminase, we inhibited glutaminase 
using ‘compound 968’, a cell permeable benzophenanthridinone that acts as an 
allosteric inhibitor of mitochondrial glutaminase activity. We inhibited glutaminase 
when treated with proTAME or Aβ for 24 hours and measured extracellular 
glutamate levels.  
We observed that in neurons in which glutaminase was inhibited when treated with 
proTAME, the glutamate increase was completely abolished (Figure 5.28). This 
indicates that glutamate increase induced by APC/C inhibition is caused by 
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glutaminase accumulation. The glutamate increase in Aβ treated neurons was 
partially reduced when glutaminase is inhibited  (Figure 5.29). This result suggests 
that glutaminase is involved in Aβ-induced glutamate increase.   
 
 
 
 
 
 
Figure 5.28 | Extracellular glutamate increase upon APC/C inhibition is abolished when 
glutaminase is inhibited. Neurons were treated with proTAME (pT) or pT and a glutaminase 
inhibitor (GI) for 24 h. Mean values ± SD of three independent experiments are shown. There is a 
statistically significant difference between the two groups.  
 
 
 
 
 
 
Figure 5.29 | Extracellular glutamate increase upon Aβ treatment is reduced when glutaminase 
is inhibited. Neurons were treated with Aβ alone or Aβ and a glutaminase inhibitor (GI) for 24 h.  
Mean values ± SD of three independent experiments are shown. There is a statistically significant 
difference between the two groups.  
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5.4.9. Glutaminase accumulation causes apoptosis 
We then tested whether the glutaminase and glutamate increase, we observed upon 
APC/C inhibition cause excitotoxicity, inducing apoptosis.  
First, we used flow cytometry analysis to determine whether inhibition of APC/C 
activity induced apoptosis in neuron cells. They were treated with proTAME for 0, 
4, 10, 16 and 24 h and were carefully detached using trypsin and subjected to flow 
cytometry using an ‘Annexin V-FITC Apoptosis Detection Kit’. We observed a 
significant increase in apoptosis upon the treatment after 24 h (Figure 5.30).  
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Figure 5.30 | APC/C inhibition by proTAME causes apoptosis in primary neurons. (a) 
Representative assays of flow cytometry analysis for apoptosis in neurons after 0, 4, 10, 16 and 24 
hours. (b) Flow cytometry analysis for apoptosis of neurons shows the fold change ± SD of apoptotic 
cells level upon a time-course of pT treatment. Three independent experiments were quantified and 
were significant at 24 h of treatment (p < 0,01). 
 
Moreover, neurons were next treated with proTAME alone or proTAME and the 
glutaminase inhibitor, as described above, for 20 h. Neurons were carefully 
detached using trypsin and subjected to flow cytometry using an ‘Annexin V-FITC 
Apoptosis Detection Kit’. We observed proTAME treatment caused apoptosis in 
neurons, which was reduced when glutaminase was inhibited at the same time 
(Figure 5.31). 
pT = 24 h b 
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Figure 5.31 | APC/C inhibition induces apoptosis, which is reduced when glutaminase is 
inhibited at the same time. Representative assays of flow cytometry analysis of neurons under (a) 
control conditions, (b) treated with proTAME or (c) proTAME and glutaminase inhibitor ‘compound   
968‘ for 20 h. (d) Mean FITC values ± SD are shown and are statistically significant (p < 0,005, p < 
0,01).   
We also checked whether the inhibition of glutaminase alone affects the viability 
and apoptosis levels in neurons. There was no difference between the controls and 
neurons treated with the inhibitor (Figure 5.32).  
 
a b 
c d 
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Figure 5.32 | Glutaminase Inhibitor treatment in primary neurons. (a) Representative assays of 
flow cytometry analysis for apoptosis of neurons under control conditions, or treated with the 
glutaminase inhibitor (GI) for 20 h. (b) Mean FITC values ± SD are shown from data of three 
independent experiments. 
 
Next, we tested whether apoptosis induced by Aβ can be ameliorated by 
glutaminase inhibition. Neurons were treated with Aβ or Aβ and the glutaminase 
inhibitor for 20 h. Apoptosis was measured as described above by flow cytometry. 
Control GI 
103 
 
We observed Aβ treatment induced apoptosis, which was ameliorated by inhibition 
of glutaminase (Figure 5.33). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.33 | Aβ-induced apoptosis is ameliorated when glutaminase is inhibited. Representative 
assays of flow cytometry analysis of neurons under (a) control conditions, (b) treated with Aβ (c) Aβ 
and glutaminase inhibitor ‘compound   968‘ for 20 h. (d) Mean FITC values ± SD are shown and are 
statistically significant (p < 0,001; p < 0,01).  
 
a b 
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These results show that the glutamate increase induced by Aβ or proTAME causes 
apoptosis, mediated by glutaminase. The inhibition of glutaminase promotes cell 
viability in these toxic conditions.  
 
5.4.10. Glutamine is required for glutamate increase 
Glutaminase catalyses the reaction from glutamine to glutamate and ammonia. To 
test to which extend glutamate is metabolized from glutamine after the treatment 
with proTAME or Aβ, we tested if the removal of glutamine from the medium 
affects the glutamate levels in these treatment conditions.  
Neurons were treated with proTAME or Aβ  in control medium or glutamine-free 
medium for 24 h. We observed no increase of glutamate when glutamine was 
removed from the medium (Figure 5.34).  
 
 
  
 
 
 
 
Figure 5.34 | Extracellular glutamate increase observed upon proTAME (pT) or Aβ treatment is 
abolished when glutamine is removed from the medium. Neurons were treated with pT or Aβ in 
medium with or without glutamine for 24 h. Mean values ± SD of three independent experiments are 
shown. There is a statistically significant difference between the two groups.  
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5.4.11. Ammonia increases when APC/C is inhibited by proTAME 
We then tested if ammonia, the by-product of the transformation of glutamine to 
glutamate, also increases when APC/C is inhibited.  
Neurons were treated with proTAME as described above for 24 h with or without 
glutamine in the medium. The supernatants were collected and ammonia was 
measured using an ammonia assay kit. We observed a significant increase of 
ammonia when APC/C was inhibited. The control condition, without glutamine, 
showed that there was no increase in ammonia when glutamine was removed from 
the medium (Figure 5.35). 
 
  
 
 
 
 
 
 
Figure 5.35 | Extracellular ammonia increases upon APC/C inhibition. Neurons were treated 
proTAME (pT) in medium with or without glutamine for 24 h. Mean values ± SD of three 
independent experiments are shown. There is a statistically significant difference between the two 
groups.  
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5.5. Intracellular Ca2+ Levels Increase Upon APC/C Inhibition 
Excitotoxicity is characterized by increased Ca
2+ 
influx through glutamate receptor 
channels. We had observed increased glutamate levels upon APC/C inhibition by 
proTAME or Aβ treatment. Here we tested whether the increased extracellular 
glutamate levels lead to an intracellular Ca
2+ 
increase.  
Neurons were isolated and cultured in chamber slides for microscope analysis as 
described in the method section. They were treated with Aβ, proTAME, or 
proTAME and glutaminase inhibitor ‘compound 968’ for 24 h. Glutamate 
treatment (500 µM) was used as a positive control. Cytochemical analysis using 
Fluo4 showed that there was a rise in the intracellular Ca
2+
 level after 24 h of 
treatment with Aβ or proTAME. Such levels were similar to those of cells treated 
directly with glutamate (500 µM). When glutaminase was inhibited in neurons, 
which were treated with proTAME, the increase in Ca
2+
 levels was abolished 
(Figure 5.36).  
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Figure 5.36 | Ca2+ increases upon APC/C inhibition. (a) Representative images of calcium by Fluo4 
staining in neurons upon different treatments C, Aβ (5 µM), glutamate (500 µM), proTAME (12 µM), 
proTAME (12 µM) + GI (100 µM) for 24 h. Ca2+ staining intensities (Fluo4) were normalized to 
nuclei staining intensities (Hoechst). (b) The mean values ± SD from images of three independent 
experiments are shown and are statistically significant. Scale bar = 200 µM. 
 
5.6. Upstream Regulators of Cdh1 
5.6.1. Cdk5 increases with Aβ and glutamate treatment in neurons 
It was shown that cdk5 phosphorylates cdh1 in excitotoxicity (Maestre et al., 
2008). We observed that cdh1 decreases in neurons when treated with Aβ. It has 
been reported that Aβ causes dysregulation in Ca2+ homeostasis and that this leads 
an increase in cdk5. Here we tested whether cdk5 is affected by Aβ or glutamate, 
as we have previously observed increased levels of Ca
2+ 
upon those treatments.   
Neurons were treated with Aβ or glutamate as described above and cdk5 protein 
levels were measured by western blotting. We detected cdk5 at the corresponding 
molecular weight of 30 kDa by a specific antibody (Figure 5.37 a).  In three 
b 
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independent experiments we observed that cdk5 accumulates when treated with Aβ 
or glutamate (Figure 5.37 a-d).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.37 | Cdk5 increases upon Aβ or glutamate treatment. (a-c) Neurons in primary culture 
were treated with Aβ or glutamate for 24 h. Cdk5 and α-tubulin levels were determined in whole-cell 
lysates by immunoblotting using specific antibodies for cdk5 (dilution 1:1000) and α-tubulin (dilution 
1:1000). Blots were quantified by densitometry and normalized with α-tubulin; values are indicated 
below the blots. (d) The mean values ± SD of cdk5, normalized to α-tubulin, showed a significant 
increase after the treatment (p < 0,05). 
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5.6.2. p25/p35 increases with Aβ and glutamate treatment in neurons 
The activator of cdk5 is p35. The Ca
2+
 activated protease calpain cleaves p35 to 
p25, a more stable peptide. Therefore the increase in Ca
2+
 leads to a more stable 
Cdk5-p25 complex. We have observed that cdk5 increases when treated with Aβ or 
glutamate and tested here the protein levels of p35 and p25 upon these treatments. 
Neurons were treated as described above and p35 and p25 protein levels were 
measured by western blotting. 
We detected p35 and p25 at the corresponding molecular weight of 35 and 25 kDa 
by a specific antibody (Figure 5.38 a). In three independent experiments we 
observed that p25 accumulates significantly when treated with Aβ or glutamate 
(Figure 5.38 a-c).  
 
 
 
 
 
 
 
 
 
 
 
 
a 
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Figure 5.38 | p25/p35 increases upon Aβ or glutamate treatment. (a-b) Neurons in primary culture 
were treated with Aβ or glutamate for 24 h. p25/p35 and α-tubulin levels were determined in whole-
cell lysates by immunoblotting using specific antibodies for p25/p35 (dilution 1:1000) and α-tubulin 
(dilution 1:1000). Blots were quantified by densitometry and normalized with α-tubulin; values are 
indicated below the blots. (c) The mean values ± SD of p25/p35, normalized to α-tubulin, showed a 
significant increase after the treatment. 
 
5.6.3. Cdk5 mediates decrease of cdh1 and glutaminase accumulation 
We have observed that cdk5 and its activator p25 increases upon treatment with 
Aβ. It is also known that it is a kinase that phosphorylates cdh1, leading to its 
inactivation and degradation. Here we tested if the inhibition of cdk5 by roscovitin 
leads to a stabilization of cdh1 when treated with Aβ. We also measured 
glutaminase levels upon cdk5 inhibition.   
Neurons were treated with Aβ (5 µM) alone or Aβ and roscovitin (15 µM) for 24 h. 
After the treatment, neurons and their supernatants were collected. We observed 
that the Aβ-induced cdh1 decrease is partially reversed when cdk5 is inhibited. In 
the same line, glutaminase accumulation is limited upon inhibition of cdk5 in Aβ 
treated neurons (Figure 5.39).  
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Figure 5.39 | Cdk5 inhibition reduces Aβ-induced decrease of cdh1 and glutaminase 
accumulation. (a-d) Neurons in primary culture were treated with roscovitine (RV), Aβ or Aβ and 
RV for 24 h. Cdh1, glutaminase (gls) and α-tubulin levels were determined in whole-cell lysates by 
immunoblotting using specific antibodies for cdh1 (dilution 1:1000), gls (dilution 1:1000) and α-
tubulin (dilution 1:1000). Blots were quantified by densitometry and normalized with α-tubulin; 
b 
c 
d 
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values are indicated below the blots. (d) The mean values ± SD are shown and the result demonstrates 
a significant change in cdh1 and glutaminase levels after the treatments. 
 
5.6.4. Glutamate increase by Aβ is reduced upon cdk5 inhibition  
We have observed that extracellular glutamate increases in neuron when treated 
with Aβ, mediated by cdh1 decrease and glutaminase accumulation. Furthermore, 
we showed that cdk5 mediates Aβ-induced alterations. Here we measured the 
extracellular glutamate levels of neurons treated with Aβ or Aβ and roscovitin, a 
cdk5 inhibitor. The treatments were accomplished as described above and 
supernatants were collected after 24 h. Glutamate increased significantly in 
samples treated with Aβ after 24 h and this was slightly reversed by cdk5 inhibition 
(Figure 5.40).  
 
 
 
  
 
 
Figure 5.40 | Extracellular glutamate increase induced by Aβ is reduced when cdk5 is inhibited. 
Neurons were treated with roscovitine (RV), Aβ or Aβ and RV for 24 h and glutamate was measured 
in the supernatant. Mean values ± SD of three independent experiments are shown. There is a 
statistically significant difference between the two groups.  
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5.6.5. Pten decreases upon Aβ treatment 
We have observed that cdk5-p25 regulates cdh1 upon Aβ treatment and 
consequently also, glutaminase and glutamate levels. We sought to identify 
whether there were other upstream regulators of cdh1. We looked for possible 
candidates in the literature according to the following criteria: (a) A protein that 
functions as a kinase or phosphatase, which has been related to cdh1 regulation and 
(b) that is known to be involved in AD. A protein fulfilling these criteria is the 
phosphatase and tensin homologue (Pten). 
PTEN is another known upstream regulator of APC/C-Cdh1, responsible for 
assembly of APC/C with cdh1 in the nucleus (Garcia-Cao et al., 2012). Loss of 
PTEN negatively affects the activity of the E3 ligase APC/C-Cdh1 (Cordero-
Espinoza et al., 2013). PTEN is one of the most frequently mutated/deleted tumor 
suppressors in human cancers. Moreover, PTEN deficiency results in 
hyperphosphorylation of tau (Kerr et al., 2006; Nayeem et al., 2007).     
Neurons in primary culture were treated with Aβ (5 µM) for 20 h as described 
above. The samples were subjected to western blotting and we detected Pten at the 
corresponding molecular weight of 54 kDa by a specific antibody (Fig 5.41 a). We 
observed that Pten decreases when treated with Aβ (Figure 5.41 a-c).  
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Figure 5.41 | Pten decreases upon Aβ treatment. (a-b) Western blot images of Pten under control 
conditions or with Aβ. Pten and α-tubulin levels were determined in whole-cell lysates by immuno-
blotting using specific antibodies for Pten (dilution 1:1000) and α-tubulin (dilution 1:1000). Blots 
were quantified by densitometry and normalized with α-tubulin levels, values are indicated below the 
blots. (c) The mean values ± SD of three independent experiments are shown. 
 
 
 
a 
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5.7. Glutamate Treatment in Neurons  
Maestre et al. (2008) showed that cdh1 is phosphorylated by cdk5 in excitotoxicity. 
We observed that cdh1 decreases upon Aβ treatment, which has been shown to 
cause dysregulation in Ca
2+ 
homeostasis. Therefore, we tested here whether 
glutamate, which induces an increase in intracellular Ca
2+ 
levels, affects cdh1 and 
glutaminase levels.  
Neurons in primary culture were treated with Aβ (5 µM) or glutamate (500 µM) for 
24 h. We observed that glutamate treatment caused a decrease in the cdh1 protein 
level, similar to the one caused by Aβ (Figure 5.42 a-d). 
 
 
 
 
 
 
 
 
 
 
Figure 5.42 | Cdh1 decreases upon treatment with glutamate. (a-c) Western blot images of cdh1 
and under control conditions, with Aβ or glutamate (a) 200 µM or 500 µM and (b-c) 500 µM 
treatment. Cdh1 and α-tubulin levels were determined in whole-cell lysates by immune-blotting using 
a b 
c d 
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specific antibodies for cdh1 (dilution 1:1000) and α-tubulin (dilution 1:1000). Blots were quantified 
by densitometry and normalized with α-tubulin levels, values are indicated below the blots. (d) The 
mean values ± SD of three independent experiments of controls, Aβ and glutamate (500 µM) are 
indicated. 
 
Next, we measured the levels of glutaminase in these samples. We observed that 
the glutamate treatment caused an increase in glutaminase, similar to that caused 
by Aβ (Figure 5.43). The results indicate that glutamate affects cdh1-glutaminase 
levels in a similar way as Aβ. The next step was to analyse apoptosis upon 
glutamate treatment and if it can be prevented by glutaminase inhibition.  
 
 
 
 
 
 
 
 
 
 
Figure 5.43 | Glutaminase (gls) increases upon treatment with glutamate. (a-c) Western blot 
images of gls and under control conditions, with Aβ or glutamate (a) 200 µM or 500 µM and (b,c) 
500 µM treatment. Gls and α-tubulin levels were determined in whole-cell lysates by immune-
a b 
c 
d 
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blotting using specific antibodies for gls (dilution 1:1000) and α-tubulin (dilution 1:1000). Blots were 
quantified by densitometry and normalized with α-tubulin levels, values are indicated below the blots. 
(d) The mean values ± SD of three independent experiments of controls, Aβ and glutamate (500 µM) 
are shown and are statistically significant. 
 
5.7.1. Apoptosis in glutamate-treated neurons 
First, we tested whether glutamate induced apoptosis in our experimental setting. 
Primary neurons were treated with Aβ (5 µM) or glutamate (500 µM) for 20 h and 
analysed by confocal microscopy using Annexin staining. We observed that 
apoptosis was induced at 500 µM glutamate comparable to apoptosis induced upon 
Aβ treatment (Figure 5.44). We continued the apoptosis analysis by flow 
cytometry.  
 
 
 
 
 
 
 
 
Figure 5.44 | Apoptosis increases upon Aβ and glutamate treatment. (a) Representative images of 
annexin stained neurons upon the treatments C, Aβ (5 µM), glutamate (500 µM).  
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5.7.2. Glutamate induces apoptosis mediated by glutaminase  
Neurons were treated with glutamate (500 µM) alone or glutamate and glutaminase 
inhibitor for 20 h. Neurons were carefully detached using trypsin and subjected to 
flow cytometry using an ‘Annexin V-FITC Apoptosis Detection Kit’. We observed 
glutamate treatment induced apoptosis in neurons, which was reduced by 
glutaminase inhibition (Figure 5.45). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.45 | Glutamate induced apoptosis is ameliorated when glutaminase is inhibited. 
Representative assays of flow cytometry analysis of neurons under (a) control conditions, (b) treated 
a 
b 
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with glutamate 500 µM (c) glutamate 500 µM and glutaminase inhibitor ‘compound   968‘ for 20 h. 
(d) Mean FITC values ± SD are shown.  
 
5.8. APC/C-Cdh1 in vivo 
The critical facts of the findings in neuron culture were then tested in in vivo 
models.  
5.8.1. Aβ or glutamate microinjection in hippocampus affects cdh1 and 
glutaminase 
We used microinjection in the brain of Wistar rats to test the effect of Aβ or 
glutamate on cdh1. We injected 10 µl volume of vehicle solution, Aβ (5 µM) or 
glutamate (1 mM) in the CA1 region of rat hippocampus according to stereotaxic 
adjustments and two days later the animals were sacrificed. The brains were 
prepared for immunohistochemical analysis. The result showed that cdh1 is located 
in the nucleus and in the cytoplasm in control conditions (vehicle injection) in CA1 
neurons. Injection of Aβ or glutamate causes nuclear export of cdh1, which results 
in a 25% decrease of nuclear cdh1 (Figure 5.46 a-b). Both treatments also caused 
an increase in glutaminase in neurons in the pyramidal CA1 layer (Figure 5.46 a-
b).  
 
 
 
 
 
 
a 
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Figure 5.45 | Cdh1 in hippocampal CA1 brain slices (40 µm) after microinjection of Aβ or 
glutamate. (a) Representative images of cdh1 and dapi stained (nucleus) hippocampal slices show 
nuclear export of cdh1 when treated with Aβ or glutamate compared to vehicle injection. (b) Results 
are show as mean ± SD of images of three independent experiments; percentages of nuclear and 
cytoplasmic cdh1 are shown (p[C; Aβ] < 0,01; p[C;Glut] < 0,01). 
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Figure 5.46 | Glutaminase in hippocampal CA1 brain slices (40 µm) after microinjection of Aβ 
or glutamate. (a) Representative images of glutaminase (gls) and dapi stained (nucleus) hippocampal 
slices show that glutaminase levels increase upon treatment with Aβ or glutamate. (b) Results are 
shown as mean ± SD of glutaminase area normalized to dapi area (p[C; Aβ] < 0,05; p[C;Glut] < 0,001). 
Scale bar = 75 µm.  
 
5.8.2. Cdh1 and glutaminase in APP/PS1 mice by immunoblotting 
After the in vivo study using acute Aβ or glutamate treatment, we tested the role of 
APC/C-Cdh1 in AD pathophysiology in the APP/PS1 mouse model of AD. 
APP/PS1 mice are subjected to chronic exposure to Aβ. We compared the protein 
levels of cdh1 and glutaminase in wild type (WT) and APP/PS1 mice at the age of 
9 months (n=12).  
Using western blot analysis, we observed lower levels of cdh1 in cortex 
homogenates of APP/PS1 compared to WT mice. Analysis of glutaminase in the 
same samples showed higher levels in APP/PS1 than in the WT mice (Figure 5.47).  
 
 
 
 
 
 
 
a b 
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Figure 5.47 | Cdh1 and glutaminase in APP/PS1 mice. (a) Western blot analysis of cdh1 and 
glutaminase protein levels were measured in homogenates of mouse cerebral cortex of 3 wild type 
(WT) and 3 transgenic APP/PS1 mice. Cdh1 is decreased in APP/PS1 mice compared to WT [images 
of cdh1 bands are from the same western blot]. Glutaminase (gls) is increased in APP/PS1 mice 
compared to WT. (b) Cdh1 and gls western blot were quantified by densitometry and normalized with 
α-tubulin levels, mean ± SD of three independent samples are shown in the histogram. 
 
5.8.3. mRNA levels of cdh1, APC/C2 and glutaminase in WT and APP/PS1 
mice 
In the previous experiments we have observed a difference in the protein levels of 
cdh1 and glutaminase in WT and APP/PS1 mice. Next, we tested whether there is 
there a difference in mRNA expression of cdh1, APC/C2 or glutaminase in WT 
and APP/PS1 cortex homogenates using qPCR. We observed no statistical 
significant difference in the expression of these genes. This result indicates that 
differences in cdh1 and glutaminase protein levels occur due to post-translational 
modifications (Figure 5.48).  
 
c 
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Figure 5.48 | mRNA levels of APC/C2, cdh1 and glutaminase in mouse brain homogenates. RNA 
was isolated from cortex samples using Trizol and was then retro-transcribed to cDNA. Specific 
primers were used to determine APC/C, cdh1, glutaminase and GAPDH levels by real time qPCR. 
Mean values ± SD of cdh1, APC/C2 and glutaminase normalized to GAPDH are shown in the 
histogram. There is no statistically significant difference (n=3).  
 
5.8.4. Cdh1 and glutaminase in APP/PS1 mice by immunohistochemistry  
For immunohistochemical analysis we isolated hippocampi of 6 animals (3 WT, 3 
APP/PS1 mice). They were fixed in 4% PFA, embed in paraffin and 5 µm slices 
were prepared. The slices were mounted on chamber glass, incubated with cdh1 or 
glutaminase antibodies and stained using DAB-peroxidase. Nuclei were stained 
with hematoxylin. We observed less cdh1 in slices from APP/PS1 mice compared 
to slices prepared from WT (Figure 5.49 a-c). In slices of the same animals we 
observed more glutaminase staining (Figure 5.50 a-b). 
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Figure 5.49 a-c | Immunohistochemical staining of cdh1 in WT and APP/PS1 mice. Paraffin 
embed hippocampus slices (5 µm) of wildtype (WT) and APP/PS1 mice were stained with cdh1 
(1:100) (brown). Nuclei were stained with hematoxylin (blue). (a) Cdh1 and hematoxylin. Scale bar = 
20 µm. (b) Cdh1 without hematoxylin staining. Scale bar = 50 µm. (c) Cdh1 and hematoxylin. Scale 
bar = 20 µm. 
 
a 
b 
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Figure 5.50 | Immunohistochemical staining of glutaminase (gls) in WT and APP/PS1 mice. 
Paraffin embed hippocampus slices (5 µm) of wildtype (WT) and APP/PS1 mice were stained with 
glutaminase (1:100) (brown). Nuclei were stained with hematoxylin (blue). (a) Scale bar = 200 µm. 
(b) Scale bar = 50 µm. 
 
Once we had observed these differences in WT and APP/PS1 animals, we did 
additional analysis using fluorescent antibodies for cdh1 and glutaminase. 
Perfusion of six animals was carried out for immunohistochemical analysis. We 
observed a significantly lower cdh1 signal in the nucleus in transgenic animals 
compared to WT in the hippocampal CA1 region (Figure 5.51 a-b). Measurement 
a 
b 
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of glutaminase showed significantly increased levels in APP/PS1 compared to WT 
animals (Figure 5.52 a-b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.51 | Immunohistochemical analysis of cdh1 in APP/PS1 mice. (a) Representative images 
of cdh1 and nucleus (dapi) stained hippocampal slices of wild type (WT) and transgenic APP/PS1 
a 
b 
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mice. Results are show as mean ± SD of the percentage of nuclear and cytoplasmic cdh1 (p[WT; TG] < 
0,01). Scale bar = 75 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.52 | Immunohistochemical analysis of glutaminase in APP/PS1 mice. Representative 
images of glutaminase (gls) and nucleus (dapi) stained hippocampal slices of WT and APP/PS1 
b 
a 
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animals. Results are show as mean ± SD of glutaminase area normalized to dapi (p[WT; TG] < 0.001). 
Scale bar = 75 µm. 
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6. DISCUSSION 
 
In this work we studied the role of APC/C-Cdh1 in AD. Previous studies have 
reported an increased abundance of APC/C substrates in AD brains, which suggests 
a dysregulation of the protein complex in the disorder. We report for the first time 
results that show a direct implication of APC/C-Cdh1 in the disease. We found that 
Aβ reduces the steady state levels and nuclear localization of the APC/C 
coactivator subunit cdh1 in primary cortical neurons in vitro and in the 
hippocampus in vivo. Reduced cdh1 levels lead to an accumulation of the enzyme 
glutaminase, an APC/C-Cdh1 substrate. This causes enhanced glutamate 
generation, an increase in intracellular calcium levels, and apoptosis in neurons in 
culture. Similar results were observed following the treatment of cells with the 
APC/C inhibitor proTAME.  
A major conclusion of this study is that maintaining normal APC/C-Cdh1 activity 
may be a useful target in AD treatment. 
 
6.1. Aβ alters Cdh1 in Neurons  
While cdh1 levels oscillate during the cell cycle, in post-mitotic neurons cdh1 
levels are maintained in a steady state.  
It has been well documented that phosphorylation of cdh1 abolishes its ability to 
activate APC/C (Zachariae et al., 1998; Kotania et al., 1999). Cell cycle-related 
studies showed that cdh1 phosphorylation is controlled by cyclin dependent kinases 
and phosphatases (Jaspersen et al., 1999; Lukas et al., 1999). Phosphorylation of 
cdh1 promotes nuclear export (Jaquenoud et al., 2002) and it also inhibits its 
nuclear import (Zhou et al., 2003). Thus, phosphorylation of cdh1 has dual effects 
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on nuclear export and import, both of which lead to cytoplasmic retention of cdh1. 
It has been shown that phosphorylated cytoplasmic cdh1 is inactive, and it was 
suggested that nuclear decrease of cdh1 therefore contributes to the inactivation of 
APC/C (Jaquenoud et al., 2002). Furthermore, the SCF complex is involved in the 
degradation of phosphorylated cdh1 in the cytoplasm (Benmaamar and Pagano, 
2005; Almeida, 2012), which may lead to decreased cdh1 levels after 
phosphorylation.  
In our study we tested whether Aβ affects total cdh1 levels in neurons in culture 
and we also analyzed nuclear and cytoplasmic cdh1 levels. We observed a 
proteasome-dependent cdh1 decrease in total cell lysates in neurons in primary 
culture after Aβ treatment. Furthermore, cdh1 was completely abolished in the 
nucleus when treated with Aβ, which suggests that nuclear export of cdh1 
occurred. Other studies reported that nuclear export of cdh1 occurs after cdh1 
phosphorylation, which led us hypothesize that cdh1 might have been 
phosphorylated in neurons when treated with Aβ. We could not analyze 
phosphorylation of cdh1 directly, since there is no commercially available 
phospho-cdh1 antibody. 
Analysis of cdh1 protein half-life with and without Aβ treatment showed that the 
protein half-life of cdh1 is shorter when treated with Aβ. This suggests that Aβ acts 
on cdh1 in a post-translational manner.  
mRNA levels of cdh1 and APC/C2 did not change in response to Aβ treatment. We 
confirmed that mRNA expression is not affected by the treatment and concluded 
that the cdh1 decrease depends only on post-transcriptional modifications. Also the 
core subunit, APC/C2 with catalytic function, did not show a significant difference 
in expression, which allows us to conclude that the activity of APC/C is not 
affected by Aβ through downregulation of the expression this subunit.  
 
132 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 | Schematic representation of the results and conclusions summarized in this section. 
Aβ induces cdh1 nuclear export (effect direct or indirect, indicated by dashed line). Cdh1 is then 
degraded in the cytoplasm by the proteasome. 
 
Maestre et al. (2008) showed that cyclin dependent kinase 5 (cdk5) phosphorylates 
cdh1 in excitotoxic conditions in neurons. Therefore we analyzed if cdk5 was 
involved in Aβ-mediated degradation of cdh1.  
 
6.2. The Upstream Regulators of APC/C-Cdh1: Cdk5-p25 and PTEN  
Cdk5 is a serine/threonine kinase which has an important role in postmitotic 
neurons. It is considered to be a non-traditional cdk, since it has no established role 
as a cell-cycle regulator protein. However, in neurons it was shown to be involved 
in cell cycle arrest (Zhang et al., 2008; Cicero and Herru, 2005).   
Among the set of substrates of the kinase activity of cdk5 are cytoskeletal proteins 
and it was shown that cdk5 catalyses the phosphorylation of Tau proteins and 
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neurofilaments (Lew et al., 1995). Lee et al. found elevated cdk5 kinase activity in 
human AD brains compared to controls, thus it is an attractive target in AD 
research (Lee et al., 1999).   
 
Cdk5 forms a complex with one of its regulatory activators p35 or p39, which 
activates the enzymatic function of cdk5. Neurotoxic insults, like ischemia or 
the presence of Aβ that induce Ca2+ dysregulation, lead to an over-activation of 
the calcium-dependent protease calpain which cleaves p35 into a 25 kDa 
fragment termed ‘p25’. The shorter peptide p25 has a longer half-life than p35, 
because it cannot be properly degraded. Cdk5-p25 forms a stable complex leading 
to constitutive activation of the kinase. It has been shown that this leads to 
neurodegeneration (Patrick et al., 2000). Here we showed that Aβ treatment in 
neurons in culture causes an increase in cdk5-p25, and that inhibition of cdk5 
partially rescued the Aβ-induced decrease of cdh1. Taking our results and the 
previous findings together, there is strong evidence for an Aβ-induced Ca2+ – cdk5-
p25 – cdh1 signalling aberration in AD. 
 
 
 
 
 
 
Figure 6.2 | Schematic representation of results summarized from this section. Aβ and glutamate 
treatments cause intraneuronal Ca2+ dysregulations. Cdk5-p25 increases and mediates cdh1 
degradation.  
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Phosphatase and Tensin Homolog (PTEN) promotes APC/C-Cdh1 assembly in the 
nucleus, probably in a manner independent of its phosphatase activity (Song et al., 
2011). Loss of PTEN negatively affects the activity of the E3 ligase APC/C-Cdh1, 
resulting in the stabilization of glutaminase and pfkfb3 in proliferating cells 
(Cordero-Espinoza et al, 2013; Garcia-Cao et al., 2012). PTEN is one of the most 
frequently mutated/deleted tumor suppressors in human cancers. Loss of PTEN in 
the cerebellum results in hyperphosphorylation of tau and in cdk5 activation (Kerr 
et al., 2006; Nayeem et al., 2007). We reported here that Aβ decreases PTEN 
levels. We suspect that cdh1 becomes phosphorylated by cdk5 and cannot re-
assemble with APC/C properly due to low levels of PTEN, and this might be the 
reason why cdh1 remains in the cytoplasm, where it becomes degraded. 
 
6.3. Accumulation of APC/C-Cdh1 Substrates in Neurons is Related to AD  
Once we had observed the decrease of cdh1 in neurons after the treatment with Aβ, 
we analysed protein levels of substrates of APC/C-Cdh1 in these samples. We 
looked for APC/C substrates in the literature, which were expressed in neurons and 
that were known to be dysregulated in AD. Three proteins that met these 
characteristics were cyclin B1, pfkfb3 and glutaminase.  
Elevated levels of cyclin B1 in neurons are involved in the re-entry into an ectopic 
cell cycle in neurons in AD (Vicent et al., 1997; Bonda et al., 2009). We have 
observed that direct APC/C inhibition or cdh1 downregulation by Aβ treatment, led 
to an accumulation of cyclin B1. Since this protein is a well-described target of 
APC/C in neurons, we used it as a “positive control” for testing APC/C degradation 
activity. Next, we tested pfkfb3, a protein that is targeted by APC/C in neurons to 
keep basal level of glycolysis low. The controlled degradation of pfkfb3 is 
responsible to keep up an antioxidant status in neurons. Therefore the accumulation 
of this enzyme can lead to oxidative stress and apoptosis in neurons (Herrero-
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Mendez et al., 2009). However, in our experimental conditions we could not 
observe an increase in pfkfb3 upon treatment with Aβ after 20 h. It is possible that 
the basal expression level of pfkfb3 is too low to detect an accumulation of pfkfb3 
within 20 h of treatment. Pfkfb3 might also be co-regulated by other mechanisms 
and its protein level might not only depend on the degradation of APC/C-Cdh1.   
It has been reported that glutaminase is a target of APC/C-Cdh1in lymphocytes 
(Colombo et al., 2010). Glutaminase has important functions in neurons, as it a 
main source for the production of the neurotransmitter glutamate. When glutamine 
enters the mitochondria, glutaminase converts it to glutamate and ammonia. 
Alterations of glutaminase levels in AD were first reported in 1989 by Akiyama et 
al., who described a loss of glutaminase-positive neurons in late stages of AD. 
Furthermore, neurons immunoreactive to glutaminase and glutamate have been 
correlated with the formation of neurofibrillary tangles in AD (Kowall and Beal, 
1991). Burbaeva et al. (2005) reported increased levels of glutaminase in the 
prefrontal cortex of AD patients. 
First, we tested whether glutaminase is targeted for degradation by APC/C-Cdh1 in 
neurons, using siRNA to silence cdh1. We confirmed that it accumulated in 
neurons when cdh1 was depleted. Additionally, we inhibited the whole APC/C 
complex using the specific inhibitor proTAME, and observed that glutaminase 
accumulated upon that treatment. In the same line, we observed an accumulation of 
glutaminase in neurons when they were treated with Aβ. In the following parts of 
this project we analysed downstream effects of glutaminase accumulation in 
neurons.   
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6.4. Increased Glutamate Levels in AD 
We showed that Aβ treatment induced an increase in glutamate levels in the 
extracellular medium of neurons and that this was mediated by accumulation of 
glutaminase. Direct inhibition of APC/C was also sufficient to increase the 
glutamate concentration to similar levels as those found after Aβ treatment. The 
glutamate increase after both treatments with Aβ or proTAME was reduced when 
glutaminase was inhibited. Furthermore, removal of glutamine from the culture 
medium completely abolished the Aβ- or proTAME-induced glutamate increase. 
Our findings are relevant in AD research, as they describe a novel signalling way 
to induce excitotoxitiy, an event that occurs in AD.  
In the cerebrospinal fluid of AD patients, high levels of glutamate have been 
observed compared to healthy individuals of similar age (Pomara et al., 1992; 
Csernansky et al., 1996; Jiménez-Jiménez et al., 1998; Kaiser et al., 2010). 
Currently, glutamatergic systems are one of the main therapeutic targets in AD 
treatment (Zádori et al., 2014). Aβ synaptic toxicity can be partially ameliorated by 
the NMDAR antagonist memantine (Lipton, 2005; Tu et al., 2014). Studies related 
to AD, which focused on molecular mechanisms of excitotoxicity, reported that the 
glutamate increase was attributed to failure in the glutamate recycling system. 
Glutamate cannot be properly taken up by astrocytes because there is a decrease of 
the glutamate transporter GLT1 and thus the neurotransmitter remains in the 
synaptic cleft (Lauderback et al., 1999; Scimemi et al., 2013). We postulate here 
that excitotoxicity in AD does not only result from perturbations in the glutamate 
reuptake system, but also from aberrantly increased glutamate generation by 
glutaminase.  
Interestingly, Maestre et al. (2008) reported that an excitotoxic glutamate stimulus 
causes APC/C-Cdh1 inactivation. In this work, we have confirmed the previous 
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finding that glutamate reduces cdh1 protein levels and have shown that this also 
leads to glutaminase accumulation.  
It has been reported that an excitotoxic glutamate insult causes sustained NMDA 
receptor activation underlying a positive feedback loop (Norris et al., 2006; 
Rodriguez-Rodriguez et al., 2013). Our findings suggest that glutamate-induced 
glutaminase accumulation may contribute to a positive feedback loop of glutamate 
generation resulting in excitotoxicity, and thereby maintaining the down-regulation 
of APC/C activity. This would lead to the accumulation of APC/C-Cdh1 targets, of 
which some are related to neurodegenerative processes. An aberrant cyclin B1 
increase in neurons causes an ectopic cell cycle re-entry and high levels of pfkfb3 
induce oxidative stress (Maestre et al., 2008; Herrero-Mendez et al., 2009). 
Moreover, gene profiling has shown that excitotoxicity favors neuronal pathways 
that induce cell cycle re-activation and oxidative stress and that these events, 
together, accelerate neurodegeneration (Chen et al., 2013). We found that 
glutamate induced apoptosis can be ameliorated by glutaminase inhibition. We 
suggest these events, which all occur in AD, are linked through deficient APC/C 
activity.   
 
6.5. Increased Ammonia Levels in AD 
When glutamine enters the mitochondria, glutaminase converts it to glutamate and 
to ammonia. Excessive amounts of ammonia can have a neurotoxic effect by 
destroying the neuron’s mitochondria, because it opens gates/pores in the 
mitochondrial membrane and creates reactive oxygen species (ROS) (Norenberg et 
al., 2004; Halim et al., 2014). Furthermore, ammonia is elevated in blood and in the 
CSF of AD patients (Fisman et al., 1985; Branconnier et al., 1986; Kaiser et al., 
2010). Moderate chronic increase of ammonia concentration impairs NMDA 
receptor dependent long-term potentiation in the hippocampus and has therefore 
been related to neurological imbalance and memory impairment (Seiler, 2002).  
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We observed that inhibition of APC/C-Cdh1 increases ammonia in the extracellular 
medium of neurons. Since excess ammonia impairs glutamatergic synapses, and 
both glutamate and ammonia are overly produced in neurons in AD, these events 
together could seriously contribute to the pathogenesis of the disease.  
 
 
 
 
 
 
 
 
 
Figure 6.3 | Schematic representation of the results and conclusions summarized in these 
sections. Decreased APC/C activity (either by direct inhibition through proTAME or through cdh1 
decrease by Aβ) leads to an accumulation of glutaminase. This leads to an increase of glutamate and 
ammonia in the extracellular medium of neurons causing apoptosis.  
 
6.6. APC/C Inhibition and Ca2+ Dysregulation 
Glutamate activates NMDA receptors, leading to a subsequent intracellular 
increase of Ca
2+
. This is a central event for neuronal activity. However, increased 
glutamate levels lead to an overload of intracellular Ca
2+
 levels, which causes the 
main excitotoxic damage in neurons. Aβ causes a dysregulation in the Ca2+ 
homeostasis which leads to the stabilization of p25, the activator of cdk5 (La Ferla, 
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2002). Furthermore, Maestre et al. (2008) showed that cdk5-p25 phosphorylates 
cdh1 by over-activation of glutamate receptors through a Ca
2+
 mediated 
mechanism.  
We observed that in neurons in culture in which glutamate was increased by Aβ or 
APC/C inhibition, also intracellular Ca
2+
 levels were higher compared to basal 
levels. Moreover, we found that Aβ- or proTAME treatment induced neuronal 
apoptosis, which was ameliorated by the inhibition of glutaminase. This indicates 
that increased glutaminase levels, and resultant glutamate levels, induced 
excitotoxicity after the treatments with Aβ or proTAME.  
 
 
 
 
 
 
 
 
 
Figure 6.4 | Schematic representation of results and conclusions of the signalling cascade 
described in this project. Ca2+ dysregulation induced by Aβ or high glutamate levels, lead to a 
stabilization of cdk5-p25. This kinase phosphorylates cdh1 and inactivates the ubiquitin ligase. This 
leads to an accumulation of the APC/C-Cdh1 target, glutaminase, which leads to increased glutamate 
levels.   
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6.7. Aβ and Glutamate Reduce Cdh1 Levels in vivo  
We then turned to in vivo studies using acute insults (injections). Microinjection of 
Aβ1-42 oligomers in the CA1 field of the rat hippocampus caused nuclear export of 
cdh1 and increased glutaminase levels. It has been reported in a study using similar 
experimental setups, that intra-hippocampal microinjection of Aβ1-42 oligomers 
impaired spatial working memory in rats (Pearson-Leary and Mc, 2012).  
Similar to the effects of Aβ injection, a glutamate stimulus (by injection) caused 
nuclear export of cdh1 in the hippocampus, and also glutaminase was increased 
compared to controls. These findings might also be relevant for other 
neurodegenerative diseases, like ischemia. It has been reported that global ischemic 
injury induces downregulation of APC/C-Cdh1 in the CA1 field of the 
hippocampus in rat brain, and this was related to neuronal apoptosis (Zhang et al., 
2011). Ischemic injury causes an increase in the extracellular glutamate 
concentration leading to over-stimulation of the NMDA receptors in extrasynaptic 
sites. Proteins involved in this excitotoxic cascade are, among others, PTEN, 
calpain, cdk5, p25. These events cause delayed and progressive neuronal damage 
and neuronal death (damage appears three days post-ictus and continues 
progressively for months) (Lai et al., 2014). Our observation of the effect of 
glutamate on cdh1 suggests that cdh1 down-regulation in ischemia observed by 
Zhang et al., might have been induced by glutamate excitotoxicity. Moreover, 
APC/C-Cdh1 down-regulation and subsequent glutaminase accumulation may 
contribute to the generation of excitotoxic environments in ischemia. 
 
6.8. Cdh1 and Glutaminase in the Transgenic Mouse Model APP/PS1 
We then analysed cdh1 protein levels in the APP/PS1 mouse model of AD, in 
which neurons are chronically exposed to Aβ. This is a widely used model for AD, 
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as the amyloid plaque-pathology occurs in a very similar manner as in the human 
AD pathology. This model was developed to alter both, the presenilins and the 
human APP. In the mouse model there is a strong positive correlation between Aβ 
accumulation and cognitive decline. However, APP/PS1 mutant mice do not have 
formation of neurofibrillary tangles, neuronal loss or larger ventricles, which are 
other major hallmarks of AD in humans. Since in our study we analysed in 
particular the effect of Aβ on APC/C-Cdh1, we believe this mouse model was 
suitable for our study.  
We found lower levels of cdh1 (and predominantly less cdh1 in the nucleus) than 
in WT mice in the CA1 layer of the hippocampus. Glutaminase was increased in 
the same brain areas. Thus we confirmed our results in an in vivo model of AD. 
 
6.9. Our Findings in a Systemic View for AD 
Finally, our findings allow us to speculate about their possible involvement in the 
onset of the disease in a systemic view. In physiological conditions, glutaminase is 
present in high concentrations in hippocampus and the entorhinal cortex 
(Altschuler et al., 1985; Akiyama et al., 1989). Recently, the lateral entorhinal 
cortex has been identified as the primary area affected in preclinical phases of AD. 
This area projects to the CA1 region of the hippocampus in the lateral perforant 
pathway (LPP), which is the base of the declarative memory. The LPP is mostly 
composed of glutamatergic connections (Khan et al., 2014). The Aβ-induced 
glutamate toxicity could have deleterious effects specifically in these areas of the 
brain that are first affected in AD, because of the high basal glutaminase level. 
Therefore we postulate that excitotoxicity could be a crucial event in the onset of 
the disease and in memory impairment. 
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6.10. Outlook: APC/C-Cdh1 in AD research 
Substantial evidence has been provided that APC/C-Cdh1 and the downstream 
target glutaminase could have a major role in the pathophysiology of AD. Further 
indications suggest that some targets of APC/C are involved in processes related to 
AD. Nevertheless, it would be crucial to determine if cdh1 dysregulation occurs in 
the human AD brain. Indeed, loss of glutaminase-positive neurons has been 
observed, which suggests impaired glutaminase regulation in the disorder. 
However, studies in human AD brains are difficult to perform, most of all when a 
dysregulation occurs at the onset of a disease. 
We can, however, speculate about possible consequences of APC/C-Cdh1 
downregulation in AD. The altered activity of the ubiquitin ligase would affect a 
whole set substrates and several independent processes would be impaired. Among 
these are cell cycle regulation and neurogenesis, oxidative regulation, LTP and 
glutamate metabolism. High levels of cyclin B1 have been related in ectopic cell 
cycle reentry, accumulation of pfkfb3 induces oxidative stress in neurons and 
increased glutaminase levels causes excitotoxicity (Fig. 6.5). However, several 
other (unidentified) targets of APC/C might be involved either directly or indirectly 
in the pathophysiology of AD. In various knock-out models of cdh1, impaired in 
LTP and LTD were observed. Therefore, it would be reasonable to think, that 
impaired LTP in AD occurs due to the dysregulation of APC/C-Cdh1. Further 
analysis of APC/C substrates or related proteins involved in LTP and LTD 
(EphA4, GluR, Liprin alapha, FRMP) could give more insights of protein 
dysregulation in the disorder. 
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Figure 6.5 | Schematic representation of impaired processes related to AD caused by APC/C-
Cdh1 dysregulation. The accumulation of glutaminase, cyclin B1 and pfkfb3 are involved in 
excitotoxicity, cell cycle re-entry and oxidative stress, respectively.   
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7. CONCLUSIONS 
 
1. Aβ induces a decrease in total cdh1 and strongly reduces nuclear cdh1 
levels. The degradation occurs in a proteasome-dependent manner, while 
mRNA levels of cdh1 are not affected by the treatment.  
 
 
2. Cdk5-p25 meditates the decrease of cdh1 when treated with Aβ in neurons. 
 
 
3. Cyclin B1 and glutaminase accumulate in neurons upon Aβ treatment in 
neurons.  
 
 
4. When glutaminase is not properly degraded in neurons by APC/C-Cdh1, 
glutamate, ammonia and Ca
2+
 levels increase.  
 
 
5. The dysregulation of APC/C-Cdh1 and glutaminase induces 
neurodegeneration.  
 
 
6. Reduced nuclear and increased glutaminase cdh1 levels in vivo in APP/PS1 
mice, and after microinjection of Aβ and glutamate in rat hippocampus.  
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8.  APPENDIX: RESUMEN DE LA TESIS 
 
La enfermedad de Alzheimer (EA) es la causa más común de demencia entre las 
personas de edad avanzada mayores de 65 años. Las estimaciones sugieren que en 
la actualidad hay aproximadamente 47,5 millones de personas en todo el mundo 
que sufren de demencia, de los cuales el 60-70% son casos de EA (Wolrd Health 
Organization, 2015). Es una enfermedad irreversible de naturaleza progresiva, que 
conduce a un deterioro de las funciones cognitivas más allá de lo que es normal en 
un proceso de envejecimiento saludable. Entre las funciones cognitivas afectadas 
se encuentran la memoria, las habilidades de pensamiento y la orientación.  
La EA es una de las principales causas de discapacidad entre las personas mayores 
y tiene un gran impacto socio-económico. Actualmente no existe tratamiento para 
curar EA y es un campo muy activo en la investigación biomédica. Gran cantidad 
de nuevos tratamientos se están probando en diferentes etapas de la enfermedad 
para alterar su curso progresivo. 
Las principales lesiones que se encuentran en los cerebros de los pacientes de  EA 
son las placas seniles extraneuronales y los ovillos neurofibrilares (NFTs) 
intraneuronales. Las primeras están formadas fundamentalmente por depósitos de 
péptido beta-amiloide (A), un péptido que puede tener 40 ó 42 aminoácidos y que 
tiende mucho a la agregación y precipitación. Los NFTS están constituidos 
principalmente por agregados de la proteína tau asociada a microtúbulos, en un 
estado de hiperfosforilación. Estas acumulaciones causan daño a las células y 
provocan la pérdida neuronal progresiva, difusa y masiva. Las zonas más afectadas 
son la corteza cerebral, hipocampo, amígdala, y sus cortezas asociadas. Además, 
diversas moléculas y vías de señalización se alteran en la EA, lo que podría 
contribuir sustancialmente a la aparición y / o el progreso de la enfermedad. En 
146 
 
este trabajo se analiza la implicación de una ubiquitina ligasa E3, la llamada 
anaphase promoting complex/cyclosome (APC/C) en la EA. 
APC/C es un gran complejo de proteínas que forma un ‘ring finger’ ligasa de 
ubiquitina E3. Es considerada como uno de los principales reguladores del ciclo 
celular en células proliferantes. APC/C reconoce proteínas gracias a motivos de 
aminoácidos específicos, como secuencias KEN-BOX o D-BOX y las marca para 
su degradación. En la última década, se han descubierto importantes funciones 
neurobiológicas de APC/C, así como también de sus activadores Cdh1 y Cdc20. Se 
demostró que APC/C está implicada en el control de mantenimiento de la fase G0 
neuronal, en el crecimiento axonal, que coordina la neurogénesis y también en el 
desarrollo sináptico. Hasta la fecha, 15 sustratos han sido identificados, todos ellos 
directamente involucrados en procesos ubicados en el sistema nervioso central. La 
acumulación de algunas de estas proteínas diana de APC/C se ha asociado con la 
neurodegeneración. Por ello, en este trabajo se ha probado la hipótesis de que 
APC/C o más bien la inactivación de APC/C, podría tener un papel fisiopatológico 
relevante en la EA. 
 
Objetivos 
En primer lugar, estábamos interesados en la evaluación de si el péptido Aβ 
afectaba a los niveles de la proteína Cdh1 y a la actividad de la ubiquitina ligasa in 
vitro. A continuación, quisimos determinar si estaba mediada por cdk5 y si otras 
quinasas o fosfatasas regulan el Cdh1 en las neuronas. 
El segundo objetivo principal fue la descripción de la posibilidad de una regulación 
correspondiente de APC/C-Cdh1 sobre la glutaminasa en neuronas. La glutaminasa 
ha sido descrita anteriormente como un sustrato de la ubiquitina ligasa en los 
linfocitos. La regulación de la glutaminasa por APC/C podría ser de gran 
147 
 
importancia potencial, ya que esto sería vincular la actividad del APC/C con el 
metabolismo del glutamato en las neuronas. Las alteraciones en el metabolismo del 
glutamato y la excitotoxicidad juegan un papel importante en la EA. Y nosotros 
nos centramos en observar si la señalización de APC/C y sus sustratos deteriorada 
causaba neurodegeneración. 
Esto se llevó a cabo mediante estudios in vitro, y también se probó en el modelo de 
ratón APP/PS1, que se utiliza ampliamente en la investigación de la EA. 
 
Los objetivos concretos fueron: 
1. Comprobar si el péptido Aβ en neuronas en cultivo cambia la expresión de 
cdh1 y/o en los niveles de proteina de cdh1. 
2.  Comprobar si el tratamiento con Aβ en neuronas afecta a la eficacia en la 
degradación de APC/C-Cdh1 y por tanto, produce la acumulación de 
sustratos de la ubiquitin ligasa. 
3. Comprobar si la glutaminasa es regulada por APC/C-Cdh1 en neuronas y 
si fuera así, si esto lleva a la alteración en los niveles de glutamato y Ca
2+
. 
4. Determinar qué quinasas y fosfatasas regulan APC/C-Cdh1 en neuronas 
tratadas con Aβ. 
5. Comrobar si la desregulación de APC/C-Cdh1 causa neurodegeneración.  
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Metodología 
Cultivo celular, transfección y tratamientos 
Se prepararon cultivos primarios de neuronas corticales de cerebro de feto de rata 
Wistar a los 14 días de gestación. Las cortezas se diseccionaron mecánicamente y 
se dispersaron en un medio de cultivo libre de suero y el tejido se filtró a través de 
una red de nylon (90 micras de poro). Las neuronas se sembraron en frascos de 
cultivo T25 cubiertos con poli-L-lisina (superficie de 25 cm
2
), para los análisis de 
las muestras por Western blot, para las medidas de glutamato y para los análisis por 
citometría de flujo. Para microscopía de fluorescencia se sembraron neuronas en 
portaobjetos con cámaras de recubrimiento de vidrio, tratadas con poli-L-lisina 
(área superficial de 0,7 cm
2
).  
Las neuronas se cultivaron en ambos casos en medio DMEM suplementado con 
suero bovino fetal (10% v / v) y como antibióticos una mezcla de penicilina y de 
estreptomicina (1%). Se incubaron a 37°C en una atmósfera que contenía el 5% de 
CO2. A las 72 h después de la siembra, se añadió citosina-arabinósido (10 mM) al 
medio de cultivo, y un día más tarde fue sustituido el medio por medio de cultivo 
fresco que contiene la mitad de la cantidad de citosina-arabinósido. Al día 
siguiente, se retiró el medio y se sustituyó por otro medio de cultivo estándar. 
Después de 6 días, se obtuvo un cultivo puro del 95% de neuronas, que se utilizó 
para los tratamientos.  
El medio de cultivo fue sustituido por otro medio de cultivo fresco en el momento 
de los tratamientos, que se realizaron en las siguientes concentraciones: oligómeros 
Aβ (5 M), glutamato (500 mM) (G-1251, Sigma, St. Louis, EE.UU.), proTAME 
(12 M) (I-440, BostonBiochem, Cambridge, MA, EE.UU.), compuesto 968 (100 
M) (352010, Calbiochem, Nottingham, Reino Unido), roscovitina (15 M) (R 7772, 
Sigma, Missouri, ESTADOS UNIDOS), cicloheximida (3,5 M) (Sigma C7698, 
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Missouri, EE.UU.), MG132 (10 M) (M7449, Sigma, Missouri, EE.UU.). Los 
tiempos de incubación se indican en las leyendas de las figuras.  
Para los experimentos de silenciamiento de Cdh1 utilizamos Accell SmartPool 
Fzr1 siRNA (E-100432-00-0050, Dharmacon), y Accell ‘non-target’ siRNA (D-
001910-01-20, Dharmacon): 1 M siRNA por ml de medio de cultivo con suero 
reducido a 1% durante 96 h. Entonces se recogieron las células y se utilizaron para 
el tratamiento. 
 Animales transgénicos 
Se utilizaron en este estudio ratones APPswe, PSEN1dE9-85Dbo / J dobles 
transgénicos y ratones de tipo salvaje de la misma colonia (de nueve meses de 
edad). Los ratones se mantuvieron en un ciclo de luz-oscuridad de 12:12 h a 23 ± 
1°C y 60% de humedad relativa, y se les proporcionó una dieta estándar Chow 
(PANLAB SL) y agua ad libitum. 
 
Infusión Intrahipocampal 
Un grupo de nueve ratas Wistar (hembras) fueron tratadas con nitrato de atropina 
de metilo (0,4 mg/kg, i.p.), anestesiadas con una mezcla de ketamina (60 mg/kg 
i.p.) (Imalgen, 0,05 g/ml; Rhône Mérieux, Lyon, Francia) y xilazina (10 mg/kg i.p.) 
(Xilagesic, 20 mg/ml; Lab.Calier, Barcelona, España). Los animales se colocaron 
en un aparato estereotáxico Kopf (Kopf Instruments, Tujunga, EE.UU.). Con el fin 
de minimizar el sufrimiento de los animales, fue inyectada lidocaína subcutánea  en 
el área de la cirugía. En el cuero cabelludo se realiza una incisión y se retrae, y la 
posición del cabezal se ajustó a colocar bregma y lambda en el mismo plano 
horizontal. A continuación fueron realizadas perforaciones de trépano pequeñas (1 
mm de diámetro) en el cráneo de forma unilateral. 
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Las infusiones en el hipocampo se hicieron usando un sistema de cánula de acero 
inoxidable (Plastics One, Roanoke, VA) que consiste en un tubo exterior de guía 
(calibre 24) y un tubo de infusión interior (31 gauge). Las cánulas se colocaron 
estereotáxicamente 4,36 mm posterior al bregma, 1,4 mm lateral desde la línea 
media sagital, y se implantaron 3,4 mm por debajo de la superficie exterior del 
cráneo en la región del hipocampo CA1 del lado izquierdo, de acuerdo con el atlas 
de Paxinos y Watson 1998. La cánula de infusión se conectó a una microjeringa 10 
µl (Hamilton) mediante un tubo de polietileno.Un volumen total de 10 µl de 
soluciones de infusión (glutamato 1 mM en 1 x PBS; 5 µM Aβ disueltos en DMSO 
al 0,5% en 1x PBS) se inyectaron en el hipocampo a 0,5 µl/min controlada por una 
bomba de infusión. Las ratas control recibieron solución de vehículo (PBS) al 
mismo volumen y la misma velocidad. 
 
Preparación y fijación del tejido 
Después de 48 h de tratamiento, los animales se anestesiaron con una dosis letal de 
pentobarbital de sodio (100 mg/kg 20%) (Dolethal Vetoquinol Madrid, España) y 
se perfundió de modo trans-cardíaco con solución salina heparinizada (0,1%, pH 
7), seguido de paraformaldehído (4% ) en tampón de fosfato (PBS) (0,1 M, pH 
7,4). Los cerebros se post-fijaron durante 24 h en paraformaldehído (4%) en PBS a 
4°C y se mantuvieron durante 2 días en sacarosa (30%) a 4°C para crioprotección. 
Se obtuvieron secciones coronales de 40 micras  por microtomía por congelación 
(Leica) y se almacenaron en tampón de fosfato (0,1 M, pH 7,4) a 4°C.  
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Análisis de las muestras 
Para el análisis de las muestras obtenidas se utilizaron los siguientes métodos: 
marcaje por inmunohistoquímica, marcaje por inmunocitoquímica, adquisición de 
imágenes por microscopía confocal, Western Blot, medición de glutamato basado 
en un ensayo enzimático, medición de amoníaco en base a un ensayo enzimático, 
citometría de flujo para el análisis de la apoptosis y la determinación de la 
expresión de mRNA por rtPCR cuantitativa (para más detalles véase la sección 
Métodos). 
 
Número de muestras y análisis estadístico 
Los resultados se expresan como valores medios de los datos de al menos tres 
experimentos independientes; las barras de error representan la desviación 
estándar. En general, los experimentos se realizaron como duplicados, en cada 
experimento independiente. Sólo cuando el número de la muestra fue alta (en 
experimentos en que se mide tras un tratamiento a distintos tiempo), no se llevaron 
a cabo repeticiones, sin embargo en este caso, las muestras se analizaron por 
duplicado por Western Blot. Todas las reacciones de PCR se llevaron a cabo por 
triplicado. Para el análisis inmunohistoquímico, las secciones de cada cerebro se 
recogieron en series de tres a cinco muestras independientes. De estos, al menos 
dos series se analizaron por animal (por duplicado). 
Para el cálculo de la vida media de la proteína se supuso que la degradación de 
proteínas sigue una cinética de descomposición de primer orden. Inicialmente se 
hizo una transformación logarítmica de los datos de la medida de la intensidad de 
proteína. A continuación, se determinó la velocidad de disminución constante k, 
obteniéndose un coeficiente de determinación (R-cuadrado). Por otra parte, se 
estimó el error estándar de la pendiente. Para evaluar las diferencias de 
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significación se utilizó una prueba z. Se sabe que, bajo hipótesis de normalidad de 
los errores de ajuste, la diferencia entre las estimaciones de pendiente dividido por 
la raíz cuadrada media de su error estándar sigue una distribución normal estándar. 
Por último, a partir de la constante de velocidad de desintegración, se calculó la 
vida media (T (1/2) = ln (2) / k). 
Para otros análisis estadísticos, se utilizó la prueba t-test de una cola o el análisis 
del Mann-Whitney U-test. Los p-valores se clasificaron en las unidades de 
significación que se establecieron de la siguiente manera: p> 0,05, no significativo 
(NS), p <0,05 significativo (*), p <0,01 muy significativo (**), p <0,001 altamente 
significativa (***). 
 
 
 
 
 
 
 
 
 
 
 
 
153 
 
Conclusiones y Discusión 
Aβ disminuye los niveles de cdh1  
Mientras los niveles de Cdh1 oscilan durante el ciclo celular, en las neuronas post-
mitóticas los niveles Cdh1 se mantienen en un estado estacionario. Se ha 
documentado que la fosforilación de Cdh1 suprime su capacidad de activar APC/C 
(Zachariae et al, 1998;. Kotania et al., 1999). Estudios relacionados con el ciclo 
celular mostraron que la fosforilación de Cdh1 es controlado por quinasas y 
fosfatasas dependientes de ciclina (Jaspersen et al., 1999; Lukas et al., 1999). La 
fosforilación de Cdh1 promueve la exportación nuclear (Jaquenoud et al., 2002) y 
también inhibe su importación nuclear (Zhou et al., 2003). Por lo tanto, la 
fosforilación de Cdh1 tiene efectos duales de exportación nuclear y de importación, 
los cuales conducen a la retención citoplásmica de Cdh1. Se ha demostrado que 
Cdh1 citoplásmica fosforilada está inactiva, y se sugirió que la disminución nuclear 
de Cdh1, por tanto, contribuye a la inactivación de APC/C (Jaquenoud et al., 2002). 
Además, se sabe que el complejo SCF está implicado en la degradación de Cdh1 
fosforilada en el citoplasma (Benmaamar y Pagano, 2005; Almeida, 2012), lo que 
puede conducir a la disminución de los niveles de Cdh1 después de la fosforilación. 
En nuestro estudio hemos probado si A afecta a los niveles de Cdh1 tanto totales 
en las neuronas en cultivo y como los niveles de Cdh1 nucleares y citoplasmáticos. 
Se ha observado una disminución de Cdh1 en lisados de células totales en las 
neuronas en cultivo primario después del tratamiento con Aß. Además, los niveles 
de Cdh1 fue completamente disminuidos en el núcleo después del tratamiento con 
Aß, lo que sugiere que Cdh1 se ha translocado del núcleo al citosol. Así mismo, 
hemos comprobado que la degradación de Cdh1 era dependiente del proteasoma. 
Otros estudios han demonstrado que la exportación nuclear de Cdh1 se produce 
después de la fosforilación Cdh1, lo que nos ha llevado a la hipótesis de que Cdh1 
podría haber sido fosforilada en las neuronas cuando son tratados con A. No 
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pudimos analizar la fosforilación de Cdh1 directamente, ya que no hay anticuerpo 
fosfo-Cdh1 disponible comercialmente. Por ello, analizamos los niveles de una 
posible quinasa como es Cdk5. Maestre et al. (2008) demostraron que la quinasa 
dependiente de ciclina 5 (cdk5) fosforila Cdh1 en condiciones de excitotoxicidad 
en neuronas. Por lo tanto, analizamos si cdk5 estuvo implicado en la degradación 
de cdh1 tras el tratamiento con Aß. 
Análisis de niveles de proteina total de Cdh1, la vida media con y sin tratamiento 
de Aß mostró que la semivida de la proteína de Cdh1 es más corta cuando se trata 
con Aß. Esto sugiere que Aß actúa sobre Cdh1 de una manera posterior a la 
transcripcion (de mRNA). Los niveles de mRNA de Cdh1 y APC/C2 no cambiaron 
en respuesta al tratamiento Aß. Se confirmó que la expresión de mRNA no se ve 
afectada por el tratamiento y concluimos que la disminución de Cdh1 sólo depende 
de modificaciones post-transcripcionales. También una de las subunidades 
principales, APC/C2 con la función catalítica, no mostró una diferencia 
significativa en la expresión, lo que nos permite concluir que la actividad de 
APC/C no se ve afectada por Aß a través de la regulación de la expresión de esta 
subunidad. 
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Figura 1 | Representación esquemática de los resultados y conclusiones que se resumen en 
esta sección. Aß induce la exportación nuclear de Cdh1 (efecto directo o indirecto, indicado 
por la línea discontinua). Cdh1 es luego degradado en el citoplasma por el proteasoma. 
 
Los reguladores de APC/C-Cdh1: Cdk5-p25 y PTEN 
Cdk5 es una serina/treonina quinasa que tiene un papel importante en neuronas 
postmitóticas. Se considera que es una cdk no tradicional, ya que no tiene 
funciones como regulador de proteínas del ciclo celular. Sin embargo, en neuronas 
se demostró que esta involucrada en la detención del ciclo celular (Zhang et al., 
2008; Cicerón y Herru, 2005). Entre los sustratos de la actividad quinasa de cdk5 
encontramos proteínas del citoesqueleto y concretamente, se ha demostrado que 
cdk5 cataliza la fosforilación de proteínas y neurofilamentos de tau (Lew et al., 
1995). Lee et al. demostraron que hay una actividad de cdk5 elevada en cerebros 
humanos de pacientes de EA en comparación con los controles, por lo que es un 
objetivo atractivo en la investigación de esta enfermedad (Lee et al., 1999). 
Cdk5 forma un complejo con uno de sus reguladores p35 o p39, que activan la 
función enzimática de la misma. Agresiones neurotóxicas, como la isquemia o la 
presencia de Aβ que inducen una desregulación de Ca2+, conducen a una activación 
de la proteasa calpaína, que es dependiente de calcio y que escinde p35 en un 
fragmento 25 kDa denominado 'p25 '. El péptido p25 tiene una vida media más 
larga que p35, ya que no puede ser degradado correctamente. Cdk5-p25 forman un 
complejo estable que conduce a la activación constitutiva de la quinasa. Se ha 
demostrado que esto esta involucrado en a la neurodegeneración (Patrick et al., 
2000). En la presente tesis demostramos que el tratamiento con A en neuronas en 
cultivo, provoca un aumento de cdk5-p25, y que la inhibición de cdk5 rescata 
parcialmente la disminución de cdh1 inducida por Aβ. Analizando los resultados 
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anteriormente descritos, podemos concluir que existe una fuerte evidencia de que 
Aβ induzca una alteración en la señalización de Ca2+ - cdk5-p25 - cdh1 en la EA. 
 
 
 
 
 
 
 
Figura 2 | Representación esquemática de los resultados que se resumen en esta sección. 
Tratamientos de Aβ y glutamato provocan una desregulación intraneuronal de Ca2+. Cdk5-
p25 causa la degradación de cdh1. 
 
La acumulación de sustratos de APC/C-Cdh1en las neuronas se relaciona con EA 
Una vez demostrada la disminución de cdh1 en las neuronas después del 
tratamiento con Aβ, se analizaron los niveles de proteína de otros sustratos de 
APC/C-Cdh1 en las mismas muestras. Buscamos sustratos de APC/C en la 
literatura, que se expresaran en neuronas y que se sabe que estuvieran alterados en 
la EA. Tres proteínas que cumplían estas características fueron: ciclina B1, pfkfb3 
y glutaminasa. 
Los niveles elevados de ciclina B1 en las neuronas están involucrados en la re-
entrada en un ciclo celular ectópico en las neuronas en la EA (Vicent et al., 1997; 
Bonda et al., 2009). Hemos observado que tanto la inhibición de APC/C directa, 
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como la disminuición de cdh1 por tratamiento con Aβ, condujeron a una 
acumulación de la ciclina B1. Dado que esta proteína es un sustrato bien descrito 
de APC/C en las neuronas, lo usamos como un "control positivo" para la actividad 
de la degradación de APC/C. A continuación, medimos pfkfb3, una proteína que 
está controlada por la actividad de APC/C en neuronas con el fin de mantener un 
nivel basal bajo en la glucolisis. La degradación controlada de pfkfb3 es 
responsable también de mantener un nivel estable de antioxidantes en las neuronas. 
Por lo tanto, la acumulación de esta enzima puede conducir a estrés oxidativo y a 
apoptosis en neuronas (Herrero-Méndez et al., 2009). Sin embargo, en nuestras 
condiciones experimentales, no se observó un aumento en pfkfb3 tras el 
tratamiento con Aβ después de 20h. Es posible que el nivel de expresión basal de 
pfkfb3 sea demasiado baja para detectar una acumulación de pfkfb3 dentro de las 
20h de duración del tratamiento. Pfkfb3 podría también ser co-regulado por otros 
mecanismos y su nivel de proteínas no sólo depender de la degradación de APC/C-
Cdh1. 
Por otro lado, se ha demostrado que la glutaminasa es un sustrato de  APC/C-Cdh1 
en linfocitos (Colombo et al., 2010). La glutaminasa tiene funciones importantes en 
las neuronas, ya que es una fuente principal para la producción del neurotransmisor 
glutamato. Cuando la glutamina entra en la mitocondria, la glutaminasa cataliza la 
reacción que lo convierte en glutamato y amoníaco. Las alteraciones de los niveles 
de glutaminasa en la EA se vieron por primera vez en 1989 por Akiyama et al., los 
cuales describen una pérdida de neuronas 'glutaminasa-positivas', en las últimas 
etapas de la EA. Además, las neuronas inmunorreactivas a la glutaminasa y 
glutamato se han correlacionado con la formación de ovillos neurofibrilares en EA 
(Kowall y Beal, 1991). Burbaeva et al. (2005) reportaron mayores niveles de 
glutaminasa en la corteza prefrontal de pacientes con EA. 
En primer lugar, hemos probado si la glutaminasa está destinada a la degradación 
por APC/C-Cdh1 en las neuronas, utilizando siRNA para silenciar cdh1. Se 
158 
 
confirmó que se acumulaba en las neuronas cuando cdh1 esta disminuido. 
Adicionalmente, se inhibió todo el complejo APC/C utilizando el proTAME como 
inhibidor específico, y observamos que la glutaminasa se acumulaba tras el 
tratamiento. En la misma línea, se observó una acumulación de glutaminasa en las 
neuronas cuando se trataban con péptido Aβ. En los siguientes apartados de este 
proyecto se analizaron los efectos de la acumulación de glutaminasa en las 
neuronas. 
El aumento de los niveles de glutamato en la EA 
Hemos demostrado que el tratamiento con péptido Aβ induce un aumento en los 
niveles de glutamato en el medio extracelular de las neuronas y que esto es 
mediado por la acumulación de glutaminasa. La inhibición directa de APC/C 
también era suficiente para aumentar la concentración de glutamato a niveles 
similares a los de después del tratamiento con Aβ. El aumento de glutamato, 
después de ambos tratamientos bien con Aβ o proTAME, se reducía al inhibir la 
glutaminasa. Además, la eliminación de la glutamina del medio de cultivo revertió 
completamente el aumento de glutamato inducido por Aβ o proTAME. Nuestros 
resultados son relevantes en la investigación de EA, ya que describen una forma 
novedosa de señalización para inducir la excitotoxicidad, un evento que se produce 
en la EA. 
En el líquido cefalorraquídeo de pacientes con EA, se han observado altos niveles 
de glutamato en comparación con individuos sanos de edad similar (Pomara et al., 
1992; Csernansky et al., 1996; Jiménez-Jiménez et al., 1998;. Kaiser et al., 2010). 
Actualmente, los sistemas glutamatérgicos son una de las principales dianas 
terapéuticas en el tratamiento de EA (Zádori et al., 2014). El fármaco es la 
memantina, un antagonista del receptor de NMDA, que se ha demostrado mejora 
parcialmente la toxicidad sináptica causada por Aβ (Lipton, 2005; Tu et al., 2014). 
Estudios relacionados con la EA, que se centraron en los mecanismos moleculares 
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de la excitotoxicidad, informaron de que el aumento de glutamato se debía a un 
fallo en el sistema de reciclaje de mismo. El glutamato no puede ser internalizado 
adecuadamente por los astrocitos al haber una disminución de su transportador 
GLT1, y por lo tanto el neurotransmisor aumenta su concentración en la hendidura 
sináptica (Lauderback et al, 1999. Scimemi et al, 2013). Postulamos aquí que la 
excitotoxicidad en la EA no sólo resulta de perturbaciones en el sistema de la 
recaptación de glutamato, sino también por aumento de la generación de glutamato 
por la glutaminasa.  
Curiosamente, Maestre et al. (2008) demostraron que un estímulo de 
excitotoxicidad causado por el glutamato inactiva APC/C-Cdh1. En nuestro 
trabajo, hemos confirmado estos resultados, ya que hemos visto que el glutamato 
reduce los niveles de la proteína cdh1 y hemos demostrado que esto también 
conduce a la acumulación de glutaminasa. 
Se ha demostrado que una agresión excitotóxica con glutamato causa la activación 
constante del receptor de NMDA y ello lleva a un bucle de retroalimentación 
positivo (Norris et al, 2006; Rodríguez-Rodriguez et al, 2013).  
Nuestros resultados sugieren que la acumulación de glutaminasa inducida por el 
glutamato podría contribuir a este bucle de retroalimentación positivo en la 
generación de glutamato, que resultaría en excitotoxicidad, y eso mantendría la 
actividad de APC/C baja. Además, esto llevaría a la acumulación de sustratos de 
APC/C-Cdh1, de las cuales algunos estarían relacionados con procesos 
neurodegenerativos. Un aumento de la ciclina B1 por ejemplo, provoca la reentrada 
en el ciclo celular en las neuronas, dando lugar a un ciclo celular ectópico y altos 
niveles de pfkfb3 inducen estrés oxidativo (Maestre et al, 2008;. Herrero-Méndez 
et al., 2009). Por otra parte, perfiles de expresión génica han indicado que la 
excitotoxicidad favorece vías neuronales que inducen la re-activación del ciclo 
celular y estrés oxidativo y que estos eventos juntos aceleran la neurodegeneración 
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(Chen et al., 2013). Nosotros hemos encontrado que la apoptosis inducida por 
glutamato se puede mejorar inhibiendo la glutaminasa. Sugerimos que estos 
eventos en conjunto tienen lugar en el proceso fisiopatológico asociado a la EA y 
que todos están vinculados a través de una actividad deficiente de APC/C. 
 
 
 
 
 
 
 
 
Figura 3 | Representación esquemática de los resultados y conclusiones que se resumen en 
estas secciones. Disminución de la actividad APC/C (ya sea mediante la inhibición directa a 
través de proTAME o mediante por la disminución de cdh1 por Aβ) conduce a una 
acumulación de la glutaminasa. Esto conduce a un aumento del glutamato y amoníaco en el 
medio extracelular de las neuronas lo cual causa apoptosis. 
 
La inhibición de APC/C y la desregulación de Ca
2+
  
El glutamato activa receptores de NMDA, lo que lleva a un aumento del Ca
2+
 
intracelular. Este es un evento central para la actividad neuronal. Sin embargo, el 
aumento alterado de los niveles de glutamato conducen a una sobrecarga en los 
niveles de Ca
2+
 intracelular, que causa un daño de excitotoxicidad en las neuronas. 
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Sabemos que el péptido Aβ causa una desregulación en la homeostasis de Ca2+ que 
conduce a la estabilización de p25, el activador de cdk5 (La Ferla, 2002). Además, 
Maestre et al. (2008) demostraron que cdk5-p25 fosforila a cdh1 acompañado de 
un exceso de activación de los receptores de glutamato, a través de un mecanismo 
mediado por Ca
2+
. 
Hemos observado que en las neuronas en cultivo en el que el glutamato se 
incrementó tras un tratamiento con Aβ o inhibición de APC/C (con proTAME), los 
niveles intracelulares de Ca
2+
 fueron incrementados también en comparación con 
los niveles basales. Por otra parte, se encontró que el tratamiento con Aβ o 
proTAME indujo apoptosis neuronal, que mejoraba si inhibíamos la glutaminasa. 
Esto indica que el aumento de los niveles de glutaminasa, y los niveles de 
glutamato después de los tratamientos con Aβ o proTAME inducen  
excitotoxicidad. 
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Figura 4 | Representación esquemática de los resultados y conclusiones de la cascada de 
señalización que se describe en este proyecto. Una desregulación de Ca
2 +
 inducida por Aβ 
o por niveles elevados de glutamato, conducen a una estabilización de cdk5-p25. Esta 
quinasa fosforila cdh1 e inactiva a la ubiquitina ligasa. Esto conduce a una acumulación del 
sustrato de APC/C-Cdh1, la glutaminasa, lo que conduce a un aumento de los niveles de 
glutamato. 
 
 
Aβ y glutamato reducen los niveles de Cdh1 in vivo 
A continuación, quisimos comprobar nuestros resultados en un modelo in vivo. 
Para ello, utilizamos lesiones agudas por medio de microinyecciones 
intracerebrales. La infusión de oligómeros Aβ1-42 en el área CA1 del hipocampo de 
la rata causó exportación nuclear de cdh1 y un aumento de los niveles de 
glutaminasa. Se ha demostrado en un estudio previo en el que se utilizaron 
condiciones experimentales similares, que la microinyección de oligómeros de Aβ1-
42 dentro de hipocampo provocaba un deterioro de la memoria de trabajo espacial 
en ratas (Pearson-Leary y Mc, 2012). 
De forma similar a los efectos de la inyección de Aβ,  la infusión de glutamato 
monosódico causó la exportación nuclear de cdh1 en el hipocampo. Además, 
ambos tratamientos aumentaron los niveles de glutaminasa en comparación con los 
controles microinyectados con vehículo. Estos resultados también podrían ser 
relevantes para otras enfermedades neurodegenerativas, como la isquemia. Se ha 
demostrado que una lesión isquémica global induce la disminución de APC/C-
Cdh1 en la región CA1 hipocampal en el cerebro de rata, y esto además, estaba 
relacionado con la apoptosis neuronal (Zhang et al., 2011). La lesión isquémica 
provoca un aumento en la concentración de glutamato extracelular que conduce a 
la sobre-estimulación de los receptores de NMDA extrasinápticos. Las proteínas 
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implicadas en esta cascada de excitotoxicidad son entre otras PTEN, calpaína, cdk5 
y p25. El daño aparece tres días post-ictus y continúa progresivamente a lo largo de 
meses (Lai et al., 2014). Por lo que se concluye que estos eventos causan daño 
neuronal retardado y progresivo, que al final resultan en la muerte neuronal. 
Nuestra observación del efecto del glutamato sobre cdh1 sugiere que la 
disminución de cdh1 en la isquemia observado por Zhang et al., podría haber sido 
inducido por la excitotoxicidad del glutamato. Por otra parte, la  disminuición de 
APC/C-Cdh1 y la acumulación de glutaminasa subsiguiente puede contribuir a la 
generación de entornos de excitotoxicidad en la isquemia. 
 
 
Cdh1 y glutaminasa en el ratón transgénico APP/PS1 
A continuación, analizamos los niveles de la proteína cdh1 en el modelo murino de 
la EA, el doble transgénico APP/PS1, en el que las neuronas están expuestos 
crónicamente a Aβ. Este es un modelo ampliamente utilizado para el estudio de la 
EA, ya que desarrollan la principal lesión encontrada en el cerebro humano, las 
placas de A. En el modelo de ratón hay una fuerte correlación positiva entre la 
acumulación de Aβ y el deterioro cognitivo. Sin embargo, los ratones mutantes de 
APP/PS1 no tienen formación de ovillos neurofibrilares, pérdida neuronal o 
ventrículos más grandes, que son otras características principales de la AD en el ser 
humano. Dado que en nuestro estudio hemos analizado en particular el efecto de 
Aβ sobre APC/C-Cdh1, creemos que éste es el modelo adecuado para nuestro 
trabajo. 
Los estudios inmunohistológicos muestran niveles inferiores de cdh1 (y 
predominantemente menos cdh1 en el núcleo) en los ratones transgénicos 
comparados con los ratones salvajes, en la capa CA1 del hipocampo. La 
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glutaminasa tambien se encuentra aumentada en las mismas áreas del cerebro. De 
este modo se confirmó nuestros resultados en un modelo de EA in vivo. 
 
Nuestros resutados en una visión global para la EA 
Por último, nuestros resultados nos permiten especular sobre su posible 
implicación en la aparición de la enfermedad en una visión global. En condiciones 
fisiológicas, la glutaminasa está presente en altas concentraciones en el hipocampo 
y la corteza entorrinal (Altschuler et al, 1985;. Akiyama et al., 1989). 
Recientemente, la corteza entorrinal lateral ha sido identificada como la principal 
área afectada en fases preclínicas de la EA. Este área proyecta a la región CA1 del 
hipocampo por la vía perforante lateral (LPP), que es parte de uno de los circuitos 
implicados en la memoria declarativa. La LPP está compuesta principalmente de 
conexiones glutamatérgicos (Khan et al., 2014). La toxicidad del glutamato 
inducida por Aβ podría tener efectos deletéreos específicamente en estas áreas del 
cerebro que se ven afectados en fases preclínicas de la EA, debido al alto nivel de 
glutaminasa basal. Por lo tanto postulamos que la excitotoxicidad podría ser un 
evento crucial en la aparición de la enfermedad y en deterioro de la memoria. 
 
Perspectivas: APC/C-Cdh1 en la investigación en la EA 
La evidencia sustancial nos dice que APC/C-Cdh1 y la glutaminasa podrían tener 
un papel importante en la fisiopatología de la EA. Otras indicaciones sugieren que 
algunos de los sustratos de APC/C están implicados en procesos relacionados con 
la EA. Sin embargo, sería crucial determinar si la desregulación de cdh1 se produce 
en el cerebro humano de los pacientes de EA. De hecho, se ha observado pérdida 
de neuronas 'glutaminasa-positivas', lo que sugiere un deterioro de la regulación de 
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la glutaminasa en la enfermedad. Sin embargo, los estudios en los cerebros de 
humanos de EA son difíciles de realizar, sobre todo si la desregulación se produce 
en el inicio de la enfermedad. 
Podemos sin embargo, especular sobre las posibles consecuencias de una alteración 
en la regulación de APC/C-Cdh1 en la EA. La modificación de la actividad de la 
ubiquitina ligasa afectaría a un conjunto de sustratos y varias vías patológicas 
independientes pudieran verse perjudicadas a la vez. Entre ellas se encuentran la 
regulación del ciclo celular y la neurogénesis, la regulación oxidativa, el LTP y el 
metabolismo del glutamato. Los altos niveles de ciclina B1 han sido relacionados 
en una reentrada del ciclo celular ectópica, la acumulación de pfkfb3 induce estrés 
oxidativo en las neuronas y el aumento de los niveles de glutaminasa causan 
excitotoxicidad (Figura 6). Sin embargo, otros sustratos de APC/C aún no 
identificados, podrían estar involucrados directa o indirectamente en la 
fisiopatología de la EA. En varios modelos knock-out de cdh1, se ve afectado el 
proceso de long-term potentiation (LTP). Por lo tanto, sería razonable sugerir, que 
la alteración del LTP en la EA se produce debido a la desregulación de la APC/C-
Cdh1. Un análisis más detallado de los sustratos de APC/C o proteínas 
relacionadas que participan en la LTP (EphA4, GluR, Liprina alfa, FRMP) podría 
dar más puntos de vista de la desregulación de proteínas en la EA. 
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Figura 5 | Representación esquemática de los procesos alterados en la EA causado por una 
desregulación de APC/C-Cdh1. La acumulación de glutaminasa, la ciclina B1 y pfkfb3 
están involucrados en la excitotoxicidad, el la reentrada en el ciclo celular de y el estrés 
oxidativo, respectivamente. 
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